WO2007081949A2 - Small-volume oral transmucosal dosage forms - Google Patents

Small-volume oral transmucosal dosage forms Download PDF

Info

Publication number
WO2007081949A2
WO2007081949A2 PCT/US2007/000529 US2007000529W WO2007081949A2 WO 2007081949 A2 WO2007081949 A2 WO 2007081949A2 US 2007000529 W US2007000529 W US 2007000529W WO 2007081949 A2 WO2007081949 A2 WO 2007081949A2
Authority
WO
WIPO (PCT)
Prior art keywords
nanotab
drug
meg
dosage form
less
Prior art date
Application number
PCT/US2007/000529
Other languages
French (fr)
Other versions
WO2007081949A3 (en
Inventor
Pamela Palmer
Thomas Schreck
Stelios Tzannis
Larry Hamel
Andrew I. Poutiatine
Original Assignee
Acelrx Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acelrx Pharmaceuticals, Inc. filed Critical Acelrx Pharmaceuticals, Inc.
Priority to JP2008549612A priority Critical patent/JP5183490B2/en
Priority to EP20070716451 priority patent/EP1978996A4/en
Priority to CN200780007142.9A priority patent/CN101394863B/en
Priority to CA2636088A priority patent/CA2636088C/en
Priority to EP16163199.9A priority patent/EP3072504B1/en
Priority to EP20161845.1A priority patent/EP3685829A1/en
Priority to KR1020087019313A priority patent/KR101503074B1/en
Publication of WO2007081949A2 publication Critical patent/WO2007081949A2/en
Publication of WO2007081949A3 publication Critical patent/WO2007081949A3/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61JCONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J7/00Devices for administering medicines orally, e.g. spoons; Pill counting devices; Arrangements for time indication or reminder for taking medicine
    • A61J7/0015Devices specially adapted for taking medicines
    • A61J7/0038Straws
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61JCONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J7/00Devices for administering medicines orally, e.g. spoons; Pill counting devices; Arrangements for time indication or reminder for taking medicine
    • A61J7/0015Devices specially adapted for taking medicines
    • A61J7/0053Syringes, pipettes or oral dispensers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61JCONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J7/00Devices for administering medicines orally, e.g. spoons; Pill counting devices; Arrangements for time indication or reminder for taking medicine
    • A61J7/04Arrangements for time indication or reminder for taking medicine, e.g. programmed dispensers
    • A61J7/0409Arrangements for time indication or reminder for taking medicine, e.g. programmed dispensers with timers
    • A61J7/0481Arrangements for time indication or reminder for taking medicine, e.g. programmed dispensers with timers working on a schedule basis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2009Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2031Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00Inhalators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00Inhalators
    • A61M15/0065Inhalators with dosage or measuring devices
    • A61M15/0068Indicating or counting the number of dispensed doses or of remaining doses
    • A61M15/008Electronic counters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00Inhalators
    • A61M15/0065Inhalators with dosage or measuring devices
    • A61M15/0068Indicating or counting the number of dispensed doses or of remaining doses
    • A61M15/0081Locking means
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00Inhalators
    • A61M15/0065Inhalators with dosage or measuring devices
    • A61M15/0068Indicating or counting the number of dispensed doses or of remaining doses
    • A61M15/0083Timers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • GPHYSICS
    • G07CHECKING-DEVICES
    • G07FCOIN-FREED OR LIKE APPARATUS
    • G07F17/00Coin-freed apparatus for hiring articles; Coin-freed facilities or services
    • G07F17/0092Coin-freed apparatus for hiring articles; Coin-freed facilities or services for assembling and dispensing of pharmaceutical articles
    • HELECTRICITY
    • H01ELECTRIC ELEMENTS
    • H01QANTENNAS, i.e. RADIO AERIALS
    • H01Q1/00Details of, or arrangements associated with, antennas
    • H01Q1/12Supports; Mounting means
    • H01Q1/22Supports; Mounting means by structural association with other equipment or articles
    • H01Q1/2208Supports; Mounting means by structural association with other equipment or articles associated with components used in interrogation type services, i.e. in systems for information exchange between an interrogator/reader and a tag/transponder, e.g. in Radio Frequency Identification [RFID] systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61JCONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J2200/00General characteristics or adaptations
    • A61J2200/30Compliance analysis for taking medication
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61JCONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J7/00Devices for administering medicines orally, e.g. spoons; Pill counting devices; Arrangements for time indication or reminder for taking medicine
    • A61J7/04Arrangements for time indication or reminder for taking medicine, e.g. programmed dispensers
    • A61J7/0409Arrangements for time indication or reminder for taking medicine, e.g. programmed dispensers with timers
    • A61J7/0418Arrangements for time indication or reminder for taking medicine, e.g. programmed dispensers with timers with electronic history memory
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61JCONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J7/00Devices for administering medicines orally, e.g. spoons; Pill counting devices; Arrangements for time indication or reminder for taking medicine
    • A61J7/04Arrangements for time indication or reminder for taking medicine, e.g. programmed dispensers
    • A61J7/0409Arrangements for time indication or reminder for taking medicine, e.g. programmed dispensers with timers
    • A61J7/0427Arrangements for time indication or reminder for taking medicine, e.g. programmed dispensers with timers with direct interaction with a dispensing or delivery system
    • A61J7/0445Arrangements for time indication or reminder for taking medicine, e.g. programmed dispensers with timers with direct interaction with a dispensing or delivery system for preventing drug dispensing during a predetermined time period
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00General characteristics of the apparatus
    • A61M2205/27General characteristics of the apparatus preventing use
    • A61M2205/276General characteristics of the apparatus preventing use preventing unwanted use
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00General characteristics of the apparatus
    • A61M2205/35Communication
    • A61M2205/3546Range
    • A61M2205/3561Range local, e.g. within room or hospital
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00General characteristics of the apparatus
    • A61M2205/35Communication
    • A61M2205/3576Communication with non implanted data transmission devices, e.g. using external transmitter or receiver
    • A61M2205/3584Communication with non implanted data transmission devices, e.g. using external transmitter or receiver using modem, internet or bluetooth
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00General characteristics of the apparatus
    • A61M2205/35Communication
    • A61M2205/3576Communication with non implanted data transmission devices, e.g. using external transmitter or receiver
    • A61M2205/3592Communication with non implanted data transmission devices, e.g. using external transmitter or receiver using telemetric means, e.g. radio or optical transmission
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00General characteristics of the apparatus
    • A61M2205/50General characteristics of the apparatus with microprocessors or computers
    • A61M2205/52General characteristics of the apparatus with microprocessors or computers with memories providing a history of measured variating parameters of apparatus or patient
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00General characteristics of the apparatus
    • A61M2205/58Means for facilitating use, e.g. by people with impaired vision
    • A61M2205/583Means for facilitating use, e.g. by people with impaired vision by visual feedback
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00General characteristics of the apparatus
    • A61M2205/60General characteristics of the apparatus with identification means
    • A61M2205/6054Magnetic identification systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00General characteristics of the apparatus
    • A61M2205/60General characteristics of the apparatus with identification means
    • A61M2205/609Biometric patient identification means
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2209/00Ancillary equipment
    • A61M2209/08Supports for equipment
    • A61M2209/084Supporting bases, stands for equipment
    • A61M2209/086Docking stations
    • GPHYSICS
    • G07CHECKING-DEVICES
    • G07CTIME OR ATTENDANCE REGISTERS; REGISTERING OR INDICATING THE WORKING OF MACHINES; GENERATING RANDOM NUMBERS; VOTING OR LOTTERY APPARATUS; ARRANGEMENTS, SYSTEMS OR APPARATUS FOR CHECKING NOT PROVIDED FOR ELSEWHERE
    • G07C9/00Individual registration on entry or exit
    • G07C9/20Individual registration on entry or exit involving the use of a pass
    • G07C9/22Individual registration on entry or exit involving the use of a pass in combination with an identity check of the pass holder

Definitions

  • the present invention provides for small- volume oral transmucosal drug delivery dosage forms having various sizes and characteristics, referred to herein as "NanoTabs ® " and methods of using the same.
  • Reproducible and effective drug delivery technology represents an area of active research and controlled drug delivery systems offer numerous advantages relative to conventional dosage forms, which include improved efficacy, reduced toxicity, as well as improved patient compliance and convenience. This is particularly relevant to the treatment of pain, more specifically: acute, intermittent and breakthrough pain.
  • U.S. Patent Nos. 6,974,590, 6,764,696, 6,641,838, 6,585,997, 6,509,036, 6,391,335, 6,350,470, 6,200,604 and US Patent Publication Nos. 20050176790, 20050142197 and . 20050142198 describe pharmaceutical combinations of active compounds such as fentanyl and congeners thereof in combination with an effervescent agent used as a penetration enhancer to influence the permeability of the active compound across the buccal, sublingual, and gingival mucosa.
  • U.S. Patent Nos. 6,761,910 and 6,759,059 and U.S. Patent Publication No. 20040213855 disclose pharmaceutical compositions for the treatment of acute disorders such as pain by sublingual administration of an essentially water-free, ordered mixture of microparticles with at least one pharmaceutically active agent adhered to the surfaces of the carrier particles by way of a bioadhesion and/or mucoadhesion promoting agent.
  • U.S. Patent No. 6,759,059 discloses compositions and methods for sublingual administration of fentanyl or a pharmaceutically acceptable salt thereof using a tablet which is approximately 100 mg in size.
  • U.S. Patent Nos. 5,800,832 and U.S. Pat. No. 6,159,498 (Tapolsky, et al.), and U.S. Patent Publication Nos. 20030194420 and 20050013845 disclose a water soluble, biodegradable drug delivery device, e.g., a bilayer film disk having an adhesive layer and a backing layer, both water-soluble, which adheres to mucosal surfaces.
  • U.S. Patent Nos. 6, 682,716; 6,855,310; 7,070,762 and 7,070,764 and (Rabinowitz, et al.), disclose delivery of an analgesic via the inhalation route using a method which comprises: a) heating a thin layer of analgesic drug on a solid support to form a vapor; and, b) passing air through the heated vapor to produce aerosol particles.
  • U.S. Patent No. 6,252,981 discloses oral mucosal drug delivery as an alternative method of systemic drug delivery formulation and method for oral transmucosal delivery of a pharmaceutical.
  • the invention provides a drug formulation comprising a solid pharmaceutical agent in solid solution with a dissolution agent in solid form, yielding a solid solution.
  • the solid solution formulation may be further combined with buffers and other excipients as needed in order to facilitate the drug's manufacturing, storage, administration and delivery through oral mucosal tissue.
  • the formulation can be used with a variety of oral transmucosal delivery dosage forms, such as a tablet, lozenge, lozenge on a stick, chewing gum, • and buccal or mucosal patch. See, also Zhang et al, Clin Pharmacokinet. 2002;41(9):661-80.
  • transmucosal dosage forms for treatment of pain are presently in clinical development, examples of which include a buccal morphine spray and a buccal fentanyl spray (Generex Biotechnology) and an oral, fast-dissolving tablet of fentanyl for sublingual administration (RapinylTM; Endo Pharmaceuticals).
  • fentanyl buccal tablet a fentanyl buccal tablet
  • ACTIQ ® an oral transmucosal form of fentanyl citrate administered as a lollipop
  • High bioavailability is critical for efficacious treatment with a variety of drugs including opioids, since higher doses of the drug must be packaged in the commercial dosage form to counter the generally poor bioavailability.
  • An example is oxymorphone (Opana ® ) which has a bioavailability of 10% and therefore must be packaged with nine-fold more drug for the oral tablet versus the equivalent IV dosage form.
  • oxymorphone Olea ®
  • IonSysTM is an inefficient drug delivery system (transdermal) that requires three times the amount of drug packaged into the transdermal patch than is maximally delivered to the patient during regular usage.
  • compositions and methods comprising small volume oral transmucosal drug delivery dosage forms or "NanoTabs ® " which contain a predetermined unit dosage of a pharmaceutically active amount of a drug, which may be self-administered, while providing a therapeutic effect and a predictable and safe pharmacokinetic profile.
  • NanoTab ® The small size of the NanoTab ® and its placement in the sublingual cavity allow for potent, lipophilic molecules to be absorbed transmucosally with minimal saliva response and minimal swallowing of the drug.
  • This avoidance of gastrointestinal (GI) uptake allows for a more rapid and consistent onset of action, more consistent plasma concentrations and higher bioavailability.
  • This route of administration minimizes drug uptake via the GI route, which is variable and by which significant metabolism of the drug in the stomach and intestines can occur.
  • NanoTabs ® of the invention have bioadhesive characteristics and can adhere to the oral mucosa, e.g., a sublingual or buccal membrane.
  • Such NanoTabs ® can be of the hydrogel-forming or eroding type.
  • the NanoTabs ® of the invention have a mass of less than 100mg and a volume of less than lOO ⁇ l. More specifically, the invention provides NanoTabs ® with a mass selected from the group consisting of less than lOOmg, less than 90mg, less than 80mg, less than 70mg, less than 60mg s less than 50mg, less than 40mg, less than 30mg, less than 20mg and less than lOmg and/or a volume selected from the group consisting of less than lOO ⁇ l, less than 90 ⁇ l, less than 80 ⁇ l, less than 70 ⁇ l, less than 60 ⁇ l, less than 50 ⁇ l, less than 40 ⁇ l, less than 30 ⁇ l, less than 20 ⁇ l and less than lO ⁇ l.
  • a NanoTab ® of the invention finds utility in oral transmucosal administration of any drug that can be absorbed via the transmucosal route and which suffers from GI and first-pass metabolism and
  • the NanoTabs ® of the invention comprise from about 0.25 ⁇ g to 99.9mg, from about l ⁇ g to 50mg, or from about l ⁇ g to lOmg of the drug.
  • the invention provides a NanoTab ® wherein the drug is an opioid selected from the group consisting of sufentanil, alfentanil, fentanyl, lofentanil, carfentanil, remifentanil, trefentanil, and mirfentanil.
  • the drug is an opioid selected from the group consisting of sufentanil, alfentanil, fentanyl, lofentanil, carfentanil, remifentanil, trefentanil, and mirfentanil.
  • NanoTabs ® which comprise an opioid drug in an amount selected from the group consisting of from about 0.25 meg to 200 micrograms (meg) of sufentanil, from about 2.5 meg to 100 meg of sufentanil, from about 0.02 meg to 5 micrograms per kilogram (meg/kg) of sufentanil, e.g., about 2.5, 5.
  • sufentanil from about 10 meg to 10 mg of alfentanil, from about 2 meg to 1500 meg of fentanyl, from about 50 meg to 1500 meg of fentanyl, 200 meg to 1500 meg of fentanyl, from about 0.25 meg to 99.9 mg of lofentanil, from about 0.25 meg to 99.9 mg of carfentanil, from about 0.25 meg to 99.9 mg of carfentanil, from about 0.25 meg to 99.9 mg of remifentanil, from about 0.25 meg to 99.9 mg of trefentanil, from about 0.25 meg to 99.9 mg of mirfentanil.
  • the NanoTab ® is designed for self-administration by a subject with or without a device, wherein the NanoTab ® has a shape selected from the group consisting of a round disc with a flat, concave, or convex face, an ellipsoid shape a spherical shape and a polygon with three or more edges and flat, concave, or convex faces.
  • a NanoTab of the invention may be characterized by an erosion time of from 30 seconds up to a 1 minute, 2 minutes, 3 minutes, 4 minutes, 5 minutes, 10 minutes, 15 minutes, 30 minutes, 1 hour, 2 hours, 4 hours, 8 hours or longer.
  • the bioavailability of a drug following a single or following repeated oral transmucosal administration of a NanoTab ® of the invention to a subject is greater than 65%, greater than 75%, greater than 85%, greater than 90% or greater than 94%.
  • the NanoTabs ® of the invention are further characterized by a C max with a coefficient of variation of less than 30% or 40%; an AUC with a coefficient of variation of less than 30% or 40%; a T max with a coefficient of variation of less than 40%; a plasma half-life of from about 30 minutes to about 4 hours; and a therapeutic time ratio of greater than 0.07 or from about 0.5 to about 2.0 following a single oral transmucosal administration to a subject.
  • the amount of drug in the NanoTab ® that is absorbed via the oral transmucosal route is at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98% or at least 99% of the total amount of drug in the dosage form.
  • the invention further provides a method of treating a subject exhibiting a symptomatic medical condition, by administering a NanoTab ® of the invention as described herein such that the drug is effective to treat the symptomatic medical condition.
  • the symptomatic medical condition is pain, e.g., acute pain, breakthrough pain or post-operative pain and the NanoTab ® comprises an opioid such as sufentanil or a congener thereof.
  • Figure 1 is a graphic depiction of the in vitro dissolution kinetics of sufentanil NanoTab ® formulations #46-#48 which were used in the human clinical study described in Example 1.
  • the present invention provides an oral transmucosal dosage form or NanoTab ® that provides for high bioavailability, low variability in T ma ⁇ , low variability in C max and low variability in AUC.
  • the NanoTabs ® of the invention also provide for controlled dissolution, solubility and stability, resulting in controlled release of the drug over time resulting in prolonged plasma levels within the therapeutic window.
  • the invention is based on a small solid oral transmucosal dosage form or NanoTab ® , some embodiments of which adhere to the oral mucosa during the period of drug delivery.
  • the transmucosal dosage form minimizes the saliva response and therefore minimizes delivery of the drug to the GI tract, such that the majority of drug is delivered across the oral mucosa.
  • the following disclosure describes the NanoTab ® dosage forms which constitute the invention.
  • the invention is not limited to the specific dosage forms and methodology or medical conditions described herein, as such may, of course, vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the present invention.
  • NanoTab ® refers to a small volume dosage form that has a volume of from about 0 ul (microliters) to about lOOul and a mass of from about 0 mg (milligrams) to about lOOmg.
  • a NanoTab ® of the invention may or may not have bioadhesive characteristics and is a dissolvable drug-containing dosage form which may have characteristics of hydrogel-forming or eroding tablets.
  • formulation or “drug formulation” or “dosage form” as used herein refers to a physical entity containing at least one therapeutic agent or medication for delivery to a subject. It may be in the form of a lozenge, pill, tablet, capsule, membrane, strip, liquid, patch, film, gel, spray, gum or other form.
  • the terms "drug”, “medication”, “pharmacologically active agent” and the like are used interchangeably herein and generally refer to any substance that alters the physiology of an animal.
  • the NanoTabs ® of the invention may be used to deliver any drug that may be administered by the oral transmucosal route in an amount amenable to administration via the small size of the NanoTabs ® , i.e. 0.25 ⁇ g to 99.9mg, l ⁇ g to 50mg or l ⁇ g to 10mg.
  • drug as used herein with reference to a NanoTabs ® of the invention means any “drug”, “active agent”, “active”, “medication” or “therapeutically active agent” that can be effectively administered by the oral transmucosal route.
  • drug as applied to the treatment of pain (analgesia) includes sufentanil, sufentanil congeners, such as alfentanil, fentanyl, lofentanil, carfentanil, remifentanil, trefentanil, and mirfentanil, as well as dosage forms comprising one or more therapeutic compounds.
  • sufentanil or the phrase “sufentanil or a congener” is not meant to be limiting to use of, or dosage forms comprising only one of these selected opioid compounds.
  • sufentanil alone or to a selected sufentanil congener alone, e.g., reference to "fentanyl,” is understood to be only exemplary of the drugs suitable for delivery according to the methods of the invention, and is not meant to be limiting in any way.
  • a dosage form of the invention may include more than one therapeutic agent, wherein exemplary combinations of therapeutic agents include a combination of two or more opioid analogues, such as sufentanil plus an opioid such as alfentanil, fentanyl, lofentanil, carfentanil, remifentanil, trefentanil, and mirfentanil, or opium alkaloids such as morphine and codeine; semi-synthetic opioids such as heroin and oxycodone; and fully synthetic opioids such as pethidine and methadone, that have structures unrelated to the opium alkaloids, or any other drug that might be disinterred in combination.
  • opioid analogues such as sufentanil plus an opioid such as alfentanil, fentanyl, lofentanil, carfentanil, remifentanil, trefentanil, and mirfentanil
  • opium alkaloids such as morphine and codeine
  • subject includes any subject, generally a mammal (e.g., human, canine, feline, equine, bovine, ungulate etc.), in which treatment for a disorder, such as management of pain or anesthetization, is desired.
  • a mammal e.g., human, canine, feline, equine, bovine, ungulate etc.
  • mucosal membrane refers generally to any of the mucus-coated biological membranes in the body. Absorption through the mucosal membranes of the oral cavity is of particular interest. Thus, buccal, sublingual, gingival and palatal absorption are specifically contemplated by the present invention. In a preferred embodiment, the penetration enhancers of the present invention are used to improve absorption through those oral tissues which most resemble the skin in their cellular structure, i.e. the gingiva and palate.
  • transmucosal delivery of a drug and the like is meant to encompass all forms of delivery across or through a mucosal membrane.
  • oral transmucosal delivery of a drug includes delivery across any tissue of the mouth, pharynx, larynx, trachea, or upper gastrointestinal tract, particularly including the sublingual, gingival and palatal mucosal tissues.
  • oral dosage form oral transmucosal dosage form
  • oral transmucosal dosage form refers to a dosage form for use in practicing the present invention.
  • the oral dosage form is typically a "sublingual dosage form", but in some cases other oral transmucosal routes may be employed.
  • the invention relies upon such oral dosage forms for sustained delivery of drugs across the oral mucosa.
  • oral transmucosal drug delivery refers to a dosage form wherein drug delivery occurs substantially via the transmucosal route and not via swallowing followed by GI absorption.
  • the dosage forms of the current invention are designed to provide for a drug dissolution rate that allows for maximal delivery via the oral mucosa, typically via placement of the dosage form within the sublingual cavity.
  • sublingual means literally “under the tongue” and refers to a method of administering substances via the mouth in such a way that the substances are rapidly absorbed via the blood vessels under the tongue rather than via the digestive tract. Owing to the highly vascularized nature of the sublingual mucosal membrane and the reduced number of epithelial cell layers compared to other mucosal membranes, absorption of therapeutic substances occurs rapidly, thus allowing for direct access to the systemic circulation and thus quick onset of action while avoiding all complication of oral administration.
  • hydrogel-forming preparation means a solid formulation largely devoid of water which upon contact with bodily fluids, and in particular those in the oral mucosa, is capable of absorbing an aqueous solution such as water, in such a way that it swells, while maintaining a structural matrix and forms a hydrated gel in situ.
  • the formation of the gel follows unique disintegration (or erosion) kinetics while allowing for control of the therapeutic drug release over time, which occurs primarily by diffusion.
  • T max means the time point of maximum observed plasma concentration.
  • C max means the maximum observed plasma concentration.
  • AUC as used herein means "area under the curve" in a plot of concentration of drug in plasma versus time. AUC is usually given for the time interval zero to infinity, however, clearly plasma drug concentrations cannot be measured 'to infinity' for a patient so mathematical approaches are used to estimate the AUC from a limited number of concentration measurements. In a practical sense, the AUC (from zero to infinity) represents the total amount of drug absorbed by the body, irrespective of the rate of absorption. This is useful when trying to determine whether two formulations of the same dose release the same dose of drug to the body. The AUC of a transmucosal dosage form compared to that of the same dosage administered intravenously serves as the basis for a measurement of bioavailability.
  • TTR Therapeutic Time Ratio
  • disintegration means the physical process by which a tablet breaks down and pertains to the physical integrity of the tablet alone. This can occur via a number of different ways including breaking into smaller pieces and ultimately, fine and large particulates or, alternatively, eroding from the outside in until the tablet has disappeared.
  • dissolution means the process by which the active ingredient is dissolved from the tablet in the presence of a solvent, in vitro, or physiological fluids in vivo, e.g., saliva, irrespective of the mechanism of release, diffusion of erosion.
  • Swelling ratio means the mass ratio of the dosage form after full exposure to water as compared to its mass in the dry state prior to exposure.
  • such a 'swelling ratio 5 may be defined as the ratio of the volume of a dosage form of the invention following contact with water as compared to the volume of the same dosage form prior contact with water.
  • bioadhesion refers to adhesion to a biological surface more in general, including mucosal membranes.
  • terapéuticaally effective amount means an amount of a therapeutic agent, or a rate of delivery of a therapeutic agent (e.g., amount over time), effective to facilitate a desired therapeutic effect, such as pain relief.
  • desired therapeutic effect e.g., the degree of pain relief, and source of the pain relieved, etc.
  • the precise desired therapeutic effect will vary according to the condition to be treated, the tolerance of the subject, the drug and/or drug formulation to be administered (e.g., the potency of the therapeutic agent (drug), the concentration of drug in the formulation, and the like), and a variety of other factors that are appreciated by those of ordinary skill in the art.
  • sustained drug delivery refers to release or administration of a drug from a source (e.g., a drug formulation) over a protracted period of time, for example, over a period of a minute or more. Sustained drug delivery is in effect the opposite of bolus drug delivery.
  • a drug formulation is said to "adhere" to a surface, such as a mucosal membrane, it is meant that the formulation is in contact with the surface and is retained upon the surface without the application of an external force. Adhesion is not meant to imply any particular degree of sticking or bonding, nor is it meant to imply any degree of permanency.
  • active agent or “active” may be used interchangeably herein with the term “drug” and is used herein to refer to any therapeutically active agent.
  • non-occlusive is used herein in its broadest sense to refer to not trapping or closing the skin to the atmosphere by means of a patch device, fixed reservoir, application chamber, tape, bandage, sticking plaster, or the like which remains on the skin at the site of application for a prolonged length of time.
  • mucosal-depot is used herein in its broadest sense to refer to a reservoir or deposit of active agent within or just beneath the mucosal membrane.
  • mucoadhesion is used herein in to refer to adhesion to mucosal membranes which are covered by mucus, such as those in the oral cavity and is used 2007/000529
  • bioadhesion refers to adhesion to any biological surface.
  • drug delivery device is used interchangeably herein with the term “dispensing device” and means a device that dispenses oral transmucosal dosage forms such as a NanoTab ® of the invention, comprising a formulation as further described herein.
  • the present invention provides oral transmucosal drug delivery dosage forms or NanoTabs ® , that produce a reduced saliva response when compared with other oral dosage forms, thus providing high absorption rates of the pharmaceutically active substance provided in the dosage form across the oral mucosa, and reduced uptake via the gastrointestinal tract and therefore offering a more consistent and reproducible means of drug delivery.
  • the oral dosage form or NanoTab ® is typically a "sublingual dosage form", but in some cases other oral transmucosal routes may be employed.
  • the invention relies upon such oral dosage forms for sustained delivery of drugs across the oral mucosa.
  • the dosage form is a substantially homogeneous composition which comprises one or more active ingredients and may comprise one or more of: mucoadhesives (also referred to herein as "bioadhesives") that provide for adherence to the mucosa of the mouth of a patient; one or more binders that provide binding of the excipients in a single tablet; one or more hydrogel forming excipients; one or more bulking agents; one or more lubricants; one or more absorption enhancers; one or more buffering excipients; as well as coatings and other excipients and factors that modify and control the drug's dissolution time and kinetics or protect the active drug from degradation.
  • mucoadhesives also referred to herein as "bioadhesives”
  • bioadhesives also referred to herein as "bioadhesives”
  • binders that provide binding of the excipients in a single tablet
  • hydrogel forming excipients one or more bulking agents
  • Sublingual delivery is preferred as the sublingual mucosa is more readily permeable to medications than other mucosal areas, such as the buccal mucosa, resulting in more rapid uptake (Shojaei AH, et al. Buccal mucosa as a route for systemic drug delivery: a review. Journal of Pharmacy and Pharmaceutical Sciences. 1:15-30, 1998).
  • NanoTabs ® of the invention provide for the delivery of a greater percentage (and amount) of drug via the oral mucosa and a corresponding decrease in delivery via the GI tract as compared to traditional oral dosage forms or clinically used oral transmucosal dosage forms.
  • the preferred site for oral transmucosal drug delivery is the sublingual area, although in certain embodiments it may be advantageous for the dosage form to be placed inside the cheek, or to adhere to the roof of the mouth or the gum.
  • the dosage forms of the invention are adapted for oral transmucosal (for example sublingual) delivery of a drug and typically have a dissolution time of up to about 60 minutes, in some cases up to about 120 minutes and in other cases as long as several hours.
  • Application of the drug delivery dosage forms of the present invention is not limited to any particular therapeutic indication. Examples of application of the drug delivery dosage forms of the invention for the treatment of pain are provided herein, however, the NanoTabs ® of the invention find utility in treatment of any of a number of medical conditions and disorders, and are not limited to any particular drug or patient population. As such, use of the NanoTabs ® of the invention administration of drugs to finds utility in administration of drugs to both pediatric and adult populations and in treatment of human and non-human mammals.
  • NanoTabs ® of the invention finds utility in administration of drugs to pediatric and adult populations and in treatment of human and non-human mammals, as well as in opioid tolerant and opioid na ⁇ ve patient populations.
  • the dosage forms or NanoTabs ® of the invention are generally adapted to adhere to the oral mucosa (i.e. are bioadhesive) during the period of drug delivery, and until most or all of the drug has been delivered from the dosage form to the oral mucosa.
  • the dosage forms or NanoTabs ® of the invention are not bioadhesive.
  • a NanoTab ® of the invention has a volume of from about OuI (microliters) to about 10OuI 5 a mass of from about Omg (milligrams) to about lOOmg, athickness of from about 0.1mm to about 10.0mm, e.g., from about 0.5 to about 3.0 mm; and a diameter of from about 1.0mm to about 30.0mm, from about 1.0mm to about 10.0mm, e.g., about 3.0mm.
  • a NanoTab ® of the invention has a mass selected from the group consisting of less than lOOmg, less than 90mg, less than 80mg, less than 70mg, less than 60mg, less than 50mg, less than 40mg, less than 30mg, less than 20mg and less than 10mg.
  • a NanoTab ® of the invention may also have a volume selected from the group consisting of less than lOO ⁇ l, less than 90 ⁇ l, less than 80 ⁇ l, less than 70 ⁇ l, less than 60 ⁇ l, less than 50 ⁇ l, less than 40 ⁇ l, less than 30 ⁇ l, less than 20 ⁇ l and less than lO ⁇ l.
  • NanoTab ® dosage forms of the invention may have essentially any shape that fits the parameters recited herein with respect to NanoTab ® dimensions.
  • Exemplary shapes are selected from the group consisting of a round disc with a flat, concave, or convex face, an ellipsoid shape, a spherical shape, a polygon with three or more edges and flat, concave, or convex faces.
  • NanoTab ® shapes may be symmetrical or asymmetrical, and may have features or geometries that allow for controlled, convenient, or easy storage, handling, packaging or dosing. Figure 6 illustrates some of these shapes.
  • Oral vs. GI uptake In general, greater than 30%, greater than 50%, greater than 75% or greater than 95-99% of the drug in a NanoTab ® of the invention is taken up via the oral mucosa.
  • the NanoTab ® is adapted to deliver 30% or more of the total amount of drug contained in a single drug dosage form to an individual via the oral mucosa.
  • the percentage of the total amount of drug contained in a single drug dosage delivered transmucosally may be greater than 30-40%, 40-50%, 60-70%, 70- 80%, 80-90% and preferably greater than 95%.
  • at least 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98% or 99%, of the total amount of drug contained in a single drug dosage form is delivered via the oral mucosa.
  • the Delivery of a greater percentage (and amount) of drug via the oral mucosa and the corresponding lack of delivery via the GI tract provides a significant improvement over prior methods of drug delivery.
  • Reduced Saliva Response The NanoTab ® drug dosage forms of the present invention are designed and adapted to reduce the saliva response, reducing the amount of drug swallowed, and thereby delivering a substantial amount of drug to a subject via the oral mucosa.
  • the NanoTabs ® of the invention also provides oral transmucosal dosage forms with improved dissolution profiles over previously described oral or oral transmucosal dosage forms, efficacious delivery of drug via the oral mucosa, and a consistent plasma level within the therapeutic window.
  • Erosion time The dosage forms of the invention are designed to provide for an erosion rate that allows for maximal delivery via the oral mucosa, typically via placement of the dosage form in the sublingual location. Erosion times for sublingual administration of the a NanoTab ® of the invention is typically from about 30 seconds up to 1 minute, 2 minutes, 3 minutes, 4 minutes, 5 minutes, 10 minutes, 15 minutes, 30 minutes, 1 hour, 2 hours, 4 hours and 8 hours.
  • Dissolution time The oral transmucosal formulations of the present invention are typically designed to achieve drug dissolution times of that will vary from 30 seconds up to 1 minute, 2 minutes, 3 minutes, 4 minutes, 5 minutes, 10 minutes, 15 minutes, 30 minutes, 1 hour, 2 hours, 4 hours, 8 hours or longer dependent upon the patient and circumstances of drug administration as well as the intrinsic drug pharmacokinetics. It will be understood that the composition of the oral transmucosal formulations of the present invention may be adjusted to provide for both a range of doses and a range of dissolution times to fit particular clinical situations.
  • a pharmaceutical dosage form of the invention for oral transmucosal delivery may be solid or non-solid.
  • the dosage from is a solid that turns into a hydrogel following contact with saliva.
  • the dosage from is a solid that erodes without forming a hydrogel following contact with saliva.
  • a dosage form of the invention is a substantially homogeneous formulation which comprises 0.01-99% w/w of the active ingredient(s) (drug, medication, etc.) and further comprises one or more of: mucoadhesives (also referred to herein as "bioadhesives") that provide for adherence to the mucosa of the mouth of a patient; one or more binders that provide binding of the excipients in a single tablet; one or more hydrogel forming excipients; one or more bulking agents; one or more lubricants; one or more absorption enhancers; one or more buffering excipients; one or more coatings; one or more controlled release modifiers; and one or more other excipients and factors that modify and control the drug's dissolution or disintegration time and kinetics or protect the active drug from degradation.
  • mucoadhesives also referred to herein as "bioadhesives”
  • bioadhesives also referred to herein as "bioadhe
  • Excipients are not limited to those above, and numerous suitable nontoxic pharmaceutically acceptable carriers for use in oral dosage forms can be found in Remington's Pharmaceutical Sciences, 17th Edition, 1985.
  • the dosage forms of the invention for oral transmucosal drug delivery may include at least one bioadhesive (mucoadhesive) agent or a mixture of several bioadhesives to promote adhesion to the oral mucosa during drug delivery.
  • bioadhesive or mucoadhesive agents may also be effective in controlling the dosage form erosion time and/or, the drug dissolution kinetics over time when the dosage form is wetted by saliva.
  • some of the mucoadhesives named in this invention may also serve as binders in the formulation to provide necessary bonding to the dosage form.
  • Exemplary mucoadhesive or bioadhesive materials are selected from the group consisting of natural, synthetic or biological polymers, lipids, phospholipids, and the like.
  • natural and/or synthetic polymers include cellulosic derivatives (such as methylcellulose, carboxymethyl cellulose, hydroxyethyl cellulose, hydroxyethylmethyl cellulose, etc) , natural gums (such as guar gum, xanthan gum, locust bean gum, karaya gum, veegum etc), polyacrylates (such as carbopol, polycarbophil, etc), alginates, polyoxyethylenes, polyethylene glycols (PEG) of all molecular weights (preferably between 1000 and 40,000 Da, of any chemistry, linear or branched), dextrans of all molecular weights (preferably between 1000 and 40,000 Da of any source), block copolymers, such as those prepared by combinations of lactic & glycolic acid (PLA, PGA, PLGA of various
  • polyethylene glycols from the group of polyethylene glycols, polyoxyethylenes, polyacrylic acid polymers, such as Carbopols (such as Carbopol 71G- 934P, 971P 974P) and polycarbophils (such as Noveon AA-I , Noveon CA-I, Noveon CA-2), cellulose and its derivatives and most preferably it is polyethylene glycol, carbopol, and/or a cellulosic derivative or a combination thereof.
  • Carbopols such as Carbopol 71G- 934P, 971P 974P
  • polycarbophils such as Noveon AA-I , Noveon CA-I, Noveon CA-2
  • the mucoadhesive/bioadhesive is typically present at 1-50% w/w, preferably 1-40% w/w or most preferably between 5-30% w/w.
  • a formulation of the invention may contain one or more different bioadhesives in any combination.
  • the dosage forms of the invention for oral transmucosal drug delivery may also include a binder or mixture of two or more binders which facilitate binding of the excipients into a single dosage form.
  • binders are selected from the group consisting of cellulosic derivatives (such as methylcellulose, carboxymethyl cellulose, hydroxyethyl cellulose, hydroxyethylmethyl cellulose, etc), polyacrylates (such as Carbopol, polycarbophil, etc), Povidone (all grades), Polyox of any molecular weight or grade irradiated or not, starch, polyvinylpyrrolidone (PVP), Avicel, and the like.
  • PVP polyvinylpyrrolidone
  • the binder is typically present at 0.5-60% w/w, preferably 1-30% w/w and most preferably 1.5-15% w/w.
  • the dosage forms of the invention for oral transmucosal drug delivery may further include one or more hydro gel-forming excipients.
  • the dosage forms of the invention for oral transmucosal drug delivery may also include at least one controlled release modifier which is a substance that upon tablet hydration will preferentially adhere to the drug molecules and thus reduce the rate of its diffusion from the oral dosage form. Such excipients may also reduce the rate of water uptake by the formulation and thus enable a more prolonged drug dissolution and release from the tablet.
  • controlled release modifiers are capable of binding molecularly to the active via physical (and therefore reversible) interactions, thus increasing the effective molecular weight of the active and thus further modifying their permeation (diffusion) characteristics through the epithelial and basal membranes of the sublingual mucosa.
  • Such binding is reversible in nature and does not involve any chemical modifications of the active, thus it does not affect in any way its pharmacological action.
  • such controlled release modifiers upon hydration may form concrete structures that may entrap spontaneously the active and thus further prolong its action.
  • Exemplary controlled release modifiers are selected from the group consisting of lipids, phospholipids, sterols, surfactants, polymers and salts.
  • the selected excipient(s) are lipophilic and capable of naturally complexing to the hydrophobic or lipophilic drugs.
  • the degree of association of the release modifier and the drug can be varied by altering the modif ⁇ er-to-drug ratio in the formulation.
  • the controlled release modifier may be a charged polymer either synthetic or biopolymer bearing a net charge, either positive or negative, and which is capable of binding to the active via electrostatic interactions thus modifying both its diffusion through the tablet and/or the kinetics of its permeation through the mucosal surface.
  • a controlled release modifier may typically be present at 0-80% w/w, preferably 1- 20% w/w, most preferably 1-10% w/w.
  • the dosage forms of the invention for oral transmucosal drug delivery also typically include at least one filler (bulking agent).
  • exemplary bulking agents are selected from the group consisting of lactose USP, Starch 1500, mannitol, sorbitol, malitol or other non-reducing sugars; microcrystalline cellulose (e.g., Avicel), dibasic calcium phosphate dehydrate, sucrose, and mixtures thereof.
  • the filler/bulking agent is typically present at 20-99% w/w, preferably 40- 80% w/w.
  • the dosage forms of the invention for oral transmucosal drug delivery may also include at least one lubricant.
  • exemplary lubricants are selected from the group consisting of magnesium stearate, stearic acid, calcium stearate, talc, stearowet and sterotex and the like.
  • the lubricant is typically present at 0.01-8% w/w, preferably between 0.1-3% w/w.
  • the formulation may also contain flavors or sweeteners and colorants such as aspartame, mannitol, lactose, sucrose, other artificial sweeteners; ferric oxides and FD&C lakes.
  • flavors or sweeteners and colorants such as aspartame, mannitol, lactose, sucrose, other artificial sweeteners; ferric oxides and FD&C lakes.
  • the formulation may also contain additives to help stabilize the drug substance from chemical of physical degradation.
  • degradation reactions may include oxidation, hydrolysis, aggregation, deamidation, etc.
  • Appropriate excipients that can stabilize the drug substance may include anti-oxidants, anti-hydrolytic agents, aggregation-blockers etc.
  • Anti-oxidants may include BHT, BHA, vitamins, citric acid, EDTA etc.
  • Aggregation blockers may include surfactants, amino-acids, etc.
  • the formulation may also contain surfactants to increase wetting of the tablet, especially if faster release kinetics are desired, which could result in faster initiation of mucoadhesion.
  • surfactants should be from 0.01 to 3% weight percent of the composition.
  • Exemplary surfactants are selected from the group consisting of ionic (sodium lauryl sulfate, etc), non-ionic such as polysorbates (T ween and Span surfactant series), bile salts (such as sodium taurocholate, sodium taurodeoxycholate, sodium glycodeoxycholate, sodium glycocholate, etc), various alkyl glycosides, and mixtures thereof.
  • a dosage form of the invention may additionally comprise one or more excipients that may affect both tablet disintegration kinetics and drug release from the tablet, and thus pharmacokinetics.
  • Such additives are disintegrants such as those known to those skilled in the art and may be selected from a group consisting of starch, carboxy-methycellulose type or crosslinked Polyvinyl Pyrrolidine (such as cross-povidone, PVP-XL), alginates, cellulose-based disintegrants (such as purified cellulose, methylcellulose, crosslinked sodium carboxy methylcellulose (Ac-Di-SoI) and carboxy methyl cellulose), microcrystalline cellulose (such as Avicel), ion exchange resins (such as Ambrelite IPR 88), gums (such as agar, locust bean, karaya, Pectin and tragacanth), guar gums, gum Karaya, chitin and chitosan, Smecta, gellan gum, Isapg
  • disintegrants are used at a low level in the solid dosage form, typically 1 — 20 % w/w relative to the total weight of the dosage unit.
  • the dosage forms comprise at least one biodegradable polymer of any type useful for extended drug release.
  • exemplary polymer compositions include polyanhydrides and co-polymers of lactic acid and glycolic acid, poly(dl-lactide-co-glycolide) (PLGA), poly(lactic acid) (PLA), poly(glycolic acid) (PGA), polyorthoesters, proteins, and polysaccharides.
  • the dosage forms of the invention for oral transmucosal drug delivery may further include one or more absorption enhancers, one or more buffering excipients and/or one or more coatings to improve, for example, hardness and friability.
  • the active ingredient can be chemically modified to significantly modify the pharmacokinetics in plasma. This may be accomplished for example by conjugation with polyethylene glycol (PEG), including site-specific PEGylation. PEGylation, which may improve drug performance by optimizing pharmacokinetics, decreasing immunogenicity and dosing frequency.
  • PEG polyethylene glycol
  • TheNanoTabs ® of the present invention are provided in a number of dosage forms that vary according to the nature and amount of active ingredients while maintaining the features of the NanoTabs ® of the invention for controlled dissolution in the oral cavity. Thus, a greater percentage of drug absorption takes place via the oral mucosal route and not the GI route and resulting in controlled release of the drug over time resulting in prolonged plasma levels within the therapeutic window.
  • the " NanoTabs ® of the present invention further provide for high bioavailability, low variability in T m3x , low variability in C ma ⁇ and low variability in AUC.
  • a homogeneous dosage form comprising a formulation according to the present invention
  • a homogeneous dosage form comprising a formulation according to the present invention
  • the dosage form adheres upon contact.
  • the dosage form absorbs water, resulting in the formation of a hydrogel network, comprising micro- and macro-pores (or channels). Hydration of the drug affects dissolution and subsequent diffusion through the porous network of the dosage form.
  • Hydrogel dosage forms of the invention are characterized by swelling to at least 110% of the initial volume upon contact with an aqueous solution.
  • Hydrogel formation in the dosage forms of the invention takes place in the presence of certain hydrogel-enabling excipients that have the capacity to absorb water and form gels.
  • excipients include Polyox of all grades, polyethylene glycols (of all grades), PEG-based copolymers, whether homopolymers or heteropolymers (such as Poloxamer, etc), Dextran, HPMC, starch, etc, as detailed above.
  • any combination of such excipients may favor hydrogel formation upon contact with bodily fluids.
  • dosage forms referred to herein as “eroding-type” dosage forms are provided.
  • Such “eroding-type” dosage forms although they may absorb significant amounts of water (depending on their composition) they do not have the same capacity of swelling and consequently they do not form gels as described for the hydrogel type formulations defined above. These "eroding-type” formulations adhere to the sublingual cavity upon contact, similar to the hydrogel formulation.
  • Such eroding-type dosage forms are typically characterized by a lack of inclusion of hydro gel-forming excipients.
  • the percentage weight to weight (w/w) composition of the various components of the dosage form will impact the mechanism of erosion.
  • small amounts of particular hydrogel-enabling excipients may not induce formation of a hydrogel and as such, some hydrogel-enabling excipients may be included in eroding formulations without changing their erosion-based disintegration mechanism. It is both the combination of excipients and their percent weight composition that gives a hydrogel its capacity to swell and maintain a structural matrix upon contact with an aqueous solution.
  • a hydrogel-enabling excipient in a given formulation will not necessarily make the dosage form "swell" as is typical of a hydrogel formulation.
  • a dosage form which becomes a hydrogel swells to at least 110% of its initial volume upon contact with an aqueous fluid.
  • the dosage forms of the present invention are designed to work effectively in the unique environment of the oral cavity such that a limited amount of fluid, a relatively short US2007/000529
  • the dosage forms are also designed to improve dissolution, solubility, and stability of the drug.
  • the advantages of the present invention include the ability to provide higher levels of drug absorption via oral transmucosal delivery, and consistent dose-to-effect times, making the present formulation a significant improvement for the treatment of acute or break-through pain.
  • the oral transmucosal dosage forms of the present invention are designed to avoid the high peak plasma levels of intravenous dosage forms by utilizing the sublingual mucosa and by independently controlling both tablet disintegration (or erosion) and drug dissolution and release from the tablet over time to provide a safer delivery profile.
  • the oral transmucosal dosage forms of the present invention provide individual, repetitive doses that include a defined amount of the active agent, thereby allowing the patient to accurately titrate the amount of drug delivered and to adjust the amount as appropriate in a safe and effective manner.
  • An advantage of the controlled-release oral transmucosal dosage forms described in this invention is that they exhibit high consistent bioavailability and can maintain the plasma drug concentration within a targeted therapeutic window with significantly lower variability for a longer duration than currently available dosage forms, whether solid dosage forms or IV dosage forms.
  • the high peak plasma levels typically observed for IV dosage forms are blunted following administration of a NanoTab ® of the invention, which are characterized by controlled release of the drug over 1 to 60 minutes or longer.
  • a rapid decline in plasma levels is avoided since the drug is continually crossing from the oral cavity into the bloodstream during the length of time of dissolution of the tablet or longer, thus providing plasma pharmacokinetics with an extended plateau phase as compared to the IV route of administration.
  • the dosage forms of this invention may improve treatment safety by minimizing the potentially deleterious side effects due to the relative reduction of the peaks and troughs in the plasma drug pharmacokinetics, which compromise treatment safety and is typical of currently available dosage forms.
  • a solid sublingual dosage form over various liquid forms for either sublingual or intranasal administration of opioids include the controlled local release of the solid dosage form and the avoidance of swallowed liquid drug via either the nasal or oral route.
  • Published pharmacokinetic data on intranasal sufentanil liquid administration (15 meg) in humans demonstrates a bioavailability of 78% (Helmers et al. Comparison of intravenous and intranasal sufentanil absorption and sedation. Canadian Journal of Anaesthesia 36:494-497, 1989).
  • Sublingual liquid sufentanil administration (5 meg) in Beagle dogs resulted in a bioavailability of 40%.
  • the aforementioned bioavailability data are less than the 91% average bioavailability that was obtained in human volunteers using sufentanil administered sublingual Iy in the form of aNanoTab ® of the invention (see Example 1 below).
  • NanoTabs ® Due to the small size of the NanoTabs ® , repeated placement in the sublingual cavity over a duration of time is possible. Minimal saliva production and minimal physical discomfort occurs due to the small size, which allows for repetitive titration over days to weeks to months. Given the lipid profile of the sublingual cavity, this route, for certain drugs, also allows for slower release into the plasma which may be due to utilization of a "depot" effect that further stabilizes plasma levels compared to buccal delivery.
  • the oral transmucosal dosage forms of the invention are designed to fit comfortably under the tongue such that the drug form disintegrates sufficiently slowly to avoid the immediate peak plasma levels followed by significant drop off seen in prior art formulations such as described in US. Patent No. 6,759,059 (Rapinyl), wherein fentanyl was administered via tablets containing 400mcg of fentanyl which resulted in a peak plasma level of 2.5ng/ml followed by an immediate drop in plasma level.
  • Fentora fentanyl buccal tablet
  • Fentora package insert also suffers from a lack of a plateau phase but rather has a steep incline up to the C ma ⁇ followed by a significant drop-off in plasma levels
  • a human clinical study was performed using healthy volunteers. The study which is detailed in Example 1 below was performed with 12 subjects (6 men and 6 women) using sublingual sufentanil NanoTabs ® containing either 2.5 ⁇ g, 5 ⁇ g or 10 ⁇ g of sufentanil base corresponding to 3.7 ⁇ g, 7.5 ⁇ g or 15 ⁇ g of sufentanil citrate, respectively (see Table 1). AU excipients were inactive and have GRAS ("generally recognized as safe”) status.
  • Sufentanil NanoTabs ® designed for sublingual use were compared to IV sufentanil, administered through an IV catheter as a continuous infusion over 10 minutes. Plasma samples were drawn from a different IV catheter at a remote location. The assay demonstrated good inter- day precision and accuracy at the high, medium and low quality control sample concentrations.
  • NanoTabs for this study eroded over a period of 10-30 minutes in all subjects.
  • a remarkably consistent pharmacokinetic profile was obtained (see Figure 2 and Table 2).
  • the bioavailability compared to IV administration for single administration of all three dosages averaged 91%, which is far superior to that measured for commercially available fentanyl transmucosal preparations, Actiq and Fentora (47% and 65%, respectively — Fentora package insert).
  • this high bioavailability is also linked to high consistency of total drug delivered to the patient.
  • the total plasma drug area under the curve (AUC 0- infinity) for sufentanil NanoTabs ® lOmcg was 0.0705 + 0.0194 hr*ng/ml (mean ⁇ standard deviation (SD)).This SD is only 27.5% of the total AUC.
  • Coefficient of variation (CV) is a term to describe the percent SD of the mean.
  • the coefficient of variation for Fentora AUC is 45% and for Actiq AUC is 41% (Fentora package insert). Therefore the total dose delivered to the patient/subject is not only more bioavailable for the sufentanil NanoTabs ® but it is more consistently the same from patient to patient.
  • the sufentanil sublingual NanoTabs ® are also superior in terms of consistent drug plasma levels early after administration.
  • the C max obtained with the 10 meg sufentanil NanoTab ® was 27.5 + 7.7 pg/ml.
  • the coefficient of variation of the C max therefore is only 28%.
  • the C max for Fentora and Actiq suffer from variability of GI uptake of drug.
  • Fentora reports a Cmax of 1.02 + 0.42 ng/ml, therefore the coefficient of variation of the C max is 41%.
  • the range of coefficients of variation for the various doses of Fentora is from 41% to 56% (package insert). Actiq coefficient of variation of C max is reported as 33% (Fentora package insert).
  • the time to Cmax is important since quick and consistent onset of pain relief is important in the treatment of acute pain.
  • the T roax for sufentanil NanoTabs ® 10 meg was 40.8 + 13.2 minutes (range 19.8 - 60 minutes).
  • the reported average T max for Fentora is 46.8 with a range of 20 — 240 minutes.
  • the T ma ⁇ for Actiq is 90.8 minutes, range 35 — 240 minutes (Fentora package insert). Therefore the consistency in onset of analgesia for sufentanil NanoTabs ® is markedly improved over Fentora and Actiq, with a 400% decrease in the slowest onset of T max .
  • the coefficient of variation of the AUC (0-infinity) for Rapinyl ranges from 25-42% depending on dose, whereas our value is 27.5% for the 10 meg sufentanil NanoTabs ® .
  • Our high bioavailability would suggest that regardless of dose, the sufentanil NanoTabs ® will have a consistently low variation of AUC, whereas this is not true for Rapinyl.
  • our AUC coefficient of variation for all three of the doses of sufentanil NanoTabs ® averaged 28.6%, demonstrating that this low variation is not dependent on dose.
  • Rapinyl demonstrates a longer plasma elimination half-life (5.4 — 6.3 hours, depending on dose) than sufentanil NanoTabs ® .
  • the plasma elimination half-life of sufentanil NanoTabs ® ranged from 1.5 — 2 hours following a single oral transmucosal administration in humans (Table 2), which allows for more titratability and avoids overdosing.
  • the half-life described herein for the exemplified NanoTabs ® may be adjusted by modification of the component and relative amounts of the excipients in the formulation used to make a given NanoTab ® .
  • the elimination half-life is an intrinsic property of the molecule and is measured most reliably using the IV route to avoid contamination from continued uptake of drug from the sublingual route.
  • the IV elimination half-life for 5 meg of sufentanil in our human study was 71.4 minutes due to the detection limits of the assay at these low doses.
  • the published IV elimination half-life for sufentanil at much higher doses is 148 minutes, due to detection of both the rapid alpha-elimination mechanism of redistribution and the longer beta phase of elimination via metabolism and excretion. This published elimination half-life is more accurate and more appropriate to use in the above equation.
  • the Therapeutic Time Ratio for these specific sufentanil NanoTabs ® ranged from 0.72 — 0.75.
  • erosion time of the NanoTab ® will be either decreased or increased, and one might see a range of Therapeutic Time Ratios from approximately 0.2 — 2.0 for sufentanil.
  • any oral transmucosal dosage form of the invention for sufentanil may exhibit Therapeutic Time Ratios in this range and therefore we are not limiting this claim to specific NanoTab attributes.
  • This Therapeutic Time Ratio is a measure of how successfully short-acting drugs are formulated to produce an increase in therapeutic time and increase safety by avoiding high peak plasma C ma ⁇ concentrations.
  • This low ratio value for the IV arm therefore, is a measure of the high peak produced by IV infusion of sufentanil and demonstrates that this formulation does not produce a significant plateau phase.
  • the first Beagle dog study was carried out to compare a sublingual 5 meg sufentanil NanoTab to IV sufentanil as described more fully in Example 2 below.
  • a total of three Beagle dogs were studied and the results are graphed in Figure 3 and tabulated in Table 3.
  • the bioavailability of the sublingual sufentanil NanoTabs ® was 75% compared to IV. Therefore, similar to the human data, this bioavailability data in dogs confirms the superior attributes of the NanoTab ® over larger dosage forms.
  • the coefficient of variation for the AUC was low, 14%, compared to the variation of other commercial transmucosal dosage forms.
  • the Therapeutic Time Ratio of the sublingual sufentanil NanoTab ® is 0.28 whereas the Ratio for IV sufentanil is 0.05 (using the published IV elimination half-life of sufentanil in dogs of 139 minutes). Therefore, similar to humans, the 5 meg NanoTab ® formulation in Table 1 resulted in a much higher Therapeutic Time Ratio (5.6-fold) compared to IV sufentanil in dogs.
  • the NanoTabs ® 's strong adherence in the sublingual cavity minimizes the variability in the surface area available for absorption, as is the case of a liquid solution, thus improving delivery of the molecule to the systemic circulation.
  • the NanoTab ® does not elicit significant saliva production, thus reducing the potential for ingestion of the released drug. Both factors contribute to the higher and more uniform drug absorption from the sublingual cavity.
  • the swallowed NanoTabs ® demonstrated extremely high variability both in the amount of drug absorbed (AUC) and the pharmacokinetics of absorption (C max , T max ) as shown in Table 7.
  • NanoTab ® can effectively deliver a variety of drugs sublingually with high bioavailability.
  • Fentanyl NanoTabs ® were created in both a medium and a slow disintegrating NanoTab ® formulations (see Tables 8 and 9). Both formulations resulted in high bioavailability (95% and 90%, respectively), much higher than with any other fentanyl oral transmucosal formulation patented to date.
  • the coefficient of variation of the AUCs was extremely low (10.5% and 4.5%, respectively).
  • Alfentanil NanoTabs ® resulted in a bioavailability of 94% compared to IV alfentanil and a coefficient of variation of 5% for the AUC 5 7% for C max and 28% for T max .
  • the Therapeutic Time Ratio was calculated as 0.33, compared to 0.04 for the IV alfentanil arm of this study (calculated using a published IV elimination half-life of 104 min for alfentanil in dogs). Therefore, the alfentanil NanoTab ® formulation (as described in Example 6) produces an 8-fold improved Therapeutic Time Ratio over the IV alfentanil arm.
  • the high bioavailability of this formulation again supports the claim that minimal swallowing of drug occurs with use of the NanoTab ® .
  • the mucoadhesive strength is determined by attaching the tablets to the bottom of a hanging platform and determining the force required to detach the formulations from a porcine buccal mucosa substrate.
  • the mucoadhesive testing system consisting of a precision load cell (GS-500 Tranducer techniques, Temecula, CA) and a hook attachment.
  • the load cell generates analogue signals, which are converted into digital signals through a data acquisition system equipped with an A/D converter (Model 500 A, Keithley Metrabyte, Taunton, MA) and an IBM computer. Data were analyzed using EasyLx software (Keithley Metrabyte).
  • a hanging platform comprised of a glass slide attached with plastic plunger (8 cm) on the top and a circular-steel projection (0.5cm) with flat surface on the bottom is attached to the load cell.
  • a flat-surfaced tablet die serves as a lower static-platform.
  • the mucosa is mounted onto the lower platform using a screw-clamp. To determine the force of adhesion, the optimum level of that variable is kept constant in the subsequent evaluations. Between each measurement, the mucosal surface is rinsed with 4 mL of purified water. The excess water is wiped with a soft tissue paper and the mucosa is wetted with a known volume of phosphate buffer of pH 6.8.
  • the hanging platform with the film is brought down and placed over the surface of mucosa with a known applied force for a required time.
  • the detachment force is measured and converted to N/cm2. Studies are performed in triplicate at room temperature (23-25 0 C). Adhesion and peak detachment force can be used to evaluate the bioadhesive strength of dosage forms comprising various formulations of the invention.
  • Drug dissolution kinetics is determined by a standard USP dissolution apparatus, such as Type I, II and/or Type IV, suitably modified for a given dosage form such as a dosage form containing a very small amount of active drug. Drug release from the dosage form can be monitored using one of the standard analytical methods, such as UV spectrophotometry, HPLC or LC/MS.
  • the dissolution medium is defined as a physiological buffer such as phosphate, Tris or other at a pH range between 6.5-7.8.
  • a dosage form of the invention may be manufactured to have a dissolution time from 30 seconds up to 1 minute, 2 minutes, 3 minutes, 4 minutes, 5 minutes, 10 minutes, 15 minutes, 30 minutes, 1 hour, 2 hours, 4 hours, 8 hours or longer.
  • Dosage form erosion can be monitored by observing the disappearance over time of the sublingual NanoTab ® by visual examination. Complete dosage form erosion may be evident by visual examination in about 30 seconds up to 1 minute, 2 minutes, 3 minutes, 4 minutes, 5 minutes, 10 minutes, 15 minutes, 30 minutes, 1 hour, 2 hours, 4 hours or as long as 8 hours or longer, dependent upon the patient and circumstances of drug administration as well as the intrinsic tablet excipients. It will be understood that the composition of the oral transmucosal formulations of the present invention may be adjusted to provide for both a range of doses and a range of erosion times to fit particular clinical situations.
  • the invention provides small volume dosage forms or NanoTabs ® for oral transmucosal delivery of a formulation comprising any drug that can be delivered by the oral transmucosal route and in an amount that is appropriate to the small size of the NanoTab ® .
  • One example of use of the NanoTabs ® of the invention is with application to pain-relief.
  • the NanoTabs ® of the invention When used for treatment of pain, they will comprise a drug such as an opioid or opioid agonist, for the treatment of acute or break-through pain.
  • Opioids are powerful analgesics and are utilized to treat both acute and chronic pain of moderate to severe intensity throughout the world. However, they can also have severe respiratory depressive effects if not used appropriately and they also suffer from a high abuse potential.
  • Opioids are still widely used for the treatment of pain, and are generally delivered intravenously, orally, epidurally, transdermally, rectally and intramuscularly. Morphine and its analogues are commonly delivered intravenously and are effective against severe, chronic and acute pain.
  • Opioids exert their actions via the mu opioid receptor, which is located on peripheral nerve terminals, both pre- and post-synaptically in the spinal cord, brainstem, mid-brain and cortical regions associated with sensory and pain processing.
  • the active agent in such formulations may include sufentanil, or a sufentanil congener such as alfentanil, fentanyl, lofentanil, carfentanil, remifentanil, trefentanil, or mirfentanil.
  • sufentanil as the active agent.
  • Another preferred embodiment utilizes a sufentanil congener as the active agent.
  • Yet another preferred embodiment utilizes a combination of sufentanil and at least one additional agent for treatment of analgesia as the active agent.
  • the active agent may also include any opioid or opioid agonist such as morphine or a derivative thereof.
  • a dosage form of the invention may comprise at least 0.001% percent by weight of the pharmaceutically active ingredient.
  • the pharmaceutically active drug is typically present in a therapeutically effective amount from about 0.25 ⁇ g to 99.9mg, from about l ⁇ g to 50mg or from about l ⁇ g to lOmg.
  • the dosage form comprises from about at least 0.005% to as much as 99.9% by weight, e.g., from about 0.25 ⁇ g to 99.9mg, from about 1 ⁇ g to 50mg or from about 1 ⁇ g to 1 Omg of sufentanil; a sufentanil congener such as alfentanil, fentanyl, lofentanil, carfentanil, remifentanil, trefentanil, or mirfentanil.
  • a sufentanil congener such as alfentanil, fentanyl, lofentanil, carfentanil, remifentanil, trefentanil, or mirfentanil.
  • a formulation of the invention includes a combination of two or more opioid analogues, such as sufentanil plus an opioid such as sufentanil, alfentanil, fentanyl, lofentanil, carfentanil, remifentanil, trefentanil or mirfentanil.
  • opioid analogues such as sufentanil plus an opioid such as sufentanil, alfentanil, fentanyl, lofentanil, carfentanil, remifentanil, trefentanil or mirfentanil.
  • opioid drugs have different pharmacokinetic profiles and different interactions with mu opioid receptor splice variants and, therefore, may be used in combination to enhance the therapeutic effect.
  • the drug dosage form of the invention may include at least one opioid drug and one or more other drugs wherein the other drug may be an opioid or non- opioid drug.
  • the non-opioid drug may be added to increase analgesic efficacy or to help deter abuse or to avoid opioid-induced side effects.
  • the oral dosage formulations of the invention include an opioid antagonist, such as naloxone.
  • naloxone is provided in an appropriate concentration to inhibit activity of the opioid component of the formulation were it to be injected.
  • the invention finds utility in the treatment of both opioid naive patients and opioid tolerant patients.
  • opioid naive patient is used herein with reference to a patient who has not received repeated administration of an opioid substance over a period of weeks to months.
  • opioid tolerant patient means a physiological state characterized by a decrease in the effects of an opioid substance (e.g., analgesia, nausea or sedation) with chronic administration.
  • An opioid substance is a drug, hormone, or other chemical substance that has analgesic, sedative and/or narcotic effects similar to those containing opium or its derivatives. If analgesic tolerance develops, the dose of opioid substance is increased to result in the same level of analgesia. This tolerance may not extend to side effects and side effects may not be well tolerated as the dose is increased.
  • the dosage form of the invention may comprise at least 0.001% percent by weight of the active ingredient, e.g., sufentanil, alfentanil, fentanyl, lofentanil, carfentanil, remifentanil, trefentanil, mirfentanil.
  • the dosage form comprises from about at least 0.005% to as much as 99.9% by weight of sufentanil, alfentanil, fentanyl, lofentanil, carfentanil, remifentanil, trefentanil or mirfentanil.
  • the percentage of active ingredient(s) will vary dependent upon the size of the dosage form and nature of the active ingredient(s), optimized to obtain maximal delivery via the oral mucosal route. In some aspects of the invention more than one active ingredient may be included in a single dosage form.
  • the formulation of the present invention generally provides appropriate pain relief in all types of patients including children, adults of all ages who are opioid tolerant or naive and non-human mammals.
  • the invention finds utility in both the inpatient and out-patient setting.
  • sufentanil clinically has predominantly been limited to IV administration in operating rooms or intensive care units.
  • Opioids are known to produce physical dependence, possible addictive behaviors and tolerance with long-term use.
  • Cells exposed to opioids can demonstrate mu opioid receptor internalization (rapid endocytosis).
  • the in vitro mu-opioid receptor endocytosis of a series of clinically used opioids was evaluated alone and in combination with morphine in human embryonic kidney (HEK) 293 cells (Koch et al., MoI Pharmacol. 67(l):12-4, 2005).
  • the results indicated that the endocytotic potency of opioid drugs is negatively correlated with their ability to cause receptor desensitization and opioid tolerance in HEK 293 cells and that opioids with high endocytotic efficacies might cause reduced opioid tolerance.
  • the results shown in Koch et al., 2005 indicate that sufentanil is an opioid with high endocytotic efficacy and is therefore less likely to cause opioid tolerance than related opioid analogues tested.
  • Sufentanil N- [(4-(Methoxy methyl- 1 ⁇ (2-(2-thienyl)ethyl)-4-piperidinyl)]-N- phenylpropanamide
  • a commercial form of sufentanil used for IV delivery is the SUFENTA FORTE ® formulation.
  • This liquid formulation contains 0.075 mg/ml sufentanil citrate (equivalent to 0.05 mg of sufentanil base) and 9.0 mg/ml sodium chloride in water. It has a plasma elimination half-life of 148 minutes, and 80% of the administered dose is excreted in 24 hours.
  • Fentanyl (N-(I -phenethyl-4-piperidyl)-N-phenyl-propanamide) was first synthesized in Belgium in the late 1950s, and has an analgesic potency of about 80 times that of morphine.
  • Fentanyl and its congeners are mu opiate agonists that were originally developed as anesthesia agents, and are often administered intravenously due to rapid onset of analgesia. Following intravenous administration, the analgesic action of fentanyl is more prompt and less prolonged than that of morphine and meperidine.
  • fentanyl has the potential for deleterious side effects including respiratory depression, nausea, vomiting and constipation. Since fentanyl has a 30% bioavailability from the GI route, this swallowed drug can contribute to the C max plasma levels to a significant degree and results in the erratic C max and T max observed with these products.
  • sufentanil and fentanyl have many similarities as potent mu-opioid receptor agonists, they have been shown to differ in many key ways. Multiple studies have demonstrated sufentanil to be in the range of 7 — 24 times more potent than fentanyl (SUFENTA ® package insert; Paix A, et al. Pain, 63:263-69, 1995; Reynolds L, et al., Pain, 110:182-188, 2004). Therefore, sufentanil may be administered using a smaller dosage form, avoiding the increased saliva response of a larger dosage form and thereby minimizing swallowing of the drug and the minimal and variable GI uptake, which is associated with a larger dosage form.
  • the lipid solubility (octanol-water partition coefficient) of sufentanil (1778:1) is greater than fentanyl (816:1).
  • Sufentanil also displays increased protein binding (91 - 93%) compared with fentanyl (80 - 85%) (SUFENTA ® and Actiq ® package inserts, respectively).
  • Sufentanil has a pKa of 8.01, whereas the pKa of fentanyl is 8.43 (Paradis et al., Therapeutic Drug Monitoring, 24:768-74, 2002).
  • sufentanil has been shown to have a faster onset of action and faster recovery times than fentanyl (Sanford et al., Anesthesia and Analgesia, 65:259- 66, 1986). This is advantageous for the treatment of acute pain when repeated dosing is available, such as in the present invention. Use of sufentanil can result in more rapid pain relief with the ability to titrate the effect and avoid overdosing.
  • sufentanil has been shown to produce endocytosis of the mu-opioid receptor 80,000 times more potently than fentanyl (Koch et al., Molecular Pharmacology, 67:280-87, 2005). The result of this receptor internalization is that neurons continue to respond to sufentanil more robustly over time than with fentanyl, suggesting that clinically less tolerance would develop to sufentanil compared to fentanyl with repeated dosing.
  • Sufentanil has been used experimentally in adults in the form of an oral liquid (Gardner-Nix J., 2001; Kunz et al., 1993), and as nasal drops (Helmers et al., 1989), and nasal spray (Jackson et al., 2002), as described above. No pharmacokinetic data has been published on sublingual sufentanil in any dosage form.
  • Congeners of sufentanil and fentanyl find use in the compositions and methods of the invention, examples of which include rem ⁇ fentanil and alfentanil.
  • Remifentanil is a potent fentanyl congener that is metabolized much more rapidly than fentanyl or sufentanil, but may be suitable for treatment of acute pain when delivered via a sustained-release formulation.
  • a NanoTab ® of the invention typically comprises from about 0.25 meg to 99.9 mg of remifentanil.
  • the dose ranges for the remifentanil formulation may include 0.1 mcg/kg — 50 mcg/kg over a time period of 20 minutes, for example, for both adult and pediatric patients. These dosages may be repeated at appropriate time intervals, which may be shorter than the time intervals for fentanyl or sufentanil.
  • Alfentanil is also a potent fentanyl congener that is rapidly metabolized but may be suitable for use in a sustained-release formulation.
  • a NanoTab ® of the invention typically comprises from about 10 meg to about 10 mg of alfentanil. Appropriate dosing of alfentanil may be in the range of 1 mcg/kg — 2000 mcg/kg over 20 minutes, for example, for both adult and pediatric patients. These dosages may be repeated at appropriate time intervals, which may be shorter than the time intervals for fentanyl or sufentanil.
  • Patients suffering from chronic painful conditions can also have intermittent exacerbations of their pain, requiring acute use of fast-acting breakthrough opioids in addition to their use of slow-onset time-release opioids for their baseline chronic pain.
  • Breakthrough pain or procedural pain can be intense for short periods of time, as short as 1 or 2 minutes or as long as 30 minutes or more, therefore there would be a significant advantage in providing an opioid formulation that produced more rapid clinically effective plasma levels with a more consistent and predictable period of effect, but also had a limited half- life to avoid excessive opioid dosing for short duration pain events.
  • IV morphine The most common analgesic used to treat moderate to severe post-operative pain is IV morphine. This is either delivered on an "as needed" basis by a nurse to the patient by an IV injection or commonly a morphine syringe is placed in a PCA pump and the patient self- administers the opioid by pressing a button which has a lock-out feature. Other opioids, such as hydromorphone and fentanyl may also be used in this manner.
  • Treatment of acute pain is also necessary for patients in an outpatient setting. For example, many patients suffer from chronic pain and require the use of opioids on a weekly or daily basis to treat their pain. While they may have a long-acting oral or transdermal opioid preparations to treat their chronic underlying pain levels, they often need short-acting potent opioids to treat their severe breakthrough pain levels.
  • Treatment of acute pain is also necessary "in the field" under highly sub-optimal conditions.
  • Paramedics or military medics often are required to treat severe acute pain in un- sterile situations, where needles used for IV or IM administration can result in unintended needle sticks, risk of infection, etc.
  • Oral opioid tablets often take 60 minutes to provide relief which is too long for someone in severe pain.
  • the drug delivery dosage forms or formulations of the invention contain from about 0.25 to about 200mcg of sufentanil per dosage form for oral transmucosal delivery. In one exemplary embodiment of the invention, each dosage form contains from about 0.25 to about 200mcg of sufentanil, alone or combination with one or more other therapeutic agents or drugs.
  • the dose will be on the low end of the range for children and the high end of the range for adults dependent upon body mass, in particular when administered long term to opioid-tolerant adults.
  • Small-volume oral transmucosal drug delivery dosage forms of sufentanil have not been described.
  • Exemplary formulations of the invention for administration to children contain from about 0.25 to about 120mcg of sufentanil per dosage form.
  • a formulation of the invention for administration to children may contain about 0.25, 0.5, 1, 2.5, 4, 5, 6, 8, 10, 15, 20, 40, 60 or 120mcg of sufentanil for oral transmucosal delivery. It follows that for pediatric patients, an exemplary dose range is from at least about 0.02 mcg/kg to about 0.5 mcg/kg with a preferable range of from about 0.05 to about 0.3 mcg/kg.
  • Exemplary formulations of the invention for administration to adults contain from about 2.5 to about 200mcg of sufentanil per dosage form.
  • a formulation of the invention for administration to adults may contain about 2.5, 3, 5, 7.5, 10, 15, 20, 40, 60, 80, 100, 120, 140, 180 or 200mcg or more of sufentanil for oral transmucosal delivery.
  • each dosage form contains from about 2 to about 1500mcg of fentanyl, alone or combination with one or more other therapeutic agents or drugs.
  • the dose will be on the low end of the range for children and the high end of the range for adults dependent upon body mass, in particular when administered long term to opioid-tolerant adults.
  • Exemplary dosage forms of the invention for administration to children contain from about 2 to about 900mcg of fentanyl per dosage form.
  • a dosage form of the invention for administration to children may contain about 2, 3.75, 7.5, 18.75, 30, 37.5, 45, 60, 75, 112.5, 150, 300, 450 or 900mcg of fentanyl for oral transmucosal delivery.
  • Exemplary dosage forms of the invention for administration to adults contain from about 18.75 to about 1500mcg of fentanyl per dosage form.
  • a dosage form of the invention for administration to adults may contain about 18.75, 22.5, 37.5, 56, 75, 112.5, 150, 300, 450, 600, 750, 900, 1050, 1350 or 1500mcg or more of fentanyl for oral transmucosal delivery.
  • a dosage form for use in the treatment of pain may comprise from about 0.25 to about 200mcg of sufentanil, from about 0. 5 to about 120mcg of sufentanil, from about 2.5 to about 40 meg of sufentanil, from about 2.5 to about 15.0 meg of sufentanil, from about 2.0 to about 1500 meg of fentanyl, from about 20 to about 1200 meg of fentanyl, or from about 100 to about 900 meg of fentanyl.
  • the dosage forms of the invention contain from about 10 to about 10000 meg of alfentanil per dosage form for oral transmucosal delivery.
  • the dose will be on the low end of the range for children and the high end of the range for adults dependent upon body mass, in particular when administered long term to opioid- tolerant adults.
  • Exemplary dosage forms of the invention for administration to children contain from about 10 to about 6300 meg of alfentanil per dosage form.
  • a dosage form of the invention for administration to children may contain about 10, 25, 50, 130, 210, 280, 310, 420, 600, 780, 1050, 2100, 3000 or 6300 meg of alfentanil for oral transmucosal delivery.
  • Exemplary dosage forms of the invention for administration to adults contain from about 70 to about 10000 meg of alfentanil per dosage form.
  • a dosage form of the invention for administration to adults may contain about 70, 140, 160, 210, 280, 310, 420, 600, 780, 1050, 2100, 3000, 6300 or 10000 meg or more of alfentanil for oral transmucosal delivery.
  • a dosage form for use in the treatment of pain may comprise from about 0.25 to about 200 meg of sufentanil in combination with from about 2 to about 1500 meg of fentanyl or from about 0.25 to about 200 meg of sufentanil or from about 2 to about 1500 meg of fentanyl in combination with one or more additional drugs.
  • the plasma level of sufentanil, alfentanil or fentanyl may reach a maximum level between 0 and 60 minutes, between 5 and 50 minutes or between 10 and 40 minutes after administration.
  • a device for NanoTab ® delivery can use a variety of mechanical or electromechanical methods to expel the NanoTab ® into the oral or sublingual space.
  • the NanoTab can be forcibly expelled by means of a spring, compressed air, or other mechanism once activated.
  • Methods of making a drug-containing dosage forms for oral transmucosal delivery such as a NanoTab ® is also provided by the invention.
  • the method includes the steps of weighing the drug and one or more of bioadhesins, binders, hydrogel forming excipients, bulking agents, lubricants or glidants and factors that affect dissolution time, possibly powder grinding, dry powder mixing and tableting via direct compression.
  • a wet granulation process may be used.
  • Such a method involves mixing the active ingredient and possibly some excipients in a mixer.
  • the binder may be one of the excipients added in the dry mix state or dissolved in the fluid used for granulating.
  • the granulating solution or suspension is added to the dry powders in the mixer and mixed until the desired characteristics are achieved. This usually produces a granule that will be of suitable characteristics for producing dosage forms with adequate hardness, dissolution, content uniformity, and other physical characteristics.
  • the product is most often dried and/or then milled after drying to get a major percentage of the product within a desired size range.
  • the product is dried after being wet sized using a device such as an oscillating granulator, or a mill.
  • the dry granulation may then processed to get an acceptable size range by first screening with a sieving device, and then milling the oversized particles.
  • an appropriate glidant is added to improve the flow properties of the granules; suitable glidants include silicas (such as SILOID and SILOX silicas — trademarks of Grace Davison Products, Aerosil - trademark of Degussa Pharma).
  • the formulation may be manufactured by alternative granulation processes, all known to those skilled in the art, such as spray fluid bed granulation, extrusion and spheronization or fluid bed rotor granulation.
  • the formulation will be converted into a dosage form for delivery to a subject using procedures routinely employed by those of skill in the art.
  • the process for preparation of the dosage form is optimized in order to achieve high dose content uniformity, which is particularly important for the potent compounds, which are generally present in mass ratios of 0.01-10% w/w.
  • a NanoTab ® dosage form of the invention may or may not have a coating on the external surface of the dosage form.
  • the dosage forms of the invention find utility in delivery of any drug that can be administered by the oral transmucosal route.
  • the small volume of an oral transmucosal dosage form or NanoTab ® of the invention is that it provides for high bioavailability, low variability in T ma x, low variability in Cmax and low variability in AUC.
  • the NanoTabs ® of the invention also provide for controlled dissolution, solubility and stability, resulting in controlled release of the drug over time resulting in prolonged plasma levels within the therapeutic window.
  • the dosage forms of the invention find utility in treating a subject suffering from pain that may be associated with any of a variety of identifiable or unidentifiable etiologies.
  • the dosage forms of the invention find utility in suppression or mitigation of pain.
  • treatment or “management” of pain is used here to generally describe regression, suppression, or mitigation of pain so as to make the subject more comfortable, as determined for example by pain score.
  • acute pain is used herein with reference to pain that is typically present for less than one month, however, in some cases pain that is present for as long as three months may also be considered to be “acute”.
  • chronic pain is used herein with reference to pain that is typically present for longer than one month.
  • the dosage forms of the invention find particular utility in the treatment of acute pain or other conditions "in the field", i.e., under highly sub-optimal conditions.
  • Paramedics or military medics often are required to treat severe acute pain or other injuries or conditions in non-sterile situations, where needles used for IV or IM administration can result in unintended needle sticks, risk of infection, etc.
  • Oral opioid tablets often take 60 minutes to provide relief which is too long for someone in severe pain.
  • the dosage forms of the invention find utility in addressing this need.
  • the dosage forms of the invention find further utility in pediatric applications, since the comfortable and secure nature of the dosage form will allow small children to readily accept this mode of therapy and will reliably deliver drug transmucosally.
  • Specific examples include, but are not limited to, treatment of pediatric acute pain when IV access is not available or inconvenient, treatment of pediatric asthma when the child is not able to use an inhaled route of administration effectively, treatment of nausea when a child can not or will not swallow a pill, pre-procedural sedation when a child is NPO (no oral intake allowed) or a more rapid onset is required.
  • the dosage forms of the invention find further utility in veterinary applications.
  • Specific examples include, but are not limited to, any treatment of an acute condition for which IV administration is not readily available or inconvenient, such as pain relief, anxiety/stress relief, pre-procedural sedation, etc.
  • Oral transmucosal drug delivery is simple, non-invasive, and can be administered by the caregiver or the patient with minimal discomfort.
  • oral transmucosal delivery of pharmaceuticals is achieved using solid dosage forms such as lozenges or tablets, however, liquids, sprays, gels, gums, powders, and films and the like may also be used.
  • oral transmucosal delivery may provide a better delivery route than GI delivery.
  • oral transmucosal delivery has shorter onset time (i.e., the time from administration to therapeutic effect) than does oral GI delivery and provides significantly improved bioavailability.
  • the dosage forms for the NanoTabs ® described above can be tested for in vivo drug pharmacokinetics in both humans and a suitable animal model following sublingual administration.
  • the following examples demonstrate the ability of the NanoTab ® dosage forms to allow a consistent absorption profile of sufentanil citrate following sublingual administration in human volunteers and an awake, alert Beagle dog model.
  • Example 1 Sublingual Sufentanil NanoTabs ® Administered Sublingually in Adult Human Volunteers.
  • Sufentanil NanoTabs ® (formulations #46 - #48 shown in Table 1) manufactured to have a volume of 5 ⁇ L, a mass of approximately 5.5 mg, and determined to have a uniform size for all dosage strengths with dimensions of approximately 3 mm in diameter and 0.8 mm in thickness.
  • Sufentanil NanoTabs ® contained either 2.5 ⁇ g, 5 ⁇ g or 10 ⁇ g of sufentanil base corresponding to 3.7 ⁇ g, 7.5 ⁇ g or 15 ⁇ g of sufentanil citrate, respectively. All excipients were inactive and have GRAS ("generally recognized as safe") status.
  • the sufentanil NanoTabs ® were tested for sublingual use. Study staff administered individual NanoTabs ® to a subject by placing them directly at the base of the frenulum using blunt-tipped forceps.
  • the bioadhesion was measured as described earlier on the sufentanil clinical trial formulation (#46 - #48) without the sufentanil component.
  • the bioadhesion force required for displacement of the NanoTab ® was measured as 0.046 + 0.01 N/cm 2 .
  • intravenous sufentanil 5 ⁇ g was diluted in 0.9% saline to a total volume of 20 mL, and was administered through an IV catheter as a continuous infusion over 10 minutes. Plasma samples were drawn from a different IV catheter at a remote location. This human trial was a cross-over design with wash-out periods between transitions from higher to lower doses. Subjects were blocked with the opioid antagonist naltrexone daily to avoid opioid-induced side-effects.
  • the total volume of blood required for pharmacokinetic sampling was approximately 455 mL.
  • Sufentanil concentrations in plasma samples were determined using a validated LC- MS/MS sufentanil human plasma assay. The assay demonstrated good inter-day precision and accuracy at the high, medium and low quality control sample concentrations. Erosion Time
  • TTR (Time spent above 50% of C max ) /(IV Terminal elimination half-life).
  • the denominator is obtained from literature and is 148 min in humans for sufentanil.
  • Example 2 In vivo Evaluation of Sublingual Sufentanil NanoTabs ® in a Dog Model.
  • the following Examples 2-5 are using the Beagle dog model and the formulations for the NanoTabs ® all are using a NanoTab ® with a total mass of 5.5 mg.
  • the in vivo pharmacokinetics (PK) of sufentanil following sublingual administration of the 5 meg NanoTabs ® (formulation #44 for dogs, which is the same as the human formulation #47) described above were evaluated in a healthy Beagle dog model. Briefly, single 5mcg NanoTabs ,® described above were administered sublingually in fully awake healthy dogs by direct placement in the sublingual cavity. A total of three dogs were evaluated. Following administration, the position of the NanoTab ® in the sublingual cavity was observed visually at 5 - 15 minute intervals following administration. The sublingual sufentanil PK was compared with that of IV administered sufentanil at the same dose level.
  • TTR (Time spent above 50% OfC 11111x ) / (IV Terminal elimination half-life).
  • the denominator is obtained from literature and is 139 mi ⁇ in beagle dogs for sufentanil.
  • Example 3 Exemplary Sufentanil Dosage Forms to Control Drug Release and In Vivo Pharmacokinetics.
  • NanoTab ® dosage form (formulation #58) was prepared with sufentanil citrate in order to evaluate a slower rate of drug release and in vivo pharmacokinetics of a longer-acting dosage form.
  • This slower disintegrating sufentanil NanoTab ® as described in Table 4 was prepared by direct compression and tested as described above.
  • the range of erosion times in dogs was 35 — 120 minutes and the bioadhesion of the placebo formulation was measured as described above and determined to be 0.18 + 0.08 N/cm 2 .
  • TTR (Time spent above 50% of C max ) / (IV Terminal elimination half-life).
  • the denominator is obtained from the literature and is 139 min in beagle dogs for sufentanil.
  • Example 4 In Vivo Study of Sublingual Sufentanil Solution and Swallowing of Sufentanil NanoTabs ® in a Dog Model.
  • the samples were centrifuged at 3,000 x g for approximately 10 minutes in a refrigerated centrifuge. Plasma was collected and frozen within 20 minutes of centrifugation at approximately -70 0 C and was maintained at the same temperature until analysis. Sample analysis was performed using a validated LC/MS/MS method for analysis of sufentanil in dog plasma.
  • a Expressed as a free base.
  • b Same animals will be used for Groups 1 through 3 with a minimum 2-day washout period between dosing.
  • d " Normal (0.9% w/w) saline was used to dilute the test article (Sufenta ® 50 ⁇ g/mL) to the desired concentration.
  • TTR (Time spent above 50% of C m ⁇ x ) / (IV Terminal elimination half-life).
  • the denominator is obtained from the literature and is 139 min. in beagle dogs for sufentanil.
  • Example 5 In vivo Evaluation of Sublingual Fentanyl NanoTabs ® in a Dog Model.
  • fentanyl NanoTab ® dosage forms were prepared with fentanyl citrate in order to evaluate the rate of drug release and in vivo pharmacokinetics of various dosage forms. Both medium (formulation #60) and slow (formulation #62) disintegrating fentanyl NanoTabs ® , as described in Table 8, were evaluated with both dosage forms prepared by direct compression. The erosion time in dogs of formulation #60 ranged from 5 -20 minutes and the bioadhesion was measured at 0.056 ⁇ 0.01 N/cm 2 for the placebo formulation.
  • the erosion time in dogs for formulation #62 ranged from 35 — 65 minutes and the bioadhesion for the placebo formulation was measured at 0.18 + 0.08 N/cm 2 .
  • the fentanyl plasma concentrations are graphed in Figure 6.
  • PK analysis was performed using a non-compartmental absorption model. The results of the PK analysis are shown in Table 10. Blood sampling and storage mirrored the conditions described earlier; sample analysis was performed using a validated LC/MS/MS method for analysis of fentanyl in dog plasma.
  • TTR (Time spent above 50% of C max ) / (IV Terminal elimination half-life).
  • the denominator is obtained from the literature and is 244 min. in beagle dogs for fentanyl.
  • Example 6 In vivo Evaluation of Sublingual Alfentanil HCl NanoTabs ® in a Dog Model.
  • NanoTab ® For purposes of illustration of another drug use for the NanoTab ® , an additional NanoTab ® dosage form was prepared with alfentanil HCl in order to demonstrate the ability of the dosage forms described in this application to effectively improve the PK of alfentanil compared to that of the IV route of administration.
  • the formulation composition, a medium disintegrating NanoTab ® is described in Table 11.
  • the erosion time in dogs of formulation #63 was 20 minutes and the bioadhesion was measured at 0.056 + 0.01 N/cm 2 for the placebo formulation.
  • a Expressed as a free base.
  • b Same animals were used for Groups 1 and 2 with a minimum 2-day washout period between dosing.
  • TTR (Time spent above 50% of C raax ) / (IV Terminal elimination half-life).
  • the denominator is obtained from literature and is 104 min. in beagle dogs.

Abstract

Small-volume oral transmucosal dosage forms or NanoTabs® comprising a predetermined amount of a pharmaceutically active drug are provided. Exemplary applications include use of the NanoTabs® to administer a drug for the treatment of acute, post-operative or breakthrough pain.

Description

SMALL-VOLUME ORAL TRANSMUCOSAL DOSAGE FORMS
Cross Reference To Other Applications
[0001] This application claims the priority benefit of U.S. Provisional Application No. 60/756,937, filed Jan. 6, 2006, the disclosure of which is incorporated herein by reference in its entirety.
Field Of The Invention
[0002] The present invention provides for small- volume oral transmucosal drug delivery dosage forms having various sizes and characteristics, referred to herein as "NanoTabs®" and methods of using the same.
Background Of The Technology
[0003] Currently, standard treatment regimens for oral administration of medications for treatment of a number of conditions have clear limitations with regard to both efficacy and toxicity. Routes of administration, formulations and dosage control among other attributes contribute to these limitations.
[0004] Reproducible and effective drug delivery technology represents an area of active research and controlled drug delivery systems offer numerous advantages relative to conventional dosage forms, which include improved efficacy, reduced toxicity, as well as improved patient compliance and convenience. This is particularly relevant to the treatment of pain, more specifically: acute, intermittent and breakthrough pain.
■ *tOOO5] Medications based on a variety of routes of administration and the development of new and improved dosage forms for the treatment of a large number of medical conditions, such as pain, is an ongoing process. There remains a need to develop safer drug dosage forms without the fluctuation in efficacious levels that are seen with medications using current commercially available dosage forms. Currently available treatment regimes for treatment of pain often fail to provide patients with sufficient or consistent therapeutic effect, often due to a slow, erratic onset of action and the difficulty in adjusting and controlling doses such that the medical condition is not treated effectively.
[0006] U.S. Patent Nos. 6,974,590, 6,764,696, 6,641,838, 6,585,997, 6,509,036, 6,391,335, 6,350,470, 6,200,604 and US Patent Publication Nos. 20050176790, 20050142197 and . 20050142198 describe pharmaceutical combinations of active compounds such as fentanyl and congeners thereof in combination with an effervescent agent used as a penetration enhancer to influence the permeability of the active compound across the buccal, sublingual, and gingival mucosa.
[0007] U.S. Patent Nos. 6,761,910 and 6,759,059 and U.S. Patent Publication No. 20040213855 disclose pharmaceutical compositions for the treatment of acute disorders such as pain by sublingual administration of an essentially water-free, ordered mixture of microparticles with at least one pharmaceutically active agent adhered to the surfaces of the carrier particles by way of a bioadhesion and/or mucoadhesion promoting agent. U.S. Patent No. 6,759,059 discloses compositions and methods for sublingual administration of fentanyl or a pharmaceutically acceptable salt thereof using a tablet which is approximately 100 mg in size.
[0008] U.S. Patent Nos. 5,800,832 and U.S. Pat. No. 6,159,498 (Tapolsky, et al.), and U.S. Patent Publication Nos. 20030194420 and 20050013845 disclose a water soluble, biodegradable drug delivery device, e.g., a bilayer film disk having an adhesive layer and a backing layer, both water-soluble, which adheres to mucosal surfaces.
[0009] U.S. Patent Nos. 6, 682,716; 6,855,310; 7,070,762 and 7,070,764 and (Rabinowitz, et al.), disclose delivery of an analgesic via the inhalation route using a method which comprises: a) heating a thin layer of analgesic drug on a solid support to form a vapor; and, b) passing air through the heated vapor to produce aerosol particles.
[0010] U.S. Patent No. 6,252,981 (Zhang et al.) discloses oral mucosal drug delivery as an alternative method of systemic drug delivery formulation and method for oral transmucosal delivery of a pharmaceutical. The invention provides a drug formulation comprising a solid pharmaceutical agent in solid solution with a dissolution agent in solid form, yielding a solid solution. The solid solution formulation may be further combined with buffers and other excipients as needed in order to facilitate the drug's manufacturing, storage, administration and delivery through oral mucosal tissue. The formulation can be used with a variety of oral transmucosal delivery dosage forms, such as a tablet, lozenge, lozenge on a stick, chewing gum, and buccal or mucosal patch. See, also Zhang et al, Clin Pharmacokinet. 2002;41(9):661-80.
[0011] A number of transmucosal dosage forms for treatment of pain are presently in clinical development, examples of which include a buccal morphine spray and a buccal fentanyl spray (Generex Biotechnology) and an oral, fast-dissolving tablet of fentanyl for sublingual administration (Rapinyl™; Endo Pharmaceuticals). Two transmucosal fentanyl preparations which currently are commercially available are a fentanyl buccal tablet (FENTORA™; Cephalon) and ACTIQ® (Cephalon), an oral transmucosal form of fentanyl citrate administered as a lollipop, both are only indicated for the management of breakthrough cancer pain in patients who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain.
[0012] Although various oral drug delivery systems and dosage forms have been described for the treatment of various medical disorders and conditions, there remains a need for improved dosage forms, formulations and treatment regimens for use in the treatment of such medical disorders and conditions, e.g., for treatment of acute and breakthrough pain.
[0013] High bioavailability is critical for efficacious treatment with a variety of drugs including opioids, since higher doses of the drug must be packaged in the commercial dosage form to counter the generally poor bioavailability. An example is oxymorphone (Opana®) which has a bioavailability of 10% and therefore must be packaged with nine-fold more drug for the oral tablet versus the equivalent IV dosage form. Especially problematic are drug systems that have large amounts of residual drug left after full usage of the product. An example is IonSys™, which is an inefficient drug delivery system (transdermal) that requires three times the amount of drug packaged into the transdermal patch than is maximally delivered to the patient during regular usage. These inefficient systems, whether oral pills or patches, can be easily abused by injecting the drug intravenously and obtaining full bioavailability of the excess drug. If a given dosage form administered by the intended route of administration provides close to full bioavailability, then abusing the drug by intravenous injection does not provide for increased bioavailability and therefore this formulation may mitigate drug abuse and diversion.
[0014] There remains a need for improved dosage forms for oral drug delivery which provide more rapid and consistent onset of action, more consistent plasma concentrations and higher and more consistent bioavailability than currently available dosage forms. The present invention addresses this need.
BRIEF SUMMARY OF THE INVENTION
[0015] The present invention provides compositions and methods comprising small volume oral transmucosal drug delivery dosage forms or "NanoTabs®" which contain a predetermined unit dosage of a pharmaceutically active amount of a drug, which may be self-administered, while providing a therapeutic effect and a predictable and safe pharmacokinetic profile.
[0016] The small size of the NanoTab® and its placement in the sublingual cavity allow for potent, lipophilic molecules to be absorbed transmucosally with minimal saliva response and minimal swallowing of the drug. This avoidance of gastrointestinal (GI) uptake allows for a more rapid and consistent onset of action, more consistent plasma concentrations and higher bioavailability. This route of administration minimizes drug uptake via the GI route, which is variable and by which significant metabolism of the drug in the stomach and intestines can occur.
[0017] The NanoTabs® of the invention have bioadhesive characteristics and can adhere to the oral mucosa, e.g., a sublingual or buccal membrane. Such NanoTabs® can be of the hydrogel-forming or eroding type.
[0018] The NanoTabs® of the invention have a mass of less than 100mg and a volume of less than lOOμl. More specifically, the invention provides NanoTabs® with a mass selected from the group consisting of less than lOOmg, less than 90mg, less than 80mg, less than 70mg, less than 60mgs less than 50mg, less than 40mg, less than 30mg, less than 20mg and less than lOmg and/or a volume selected from the group consisting of less than lOOμl, less than 90μl, less than 80μl, less than 70μl, less than 60 μl, less than 50μl, less than 40μl, less than 30μl, less than 20μl and less than lOμl. [0019] A NanoTab® of the invention finds utility in oral transmucosal administration of any drug that can be absorbed via the transmucosal route and which suffers from GI and first-pass metabolism and can therefore benefit from this dosage form.
[0020] In one aspect, the NanoTabs® of the invention comprise from about 0.25 μg to 99.9mg, from about lμg to 50mg, or from about lμg to lOmg of the drug.
[0021] In one aspect, the invention provides a NanoTab® wherein the drug is an opioid selected from the group consisting of sufentanil, alfentanil, fentanyl, lofentanil, carfentanil, remifentanil, trefentanil, and mirfentanil.
[0022] The invention provides NanoTabs® which comprise an opioid drug in an amount selected from the group consisting of from about 0.25 meg to 200 micrograms (meg) of sufentanil, from about 2.5 meg to 100 meg of sufentanil, from about 0.02 meg to 5 micrograms per kilogram (meg/kg) of sufentanil, e.g., about 2.5, 5. 10, or 15 micrograms of sufentanil, from about 10 meg to 10 mg of alfentanil, from about 2 meg to 1500 meg of fentanyl, from about 50 meg to 1500 meg of fentanyl, 200 meg to 1500 meg of fentanyl, from about 0.25 meg to 99.9 mg of lofentanil, from about 0.25 meg to 99.9 mg of carfentanil, from about 0.25 meg to 99.9 mg of carfentanil, from about 0.25 meg to 99.9 mg of remifentanil, from about 0.25 meg to 99.9 mg of trefentanil, from about 0.25 meg to 99.9 mg of mirfentanil.
[0023] The NanoTab® is designed for self-administration by a subject with or without a device, wherein the NanoTab® has a shape selected from the group consisting of a round disc with a flat, concave, or convex face, an ellipsoid shape a spherical shape and a polygon with three or more edges and flat, concave, or convex faces.
[0024] A NanoTab of the invention may be characterized by an erosion time of from 30 seconds up to a 1 minute, 2 minutes, 3 minutes, 4 minutes, 5 minutes, 10 minutes, 15 minutes, 30 minutes, 1 hour, 2 hours, 4 hours, 8 hours or longer.
[0025] The bioavailability of a drug following a single or following repeated oral transmucosal administration of a NanoTab® of the invention to a subject is greater than 65%, greater than 75%, greater than 85%, greater than 90% or greater than 94%. [0026] The NanoTabs® of the invention are further characterized by a Cmax with a coefficient of variation of less than 30% or 40%; an AUC with a coefficient of variation of less than 30% or 40%; a Tmax with a coefficient of variation of less than 40%; a plasma half-life of from about 30 minutes to about 4 hours; and a therapeutic time ratio of greater than 0.07 or from about 0.5 to about 2.0 following a single oral transmucosal administration to a subject.
[0027] The amount of drug in the NanoTab® that is absorbed via the oral transmucosal route is at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98% or at least 99% of the total amount of drug in the dosage form.
[0028] The invention further provides a method of treating a subject exhibiting a symptomatic medical condition, by administering a NanoTab® of the invention as described herein such that the drug is effective to treat the symptomatic medical condition.
[0029] In one embodiment the symptomatic medical condition is pain, e.g., acute pain, breakthrough pain or post-operative pain and the NanoTab® comprises an opioid such as sufentanil or a congener thereof.
BRIEF DESCRIPTION OF THE FIGURES
[0030] Figure 1 is a graphic depiction of the in vitro dissolution kinetics of sufentanil NanoTab® formulations #46-#48 which were used in the human clinical study described in Example 1.
[0031] Figure 2 is a graphic depiction of sufentanil plasma concentrations following intravenous dosing or sublingual single dose administration of three different strengths of sufentanil NanoTabs® in healthy human volunteers (n = 12).
[0032] Figure 3 is a graphic depiction of sufentanil plasma concentrations following sublingual administration of a sufentanil NanoTab® formulation #44 (equivalent to human #47 formulation; n=3) compared to intravenous sufentanil administration (n=3) in a healthy, conscious Beagle dog model. Error bars represents standard errors around the mean (SEM). [0033] Figure 4 is a graphic depiction of sufentanil plasma concentrations following sublingual administration of slowly disintegrating sufentanil NanoTab® formulation #58 (n=3) in a healthy, conscious Beagle dog model.
[0034] Figure 5 is a graphic depiction of sufentanil plasma concentrations following sublingual administration of a sufentanil solution (n=6) or following oral ingestion of a sufentanil NanoTab® (n=6) compared to intravenous administration of sufentanil (n=3) in a healthy, conscious Beagle dog model. Error bars represents ± standard error around the mean (SEM).
[0035] Figure 6 is a graphic depiction of fentanyl plasma concentrations following sublingual administration of medium disintegrating fentanyl NanoTab® formulation #60 (n=2) and slowly disintegrating fentanyl NanoTab® formulation #62 (n=3) compared to intravenous fentanyl administration (n=3) in a healthy, conscious Beagle dog model. Error bars represents ± standard error around the mean (SEM).
[0036] Figure 7 is a graphic depiction of alfentanil plasma concentrations following sublingual administration of an alfentanil NanoTab® (n=2) compared to intravenous alfentanil administration (n=3) in a healthy, conscious Beagle dog model. Error bars represents ± standard error around the mean (SEM).
DETAILED DESCRIPTION
[0037] The present invention provides an oral transmucosal dosage form or NanoTab® that provides for high bioavailability, low variability in Tmaχ, low variability in Cmax and low variability in AUC. The NanoTabs® of the invention also provide for controlled dissolution, solubility and stability, resulting in controlled release of the drug over time resulting in prolonged plasma levels within the therapeutic window.
[0038] The invention is based on a small solid oral transmucosal dosage form or NanoTab®, some embodiments of which adhere to the oral mucosa during the period of drug delivery. The transmucosal dosage form minimizes the saliva response and therefore minimizes delivery of the drug to the GI tract, such that the majority of drug is delivered across the oral mucosa. [0039] The following disclosure describes the NanoTab® dosage forms which constitute the invention. The invention is not limited to the specific dosage forms and methodology or medical conditions described herein, as such may, of course, vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the present invention.
[0040] It must be noted that as used herein and in the appended claims, the singular forms "a", "and", and "the" include plural references unless the context clearly dictates otherwise. Thus, for example, reference to "a drug formulation" includes a plurality of such formulations and reference to "a drug delivery device" includes systems comprising drug formulations and devices for containment, storage and delivery of such formulations.
[0041] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood to one of ordinary skill in the art to which this invention belongs. Although any methods, devices and materials similar or equivalent to those described herein can be used in the practice or testing of the invention, the preferred methods, devices and materials are now described.
[0042] All publications mentioned herein are incorporated herein by reference in their entirety for the purpose of describing and disclosing the compositions and methodologies which are described in the publications which might be used in connection with the presently described invention. The publications discussed herein are provided solely for their disclosure prior to the filing date of the present application. Nothing herein is to be construed as an admission that the invention is not entitled to antedate such a disclosure by virtue of prior invention.
Definitions
[0043] The term "NanoTab®" as used herein refers to a small volume dosage form that has a volume of from about 0 ul (microliters) to about lOOul and a mass of from about 0 mg (milligrams) to about lOOmg. A NanoTab® of the invention may or may not have bioadhesive characteristics and is a dissolvable drug-containing dosage form which may have characteristics of hydrogel-forming or eroding tablets. [0044] The term "formulation" or "drug formulation" or "dosage form" as used herein refers to a physical entity containing at least one therapeutic agent or medication for delivery to a subject. It may be in the form of a lozenge, pill, tablet, capsule, membrane, strip, liquid, patch, film, gel, spray, gum or other form.
[0045] The terms "drug", "medication", "pharmacologically active agent" and the like are used interchangeably herein and generally refer to any substance that alters the physiology of an animal. The NanoTabs® of the invention may be used to deliver any drug that may be administered by the oral transmucosal route in an amount amenable to administration via the small size of the NanoTabs®, i.e. 0.25μg to 99.9mg, lμg to 50mg or lμg to 10mg.
[0046] The term "drug" as used herein with reference to a NanoTabs® of the invention means any "drug", "active agent", "active", "medication" or "therapeutically active agent" that can be effectively administered by the oral transmucosal route.
[0047] The term "drug" as applied to the treatment of pain (analgesia) includes sufentanil, sufentanil congeners, such as alfentanil, fentanyl, lofentanil, carfentanil, remifentanil, trefentanil, and mirfentanil, as well as dosage forms comprising one or more therapeutic compounds. Use of "drug" or the phrase "sufentanil or a congener" is not meant to be limiting to use of, or dosage forms comprising only one of these selected opioid compounds. Furthermore, reference to sufentanil alone or to a selected sufentanil congener alone, e.g., reference to "fentanyl," is understood to be only exemplary of the drugs suitable for delivery according to the methods of the invention, and is not meant to be limiting in any way. It will be further understood that a dosage form of the invention may include more than one therapeutic agent, wherein exemplary combinations of therapeutic agents include a combination of two or more opioid analogues, such as sufentanil plus an opioid such as alfentanil, fentanyl, lofentanil, carfentanil, remifentanil, trefentanil, and mirfentanil, or opium alkaloids such as morphine and codeine; semi-synthetic opioids such as heroin and oxycodone; and fully synthetic opioids such as pethidine and methadone, that have structures unrelated to the opium alkaloids, or any other drug that might be disinterred in combination.
[0048] The term "congener" as used herein refers to one of many variants or configurations of a common chemical structure. 7 000529
[0049] The term "subject" includes any subject, generally a mammal (e.g., human, canine, feline, equine, bovine, ungulate etc.), in which treatment for a disorder, such as management of pain or anesthetization, is desired.
[0050] The term "mucosal membrane" refers generally to any of the mucus-coated biological membranes in the body. Absorption through the mucosal membranes of the oral cavity is of particular interest. Thus, buccal, sublingual, gingival and palatal absorption are specifically contemplated by the present invention. In a preferred embodiment, the penetration enhancers of the present invention are used to improve absorption through those oral tissues which most resemble the skin in their cellular structure, i.e. the gingiva and palate.
[0051] The term "transmucosal" delivery of a drug and the like is meant to encompass all forms of delivery across or through a mucosal membrane. In particular, "oral transmucosal" delivery of a drug includes delivery across any tissue of the mouth, pharynx, larynx, trachea, or upper gastrointestinal tract, particularly including the sublingual, gingival and palatal mucosal tissues.
[0052] The terms "oral dosage form", "oral transmucosal dosage form" may be used interchangeably herein and refer to a dosage form for use in practicing the present invention.
[0053] The oral dosage form is typically a "sublingual dosage form", but in some cases other oral transmucosal routes may be employed. The invention relies upon such oral dosage forms for sustained delivery of drugs across the oral mucosa.
[0054] The term "oral transmucosal drug delivery" as used herein refers to a dosage form wherein drug delivery occurs substantially via the transmucosal route and not via swallowing followed by GI absorption. The dosage forms of the current invention are designed to provide for a drug dissolution rate that allows for maximal delivery via the oral mucosa, typically via placement of the dosage form within the sublingual cavity.
[0055] As used herein, "sublingual", means literally "under the tongue" and refers to a method of administering substances via the mouth in such a way that the substances are rapidly absorbed via the blood vessels under the tongue rather than via the digestive tract. Owing to the highly vascularized nature of the sublingual mucosal membrane and the reduced number of epithelial cell layers compared to other mucosal membranes, absorption of therapeutic substances occurs rapidly, thus allowing for direct access to the systemic circulation and thus quick onset of action while avoiding all complication of oral administration.
[0056] As used herein, the term "hydrogel-forming preparation", means a solid formulation largely devoid of water which upon contact with bodily fluids, and in particular those in the oral mucosa, is capable of absorbing an aqueous solution such as water, in such a way that it swells, while maintaining a structural matrix and forms a hydrated gel in situ. The formation of the gel follows unique disintegration (or erosion) kinetics while allowing for control of the therapeutic drug release over time, which occurs primarily by diffusion.
[0057] The term "Tmax" as used herein means the time point of maximum observed plasma concentration.
[0058] The term "Cmax" as used herein means the maximum observed plasma concentration.
[0059] The term "AUC" as used herein means "area under the curve" in a plot of concentration of drug in plasma versus time. AUC is usually given for the time interval zero to infinity, however, clearly plasma drug concentrations cannot be measured 'to infinity' for a patient so mathematical approaches are used to estimate the AUC from a limited number of concentration measurements. In a practical sense, the AUC (from zero to infinity) represents the total amount of drug absorbed by the body, irrespective of the rate of absorption. This is useful when trying to determine whether two formulations of the same dose release the same dose of drug to the body. The AUC of a transmucosal dosage form compared to that of the same dosage administered intravenously serves as the basis for a measurement of bioavailability.
[0060] The term "F" as used herein means "percent bioavailability" and represents the fraction of drug absorbed from the test article as compared to the same drug when administered intravenously. It is calculated from the AUC (0 — infinity) of the test article following delivery from the intended route versus the AUC for the same drug after intravenous administration. It is calculated from the equation: F (%) = AUC∞ (test article)/ AUC (intravenous route/article). This is an important term that establishes the relative fraction of the drug absorbed via the test route (or article) versus the maximum possible amount available via the intravenous route. [0061] The term "Therapeutic Time Ratio" or "TTR" represents the average time that the drug is present at therapeutic levels, defined as time within which the drug plasma concentration is maintained above 50% of Cmaχ normalized by the drug's elimination half- life and it is calculated by the formula: TTR= (Time above 50% of Cmax) / (Terminal intravenous elimination half-life of the drug). The last term is obtained from literature data for the drug of interest in the appropriate species.
[0062J The term "disintegration" as used herein means the physical process by which a tablet breaks down and pertains to the physical integrity of the tablet alone. This can occur via a number of different ways including breaking into smaller pieces and ultimately, fine and large particulates or, alternatively, eroding from the outside in until the tablet has disappeared.
[0063] The term "dissolution" as used herein means the process by which the active ingredient is dissolved from the tablet in the presence of a solvent, in vitro, or physiological fluids in vivo, e.g., saliva, irrespective of the mechanism of release, diffusion of erosion.
[0064] The term "swelling ratio" as used herein means the mass ratio of the dosage form after full exposure to water as compared to its mass in the dry state prior to exposure. Swelling ratio (SR) can be defined based on a specified time of exposure to water and expressed as a ratio or a percentage, e.g., SR expressed as a percentage = (Mass after exposure to water-Initial Dry Mass)/(Initial dry Mass) x 100.
[0065] Alternatively, such a 'swelling ratio5 may be defined as the ratio of the volume of a dosage form of the invention following contact with water as compared to the volume of the same dosage form prior contact with water. Swelling ratio (SR) can be defined based on a specified time of exposure to water and expressed as a ratio or a percentage, e.g., SR expressed as a percentage = (Tablet volume after exposure - tablet volume before exposure)/(tablet volume before exposure) X 100. When the radial dimensions of such an experiment are well-controlled, the same swelling ratio can be defined in terms of the variable dimension, e.g. thickness, as: SR expressed as a percentage = (Tablet thickness after exposure - tablet thickness before exposure)/(tablet thickness before exposure) X 100. 00529
10066] The term "bioadhesion" as used herein refers to adhesion to a biological surface more in general, including mucosal membranes.
10067] The term "therapeutically effective amount" means an amount of a therapeutic agent, or a rate of delivery of a therapeutic agent (e.g., amount over time), effective to facilitate a desired therapeutic effect, such as pain relief. The precise desired therapeutic effect (e.g., the degree of pain relief, and source of the pain relieved, etc.) will vary according to the condition to be treated, the tolerance of the subject, the drug and/or drug formulation to be administered (e.g., the potency of the therapeutic agent (drug), the concentration of drug in the formulation, and the like), and a variety of other factors that are appreciated by those of ordinary skill in the art.
[0068] "Sustained drug delivery" refers to release or administration of a drug from a source (e.g., a drug formulation) over a protracted period of time, for example, over a period of a minute or more. Sustained drug delivery is in effect the opposite of bolus drug delivery.
[0069] As used herein, when a drug formulation is said to "adhere" to a surface, such as a mucosal membrane, it is meant that the formulation is in contact with the surface and is retained upon the surface without the application of an external force. Adhesion is not meant to imply any particular degree of sticking or bonding, nor is it meant to imply any degree of permanency.
[0070] The term "active agent" or "active" may be used interchangeably herein with the term "drug" and is used herein to refer to any therapeutically active agent.
[0071] The term "non-occlusive" is used herein in its broadest sense to refer to not trapping or closing the skin to the atmosphere by means of a patch device, fixed reservoir, application chamber, tape, bandage, sticking plaster, or the like which remains on the skin at the site of application for a prolonged length of time.
[0072] The term "mucosal-depot" is used herein in its broadest sense to refer to a reservoir or deposit of active agent within or just beneath the mucosal membrane.
[0073] The expression "mucoadhesion" is used herein in to refer to adhesion to mucosal membranes which are covered by mucus, such as those in the oral cavity and is used 2007/000529
interchangeably herein with the term "bioadhesion" which refers to adhesion to any biological surface.
[0074] The term "drug delivery device" is used interchangeably herein with the term "dispensing device" and means a device that dispenses oral transmucosal dosage forms such as a NanoTab® of the invention, comprising a formulation as further described herein.
Oral Transmucosal Drug Delivery Dosage Forms
[0075] The present invention provides oral transmucosal drug delivery dosage forms or NanoTabs®, that produce a reduced saliva response when compared with other oral dosage forms, thus providing high absorption rates of the pharmaceutically active substance provided in the dosage form across the oral mucosa, and reduced uptake via the gastrointestinal tract and therefore offering a more consistent and reproducible means of drug delivery.
[0076] The oral dosage form or NanoTab®, is typically a "sublingual dosage form", but in some cases other oral transmucosal routes may be employed. The invention relies upon such oral dosage forms for sustained delivery of drugs across the oral mucosa. The dosage form is a substantially homogeneous composition which comprises one or more active ingredients and may comprise one or more of: mucoadhesives (also referred to herein as "bioadhesives") that provide for adherence to the mucosa of the mouth of a patient; one or more binders that provide binding of the excipients in a single tablet; one or more hydrogel forming excipients; one or more bulking agents; one or more lubricants; one or more absorption enhancers; one or more buffering excipients; as well as coatings and other excipients and factors that modify and control the drug's dissolution time and kinetics or protect the active drug from degradation.
[0077] Sublingual delivery is preferred as the sublingual mucosa is more readily permeable to medications than other mucosal areas, such as the buccal mucosa, resulting in more rapid uptake (Shojaei AH, et al. Buccal mucosa as a route for systemic drug delivery: a review. Journal of Pharmacy and Pharmaceutical Sciences. 1:15-30, 1998).
[0078] The NanoTabs® of the invention provide for the delivery of a greater percentage (and amount) of drug via the oral mucosa and a corresponding decrease in delivery via the GI tract as compared to traditional oral dosage forms or clinically used oral transmucosal dosage forms. [0079] The preferred site for oral transmucosal drug delivery is the sublingual area, although in certain embodiments it may be advantageous for the dosage form to be placed inside the cheek, or to adhere to the roof of the mouth or the gum.
[0080] The dosage forms of the invention are adapted for oral transmucosal (for example sublingual) delivery of a drug and typically have a dissolution time of up to about 60 minutes, in some cases up to about 120 minutes and in other cases as long as several hours.
[0081] In general, greater than 30%, greater than 50%, greater than 75% or greater than 95- 99% of the drug in the dosage form is absorbed via the oral mucosa.
[0082] Application of the drug delivery dosage forms of the present invention is not limited to any particular therapeutic indication. Examples of application of the drug delivery dosage forms of the invention for the treatment of pain are provided herein, however, the NanoTabs® of the invention find utility in treatment of any of a number of medical conditions and disorders, and are not limited to any particular drug or patient population. As such, use of the NanoTabs® of the invention administration of drugs to finds utility in administration of drugs to both pediatric and adult populations and in treatment of human and non-human mammals.
[0083] When the NanoTabs® of the invention are used for the treatment of pain, the invention finds utility in administration of drugs to pediatric and adult populations and in treatment of human and non-human mammals, as well as in opioid tolerant and opioid naϊve patient populations.
NanoTab® Dosage Form Attributes
[0084] In one embodiment, the dosage forms or NanoTabs® of the invention are generally adapted to adhere to the oral mucosa (i.e. are bioadhesive) during the period of drug delivery, and until most or all of the drug has been delivered from the dosage form to the oral mucosa. In other embodiments, the dosage forms or NanoTabs® of the invention are not bioadhesive.
[0085] A NanoTab® of the invention has a volume of from about OuI (microliters) to about 10OuI5 a mass of from about Omg (milligrams) to about lOOmg, athickness of from about 0.1mm to about 10.0mm, e.g., from about 0.5 to about 3.0 mm; and a diameter of from about 1.0mm to about 30.0mm, from about 1.0mm to about 10.0mm, e.g., about 3.0mm.
10086] More specifically, a NanoTab® of the invention has a mass selected from the group consisting of less than lOOmg, less than 90mg, less than 80mg, less than 70mg, less than 60mg, less than 50mg, less than 40mg, less than 30mg, less than 20mg and less than 10mg.
10087] A NanoTab® of the invention may also have a volume selected from the group consisting of less than lOOμl, less than 90μl, less than 80μl, less than 70μl, less than 60 μl, less than 50μl, less than 40μl, less than 30μl, less than 20μl and less than lOμl.
[0088] Shape: The NanoTab® dosage forms of the invention may have essentially any shape that fits the parameters recited herein with respect to NanoTab® dimensions. Exemplary shapes are selected from the group consisting of a round disc with a flat, concave, or convex face, an ellipsoid shape, a spherical shape, a polygon with three or more edges and flat, concave, or convex faces. NanoTab® shapes may be symmetrical or asymmetrical, and may have features or geometries that allow for controlled, convenient, or easy storage, handling, packaging or dosing. Figure 6 illustrates some of these shapes.
[0089] Oral vs. GI uptake: In general, greater than 30%, greater than 50%, greater than 75% or greater than 95-99% of the drug in a NanoTab® of the invention is taken up via the oral mucosa.
[0090] In certain embodiments of the invention, the NanoTab® is adapted to deliver 30% or more of the total amount of drug contained in a single drug dosage form to an individual via the oral mucosa. In other embodiments the percentage of the total amount of drug contained in a single drug dosage delivered transmucosally may be greater than 30-40%, 40-50%, 60-70%, 70- 80%, 80-90% and preferably greater than 95%. In exemplary embodiments, at least 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98% or 99%, of the total amount of drug contained in a single drug dosage form is delivered via the oral mucosa.
[0091] The delivery of a greater percentage (and amount) of drug via the oral mucosa and the corresponding lack of delivery via the GI tract provides a significant improvement over prior methods of drug delivery. [0092] Reduced Saliva Response: The NanoTab® drug dosage forms of the present invention are designed and adapted to reduce the saliva response, reducing the amount of drug swallowed, and thereby delivering a substantial amount of drug to a subject via the oral mucosa. The NanoTabs® of the invention also provides oral transmucosal dosage forms with improved dissolution profiles over previously described oral or oral transmucosal dosage forms, efficacious delivery of drug via the oral mucosa, and a consistent plasma level within the therapeutic window.
[0093] Erosion time: The dosage forms of the invention are designed to provide for an erosion rate that allows for maximal delivery via the oral mucosa, typically via placement of the dosage form in the sublingual location. Erosion times for sublingual administration of the a NanoTab® of the invention is typically from about 30 seconds up to 1 minute, 2 minutes, 3 minutes, 4 minutes, 5 minutes, 10 minutes, 15 minutes, 30 minutes, 1 hour, 2 hours, 4 hours and 8 hours.
[0094] Dissolution time: The oral transmucosal formulations of the present invention are typically designed to achieve drug dissolution times of that will vary from 30 seconds up to 1 minute, 2 minutes, 3 minutes, 4 minutes, 5 minutes, 10 minutes, 15 minutes, 30 minutes, 1 hour, 2 hours, 4 hours, 8 hours or longer dependent upon the patient and circumstances of drug administration as well as the intrinsic drug pharmacokinetics. It will be understood that the composition of the oral transmucosal formulations of the present invention may be adjusted to provide for both a range of doses and a range of dissolution times to fit particular clinical situations.
[0095] Formulations: A pharmaceutical dosage form of the invention for oral transmucosal delivery may be solid or non-solid. In one preferred embodiment, the dosage from is a solid that turns into a hydrogel following contact with saliva. In another preferred embodiment, the dosage from is a solid that erodes without forming a hydrogel following contact with saliva.
[0096] A dosage form of the invention is a substantially homogeneous formulation which comprises 0.01-99% w/w of the active ingredient(s) (drug, medication, etc.) and further comprises one or more of: mucoadhesives (also referred to herein as "bioadhesives") that provide for adherence to the mucosa of the mouth of a patient; one or more binders that provide binding of the excipients in a single tablet; one or more hydrogel forming excipients; one or more bulking agents; one or more lubricants; one or more absorption enhancers; one or more buffering excipients; one or more coatings; one or more controlled release modifiers; and one or more other excipients and factors that modify and control the drug's dissolution or disintegration time and kinetics or protect the active drug from degradation.
[0097] Excipients are not limited to those above, and numerous suitable nontoxic pharmaceutically acceptable carriers for use in oral dosage forms can be found in Remington's Pharmaceutical Sciences, 17th Edition, 1985.
[0098] The dosage forms of the invention for oral transmucosal drug delivery may include at least one bioadhesive (mucoadhesive) agent or a mixture of several bioadhesives to promote adhesion to the oral mucosa during drug delivery. In addition the bioadhesive or mucoadhesive agents may also be effective in controlling the dosage form erosion time and/or, the drug dissolution kinetics over time when the dosage form is wetted by saliva. In addition, some of the mucoadhesives named in this invention may also serve as binders in the formulation to provide necessary bonding to the dosage form.
[0099] Exemplary mucoadhesive or bioadhesive materials are selected from the group consisting of natural, synthetic or biological polymers, lipids, phospholipids, and the like. Examples of natural and/or synthetic polymers include cellulosic derivatives (such as methylcellulose, carboxymethyl cellulose, hydroxyethyl cellulose, hydroxyethylmethyl cellulose, etc) , natural gums (such as guar gum, xanthan gum, locust bean gum, karaya gum, veegum etc), polyacrylates (such as carbopol, polycarbophil, etc), alginates, polyoxyethylenes, polyethylene glycols (PEG) of all molecular weights (preferably between 1000 and 40,000 Da, of any chemistry, linear or branched), dextrans of all molecular weights (preferably between 1000 and 40,000 Da of any source), block copolymers, such as those prepared by combinations of lactic & glycolic acid (PLA, PGA, PLGA of various viscosities, molecular weights and lactic-to-glycolic acid ratios) polyethylene glycol-polypropylene glycol block copolymers of any number and combination of repeating units (such as Pluronics, Tektronix or Genapol block copolymers), combination of the above copolymers either physically or chemically linked units (for example PEG-PLA or PEG-PLGA copolymers) mixtures. Preferably the bioadhesive excipient is selected US2007/000529
from the group of polyethylene glycols, polyoxyethylenes, polyacrylic acid polymers, such as Carbopols (such as Carbopol 71G- 934P, 971P 974P) and polycarbophils (such as Noveon AA-I , Noveon CA-I, Noveon CA-2), cellulose and its derivatives and most preferably it is polyethylene glycol, carbopol, and/or a cellulosic derivative or a combination thereof.
[00100] The mucoadhesive/bioadhesive is typically present at 1-50% w/w, preferably 1-40% w/w or most preferably between 5-30% w/w. A formulation of the invention may contain one or more different bioadhesives in any combination.
[0100] The dosage forms of the invention for oral transmucosal drug delivery may also include a binder or mixture of two or more binders which facilitate binding of the excipients into a single dosage form. Exemplary binders are selected from the group consisting of cellulosic derivatives (such as methylcellulose, carboxymethyl cellulose, hydroxyethyl cellulose, hydroxyethylmethyl cellulose, etc), polyacrylates (such as Carbopol, polycarbophil, etc), Povidone (all grades), Polyox of any molecular weight or grade irradiated or not, starch, polyvinylpyrrolidone (PVP), Avicel, and the like.
[0101] The binder is typically present at 0.5-60% w/w, preferably 1-30% w/w and most preferably 1.5-15% w/w.
[0102] The dosage forms of the invention for oral transmucosal drug delivery may further include one or more hydro gel-forming excipients. Exemplary hydrogel forming excipients are selected from the group consisting of polyethylene glycols and other polymers having an ethylene glycol backbone, whether homopolymers or cross linked heteropolymers, block copolymers using ethylene glycol units, such as polyoxyethylene homopolymers (such as Polyox N10/MW=100,0001 Polyox-80/MW=200,000; Polyox 1105/MW=900,000; Polyox- 301/MW=4,000,000; Polyox~303/MW=7,0.00,000, Polyox WSR-N-60K, all of which are tradenames of Union Carbide), hydroxypropylmethylcellylose (HPMC) of all molecular weights and grades (such as Metolose 90SH50000, Metolose 90SH30000, all of which are tradenames of Shin-Etsu Chemical company), Poloxamers (such as Lutrol F-68, Lutrol F-127, F-105 etc, all tradenames of BASF Chemicals), Genapol, polyethylene glycols (PEG, such as PEG-1500, PEG- 3500, PEG-4000, PEG-6000, PEG-S000, PEG-12000, PEG-20,000, etc.), natural gums (Xanthan gum, Locust bean gum, etc) and cellulose derivatives (HC5 HMC, HMPC, HPC, CP, CMC), polyacrylic acid-based polymers either as free or cross-linked and combinations thereof, biodegradable polymers such as poly lactic acids, polyglycolic acids and any combination thereof, whether a physical blend or cross-linked. In an embodiment, the hydrogel components may be cross-linked. The hydrogel forming excipient(s) are typically present at 0.1 -70% w/w, preferably 1-50% w/w or most preferably 1-30% w/w.
[0103] The dosage forms of the invention for oral transmucosal drug delivery may also include at least one controlled release modifier which is a substance that upon tablet hydration will preferentially adhere to the drug molecules and thus reduce the rate of its diffusion from the oral dosage form. Such excipients may also reduce the rate of water uptake by the formulation and thus enable a more prolonged drug dissolution and release from the tablet. In one embodiment, such controlled release modifiers are capable of binding molecularly to the active via physical (and therefore reversible) interactions, thus increasing the effective molecular weight of the active and thus further modifying their permeation (diffusion) characteristics through the epithelial and basal membranes of the sublingual mucosa. Such binding is reversible in nature and does not involve any chemical modifications of the active, thus it does not affect in any way its pharmacological action. In another preferred embodiment, such controlled release modifiers upon hydration may form concrete structures that may entrap spontaneously the active and thus further prolong its action. Exemplary controlled release modifiers are selected from the group consisting of lipids, phospholipids, sterols, surfactants, polymers and salts. In general the selected excipient(s) are lipophilic and capable of naturally complexing to the hydrophobic or lipophilic drugs. The degree of association of the release modifier and the drug can be varied by altering the modifϊer-to-drug ratio in the formulation. In addition, such interaction may be appropriately enhanced by the appropriate combination of the release modifier with the active drug in the manufacturing process. Alternatively, the controlled release modifier may be a charged polymer either synthetic or biopolymer bearing a net charge, either positive or negative, and which is capable of binding to the active via electrostatic interactions thus modifying both its diffusion through the tablet and/or the kinetics of its permeation through the mucosal surface. Similarly to the other compounds mentioned above, such interaction is reversible and does not involve permanent chemical bonds with the active drug. [01041 A controlled release modifier may typically be present at 0-80% w/w, preferably 1- 20% w/w, most preferably 1-10% w/w.
[0105] The dosage forms of the invention for oral transmucosal drug delivery also typically include at least one filler (bulking agent). Exemplary bulking agents are selected from the group consisting of lactose USP, Starch 1500, mannitol, sorbitol, malitol or other non-reducing sugars; microcrystalline cellulose (e.g., Avicel), dibasic calcium phosphate dehydrate, sucrose, and mixtures thereof. The filler/bulking agent is typically present at 20-99% w/w, preferably 40- 80% w/w.
[0106] The dosage forms of the invention for oral transmucosal drug delivery may also include at least one lubricant. Exemplary lubricants are selected from the group consisting of magnesium stearate, stearic acid, calcium stearate, talc, stearowet and sterotex and the like. The lubricant is typically present at 0.01-8% w/w, preferably between 0.1-3% w/w.
[0107] The formulation may also contain flavors or sweeteners and colorants such as aspartame, mannitol, lactose, sucrose, other artificial sweeteners; ferric oxides and FD&C lakes.
[0108] The formulation may also contain additives to help stabilize the drug substance from chemical of physical degradation. Such degradation reactions may include oxidation, hydrolysis, aggregation, deamidation, etc. Appropriate excipients that can stabilize the drug substance may include anti-oxidants, anti-hydrolytic agents, aggregation-blockers etc. Anti-oxidants may include BHT, BHA, vitamins, citric acid, EDTA etc. Aggregation blockers may include surfactants, amino-acids, etc.
[01091 The formulation may also contain surfactants to increase wetting of the tablet, especially if faster release kinetics are desired, which could result in faster initiation of mucoadhesion. Such surfactants should be from 0.01 to 3% weight percent of the composition. Exemplary surfactants are selected from the group consisting of ionic (sodium lauryl sulfate, etc), non-ionic such as polysorbates (T ween and Span surfactant series), bile salts (such as sodium taurocholate, sodium taurodeoxycholate, sodium glycodeoxycholate, sodium glycocholate, etc), various alkyl glycosides, and mixtures thereof. [0110] A dosage form of the invention may additionally comprise one or more excipients that may affect both tablet disintegration kinetics and drug release from the tablet, and thus pharmacokinetics. Such additives are disintegrants such as those known to those skilled in the art and may be selected from a group consisting of starch, carboxy-methycellulose type or crosslinked Polyvinyl Pyrrolidine (such as cross-povidone, PVP-XL), alginates, cellulose-based disintegrants (such as purified cellulose, methylcellulose, crosslinked sodium carboxy methylcellulose (Ac-Di-SoI) and carboxy methyl cellulose), microcrystalline cellulose (such as Avicel), ion exchange resins (such as Ambrelite IPR 88), gums (such as agar, locust bean, karaya, Pectin and tragacanth), guar gums, gum Karaya, chitin and chitosan, Smecta, gellan gum, Isapghula Husk, Polacrillin Potassium (Tulsion 339)' gas-evolving disintegrants (such as citric acid and tartaric acid along with the sodium bicarbonate, sodium carbonate, potassium bicarbonate or calcium carbonate), sodium starch glycolate (such as Explotab and Primogel), Addition of such additives facilitates the fast breakup or disintegration of the dosage form into smaller particles that dissolve more rapidly than in the absence of disintegrants. An additional benefit of inclusion of such disintegrants in the dosage forms of the present invention which contain the bioadhesive materials described herein, is that the smaller, drug-containing particles formed upon disintegration have, by virtue of the highly increased surface area of contact with the oral mucosa, superior bioadhesive properties. In addition, the increased surface area may further facilitate the fast release of the active substance and thus further accelerate drug absorption and attainment of the required therapeutic levels systemically . However, as described above, such disintegrants are used at a low level in the solid dosage form, typically 1 — 20 % w/w relative to the total weight of the dosage unit.
[0111] In one aspect of the invention, the dosage forms comprise at least one biodegradable polymer of any type useful for extended drug release. Exemplary polymer compositions include polyanhydrides and co-polymers of lactic acid and glycolic acid, poly(dl-lactide-co-glycolide) (PLGA), poly(lactic acid) (PLA), poly(glycolic acid) (PGA), polyorthoesters, proteins, and polysaccharides.
[0112] The dosage forms of the invention for oral transmucosal drug delivery may further include one or more absorption enhancers, one or more buffering excipients and/or one or more coatings to improve, for example, hardness and friability. [0113] In another aspect of the invention, the active ingredient can be chemically modified to significantly modify the pharmacokinetics in plasma. This may be accomplished for example by conjugation with polyethylene glycol (PEG), including site-specific PEGylation. PEGylation, which may improve drug performance by optimizing pharmacokinetics, decreasing immunogenicity and dosing frequency.
[0114] TheNanoTabs® of the present invention are provided in a number of dosage forms that vary according to the nature and amount of active ingredients while maintaining the features of the NanoTabs® of the invention for controlled dissolution in the oral cavity. Thus, a greater percentage of drug absorption takes place via the oral mucosal route and not the GI route and resulting in controlled release of the drug over time resulting in prolonged plasma levels within the therapeutic window. The "NanoTabs® of the present invention further provide for high bioavailability, low variability in Tm3x, low variability in Cmaχ and low variability in AUC.
[0115] In one aspect of the invention, when a homogeneous dosage form comprising a formulation according to the present invention is placed in the sublingual cavity, preferably under the tongue on either side of the frenulum linguae, it adheres upon contact. As the dosage form is exposed to the moisture of the sublingual space the dosage form absorbs water, resulting in the formation of a hydrogel network, comprising micro- and macro-pores (or channels). Hydration of the drug affects dissolution and subsequent diffusion through the porous network of the dosage form. Hydrogel dosage forms of the invention are characterized by swelling to at least 110% of the initial volume upon contact with an aqueous solution.
[0116] Hydrogel formation in the dosage forms of the invention takes place in the presence of certain hydrogel-enabling excipients that have the capacity to absorb water and form gels. Such excipients include Polyox of all grades, polyethylene glycols (of all grades), PEG-based copolymers, whether homopolymers or heteropolymers (such as Poloxamer, etc), Dextran, HPMC, starch, etc, as detailed above. In addition, any combination of such excipients may favor hydrogel formation upon contact with bodily fluids. Further, combinations of such hydrogel forming excipients with excipients that do not favor gel formation (i.e., don't have such a capacity to swell), e.g., Carbopol, certain celluloses, and the like will result in formation of hydrogel structures, albeit with modified properties. [0117] In another aspect of the invention, dosage forms referred to herein as "eroding-type" dosage forms are provided. Such "eroding-type" dosage forms, although they may absorb significant amounts of water (depending on their composition) they do not have the same capacity of swelling and consequently they do not form gels as described for the hydrogel type formulations defined above. These "eroding-type" formulations adhere to the sublingual cavity upon contact, similar to the hydrogel formulation. However, in contrast to the hydrogels, they follow a surface-erosion mechanism without prior formation of a hydrogel. As an "eroding-type" dosage form is exposed to the moisture of the sublingual space, the surface of the tablet hydrates and erodes; the subsequent layers become hydrated and erode, thus resulting in a continuous reduction in the size of the tablet.
[0118] Such eroding-type dosage forms are typically characterized by a lack of inclusion of hydro gel-forming excipients. However, it will be understood that the percentage weight to weight (w/w) composition of the various components of the dosage form will impact the mechanism of erosion. For example, small amounts of particular hydrogel-enabling excipients may not induce formation of a hydrogel and as such, some hydrogel-enabling excipients may be included in eroding formulations without changing their erosion-based disintegration mechanism. It is both the combination of excipients and their percent weight composition that gives a hydrogel its capacity to swell and maintain a structural matrix upon contact with an aqueous solution. In other words, in general, inclusion of a hydrogel-enabling excipient in a given formulation will not necessarily make the dosage form "swell" as is typical of a hydrogel formulation. A dosage form which becomes a hydrogel swells to at least 110% of its initial volume upon contact with an aqueous fluid.
Pharmacokinetics (PK)
[0119] The uptake of transmucosal medications via NanoTabs® results in a more consistent drug delivery between individual dosages and individual patients as compared to that of currently available oral transmucosal dosage forms for which a large fraction of drug uptake occurs via the GI route.
[0120] The dosage forms of the present invention are designed to work effectively in the unique environment of the oral cavity such that a limited amount of fluid, a relatively short US2007/000529
period of time for drug dissolution, and pH levels within the oral cavity do not adversely affect absorption of the drug. The dosage forms are also designed to improve dissolution, solubility, and stability of the drug. The advantages of the present invention include the ability to provide higher levels of drug absorption via oral transmucosal delivery, and consistent dose-to-effect times, making the present formulation a significant improvement for the treatment of acute or break-through pain.
[0121] The oral transmucosal dosage forms of the present invention are designed to avoid the high peak plasma levels of intravenous dosage forms by utilizing the sublingual mucosa and by independently controlling both tablet disintegration (or erosion) and drug dissolution and release from the tablet over time to provide a safer delivery profile. The oral transmucosal dosage forms of the present invention provide individual, repetitive doses that include a defined amount of the active agent, thereby allowing the patient to accurately titrate the amount of drug delivered and to adjust the amount as appropriate in a safe and effective manner.
[0122] An advantage of the controlled-release oral transmucosal dosage forms described in this invention is that they exhibit high consistent bioavailability and can maintain the plasma drug concentration within a targeted therapeutic window with significantly lower variability for a longer duration than currently available dosage forms, whether solid dosage forms or IV dosage forms. The high peak plasma levels typically observed for IV dosage forms are blunted following administration of a NanoTab® of the invention, which are characterized by controlled release of the drug over 1 to 60 minutes or longer. In addition, a rapid decline in plasma levels is avoided since the drug is continually crossing from the oral cavity into the bloodstream during the length of time of dissolution of the tablet or longer, thus providing plasma pharmacokinetics with an extended plateau phase as compared to the IV route of administration. Further, the dosage forms of this invention may improve treatment safety by minimizing the potentially deleterious side effects due to the relative reduction of the peaks and troughs in the plasma drug pharmacokinetics, which compromise treatment safety and is typical of currently available dosage forms.
[0123] Advantages of a solid sublingual dosage form over various liquid forms for either sublingual or intranasal administration of opioids include the controlled local release of the solid dosage form and the avoidance of swallowed liquid drug via either the nasal or oral route. Published pharmacokinetic data on intranasal sufentanil liquid administration (15 meg) in humans demonstrates a bioavailability of 78% (Helmers et al. Comparison of intravenous and intranasal sufentanil absorption and sedation. Canadian Journal of Anaesthesia 36:494-497, 1989). Sublingual liquid sufentanil administration (5 meg) in Beagle dogs (see Example 4 below) resulted in a bioavailability of 40%. The aforementioned bioavailability data are less than the 91% average bioavailability that was obtained in human volunteers using sufentanil administered sublingual Iy in the form of aNanoTab® of the invention (see Example 1 below).
[0124] Due to the small size of the NanoTabs®, repeated placement in the sublingual cavity over a duration of time is possible. Minimal saliva production and minimal physical discomfort occurs due to the small size, which allows for repetitive titration over days to weeks to months. Given the lipid profile of the sublingual cavity, this route, for certain drugs, also allows for slower release into the plasma which may be due to utilization of a "depot" effect that further stabilizes plasma levels compared to buccal delivery.
[0125] The oral transmucosal dosage forms of the invention are designed to fit comfortably under the tongue such that the drug form disintegrates sufficiently slowly to avoid the immediate peak plasma levels followed by significant drop off seen in prior art formulations such as described in US. Patent No. 6,759,059 (Rapinyl), wherein fentanyl was administered via tablets containing 400mcg of fentanyl which resulted in a peak plasma level of 2.5ng/ml followed by an immediate drop in plasma level. Fentora (fentanyl buccal tablet) also suffers from a lack of a plateau phase but rather has a steep incline up to the Cmaχ followed by a significant drop-off in plasma levels (Fentora package insert).
Tests For Evaluation Of NanoTabs®
[0126] Prior to the human and animal studies of sublingual NanoTabs® performed in support of the present invention and described below in the specification and in Examples 1- 6 in humans and animals, the inventors were not aware of any published pharmacokinetic data obtained in animals or humans from the use of sublingual sufentanil in any dosage form or of sublingual alfentanil in any dosage form. In Vivo Evaluation.
Human studies
[0127] A human clinical study was performed using healthy volunteers. The study which is detailed in Example 1 below was performed with 12 subjects (6 men and 6 women) using sublingual sufentanil NanoTabs® containing either 2.5 μg, 5 μg or 10 μg of sufentanil base corresponding to 3.7 μg, 7.5μg or 15 μg of sufentanil citrate, respectively (see Table 1). AU excipients were inactive and have GRAS ("generally recognized as safe") status.
[0128] Sufentanil NanoTabs® designed for sublingual use were compared to IV sufentanil, administered through an IV catheter as a continuous infusion over 10 minutes. Plasma samples were drawn from a different IV catheter at a remote location. The assay demonstrated good inter- day precision and accuracy at the high, medium and low quality control sample concentrations.
[0129] The NanoTabs for this study eroded over a period of 10-30 minutes in all subjects. After placement of each sufentanil sublingual NanoTab® in the sublingual cavity of the 12 healthy volunteers, a remarkably consistent pharmacokinetic profile was obtained (see Figure 2 and Table 2). The bioavailability compared to IV administration for single administration of all three dosages averaged 91%, which is far superior to that measured for commercially available fentanyl transmucosal preparations, Actiq and Fentora (47% and 65%, respectively — Fentora package insert). Although this high bioavailability could be due to a number of factors, it is likely that the lack of saliva produced by the small NanoTab® size significantly limits the swallowing of the drug and avoids the low bioavailability typical of drug absorption via the GI route. Both Fentora and Actiq package inserts claim at least 50% and 75% of the drug dose, respectively, is swallowed via the saliva, and both exhibit lower bioavailability than the NanoTabs® of the invention. The NanoTabs® used in this clinical trial had a volume of approximately 5 microliters (mass of 5.5 mg), a small fraction of the size of Actiq or Fentora lozenges. The dog studies described in Example 4 and discussed above demonstrate that sufentanil has very poor GI bioavailability (12%), therefore, given the high bioavailability of the sufentanil NanoTabs®, wherein drug is administered by the oral transmucosal route, the data supports the conclusion that greater than 75% of the drug is absorbed transmucosally. Therefore, less than 25% of the drug is swallowed, which is a much lower percentage than is swallowed with Fentora or Actiq.
[0130] Importantly, this high bioavailability is also linked to high consistency of total drug delivered to the patient. For example, the total plasma drug area under the curve (AUC 0- infinity) for sufentanil NanoTabs® lOmcg was 0.0705 + 0.0194 hr*ng/ml (mean ± standard deviation (SD)).This SD is only 27.5% of the total AUC. Coefficient of variation (CV) is a term to describe the percent SD of the mean. The coefficient of variation for Fentora AUC is 45% and for Actiq AUC is 41% (Fentora package insert). Therefore the total dose delivered to the patient/subject is not only more bioavailable for the sufentanil NanoTabs® but it is more consistently the same from patient to patient.
[0131] The sufentanil sublingual NanoTabs® are also superior in terms of consistent drug plasma levels early after administration. The Cmax obtained with the 10 meg sufentanil NanoTab® was 27.5 + 7.7 pg/ml. The coefficient of variation of the Cmax therefore is only 28%. The Cmax for Fentora and Actiq suffer from variability of GI uptake of drug. Fentora reports a Cmax of 1.02 + 0.42 ng/ml, therefore the coefficient of variation of the Cmax is 41%. The range of coefficients of variation for the various doses of Fentora is from 41% to 56% (package insert). Actiq coefficient of variation of Cmax is reported as 33% (Fentora package insert).
[0132] In addition to superior bioavailability and consistency in plasma concentrations, the time to Cmax, also referred to as Tmaχ, is important since quick and consistent onset of pain relief is important in the treatment of acute pain. The Troax for sufentanil NanoTabs® 10 meg was 40.8 + 13.2 minutes (range 19.8 - 60 minutes). The reported average Tmax for Fentora is 46.8 with a range of 20 — 240 minutes. The Tmaχ for Actiq is 90.8 minutes, range 35 — 240 minutes (Fentora package insert). Therefore the consistency in onset of analgesia for sufentanil NanoTabs® is markedly improved over Fentora and Actiq, with a 400% decrease in the slowest onset of Tmax.
[0133] Important in the treatment of acute pain, especially acute breakthrough pain, is a consistent and relatively short half-life of the drug. The plasma elimination half-life of the 10 meg sufentanil NanoTab® was 1.71 + 0.4 hours, which allows the drug to be titratable for various levels of pain. If the breakthrough pain event lasts longer than 1.5 hours then the patient can dose with another NanoTab®. The plasma elimination half-life of Actiq and Fentora are 3.2 hours and 2.63 hours, respectively, for the lowest doses. The half-lives for the higher doses increase substantially for these drugs, thereby limiting the titratability of these drugs.
[0134] Although still in development, published data allows us to compare the sufentanil NanoTab® pharmacokinetic data provided herein to that of Rapinyl, a fentanyl sublingual fast- dissolve lozenge. As previously mentioned, the observed bioavailability for the sufentanil NanoTabs® of the invention averaged 91% as compared to the published bioavailability for Rapinyl which is approximately 70% (Bredenberg, New Concepts in Administration of Drugs in Tablet Form, Acta Universitatis Upsaliensis, Uppsala, 2003). The coefficient of variation of the AUC (0-infinity) for Rapinyl ranges from 25-42% depending on dose, whereas our value is 27.5% for the 10 meg sufentanil NanoTabs®. Our high bioavailability would suggest that regardless of dose, the sufentanil NanoTabs® will have a consistently low variation of AUC, whereas this is not true for Rapinyl. In fact, our AUC coefficient of variation for all three of the doses of sufentanil NanoTabs® averaged 28.6%, demonstrating that this low variation is not dependent on dose.
[0135] The coefficient of variation of the Cmax for Rapinyl varies from 34 — 58% depending on dose. As shown by the data presented herein, the 10 meg sufentanil NanoTab® dose exhibited a Cmax variation of only 28%, and the average coefficient of variation of the Cmax for all three dosage strengths of the NanoTabs® (2, 5, and 10 meg) was 29.4%, indicating minimal variability depending on dose. Similarly, the coefficient of variation for Tmaχ with Rapinyl ranges from 43 — 54% depending on dose, whereas for our sufentanil NanoTabs®, this coefficient of variation for Tmax averages only 29% over all three dosage strengths. This consistent onset of action achieved with sufentanil NanoTabs® allows a safer redosing window when compared to any of the three comparator drugs, since rising plasma levels are contained to a shorter period.
[0136] Additionally, as with Fentora and Actiq, Rapinyl demonstrates a longer plasma elimination half-life (5.4 — 6.3 hours, depending on dose) than sufentanil NanoTabs®. The plasma elimination half-life of sufentanil NanoTabs® ranged from 1.5 — 2 hours following a single oral transmucosal administration in humans (Table 2), which allows for more titratability and avoids overdosing. As will be understood by those of skill in the art, the half-life described herein for the exemplified NanoTabs® may be adjusted by modification of the component and relative amounts of the excipients in the formulation used to make a given NanoTab®. The ability to titrate to higher plasma levels by administering repetitive doses of the sublingual sufentanil NanoTabs® was also tested in this human study. Repeat dosing of 5 meg NanoTabs® every 10 minutes for four dosings resulted in a bioavailability of 96%, indicating that repetitive dosing to achieve higher plasma levels while still maintaining high bioavailability is possible. Whether treating post-operative pain or cancer break-through pain, being able to efficiently titrate to an individual's own level of pain relief is important.
Plateau Plasma Levels
[0137] Another aspect of the PK curves generated by sublingual sufentanil NanoTabs® is the plateau phase, which allows for a period of consistent plasma levels, which is important for both safety and efficacy. Compared to either IV bolus administration (see Animal Studies Examples 2 - 6) or the 10 minute IV infusion in our human study (Example 1 and Figure 2), the PK profile for the sufentanil NanoTabs® is clearly safer. Rapid, high Cmaχ plasma levels are avoided. Given the ability of opioids to produce respiratory depression, avoiding these high peaks in the PK profile is advantageous.
[0138] An important mathematical ratio that demonstrates the prolonged plateau phase of the measured blood plasma levels of sufentanil following administration of a NanoTab® is the time spent above 50% of Cmax divided by the known IV terminal elimination half-life of the drug: f Therapeutic Time Ratio = Time of offset of Cma, /2 — Time of onset of Cmait /2
IV Elimination Half-Life of the Drug
[0139] The elimination half-life is an intrinsic property of the molecule and is measured most reliably using the IV route to avoid contamination from continued uptake of drug from the sublingual route. The IV elimination half-life for 5 meg of sufentanil in our human study was 71.4 minutes due to the detection limits of the assay at these low doses. The published IV elimination half-life for sufentanil at much higher doses is 148 minutes, due to detection of both the rapid alpha-elimination mechanism of redistribution and the longer beta phase of elimination via metabolism and excretion. This published elimination half-life is more accurate and more appropriate to use in the above equation. The time spent above 50% of Cmaχ on average for the 12 volunteers for the 2.5, 5 and 10 meg dosage strengths was 110 minutes, 111 minutes and 106 minutes, respectively. Therefore, the Therapeutic Time Ratio for these specific sufentanil NanoTabs® ranged from 0.72 — 0.75. As the formulation of the NanoTabs® is varied, erosion time of the NanoTab® will be either decreased or increased, and one might see a range of Therapeutic Time Ratios from approximately 0.2 — 2.0 for sufentanil. In fact, any oral transmucosal dosage form of the invention for sufentanil may exhibit Therapeutic Time Ratios in this range and therefore we are not limiting this claim to specific NanoTab attributes.
10140] This Therapeutic Time Ratio is a measure of how successfully short-acting drugs are formulated to produce an increase in therapeutic time and increase safety by avoiding high peak plasma Cmaχ concentrations. For example, as a comparison, the sufentanil IV arm of the human study demonstrated a Therapeutic Time Ratio of 10min/148min = 0.067. This low ratio value for the IV arm, therefore, is a measure of the high peak produced by IV infusion of sufentanil and demonstrates that this formulation does not produce a significant plateau phase. There is a 10-fold higher Therapeutic Time Ratio for the sufentanil formulations listed in Table 1 (the dosages used in the human study) versus IV sufentanil, indicating a prolonged therapeutic plateau profile for these NanoTab® formulations.
Animal studies
10141] A series of studies in awake, alert Beagle dogs was performed to more fully elucidate the properties of NanoTabs® using various drugs and NanoTab® formulations. Comparisons of oral transmucosal drug delivery using NanoTabs® of the invention relative to liquid sublingual administration as well as swallowed NanoTabs® were made to evaluate various attributes of the NanoTabs®. The results support our claim that the small, bioadhesive NanoTabs® of the invention are well tolerated sublingually (as demonstrated by use in awake dogs) and result in higher bioavailability and more consistent pharmacokinetic data than other oral transmucosal dosage forms, including instilled liquids.
[0142] The first Beagle dog study was carried out to compare a sublingual 5 meg sufentanil NanoTab to IV sufentanil as described more fully in Example 2 below. A total of three Beagle dogs were studied and the results are graphed in Figure 3 and tabulated in Table 3. The bioavailability of the sublingual sufentanil NanoTabs® was 75% compared to IV. Therefore, similar to the human data, this bioavailability data in dogs confirms the superior attributes of the NanoTab® over larger dosage forms. Furthermore, similar to the human data, the coefficient of variation for the AUC was low, 14%, compared to the variation of other commercial transmucosal dosage forms. The Therapeutic Time Ratio of the sublingual sufentanil NanoTab® is 0.28 whereas the Ratio for IV sufentanil is 0.05 (using the published IV elimination half-life of sufentanil in dogs of 139 minutes). Therefore, similar to humans, the 5 meg NanoTab® formulation in Table 1 resulted in a much higher Therapeutic Time Ratio (5.6-fold) compared to IV sufentanil in dogs.
[0143] Additional studies determined the effect of varying the formulation of the NanoTabs® on the pharmacokinetic profile. This study is explained more fully in Example 3 below. By prolonging the erosion time of the NanoTab®, the plasma half-life was extended from 33 minutes for the medium disintegrating NanoTab® (in Example 2) to 205 minutes. The Therapeutic Time Ratio was increased from 0.28 to 1.13 for the slow disintegrating NanoTab®. This study illustrates the flexibility of the NanoTab®, based on excipient selection, to alter the PK of the drug. This flexibility is possible due to the small size of the NanoTab®, which allows either short or prolonged contact time with the sublingual mucosa without dislodging or creating excess saliva which would prematurely wash the drug into the GI tract.
[0144] Another study in Beagle dogs was performed to evaluate the advantages of the sublingual NanoTab® dosage form over liquid administration sublingually. This study is described more fully in Example 4 below. The results indicate that although delivery of sufentanil (5 meg) in an instilled liquid dosage form to the sublingual cavity results in rapid Tmax, this method of drug administration results in very low bioavailablity (40%) compared to sublingual sufentanil NanoTabs® (75%). This is probably due to swallowing of the liquid drug. Moreover, the AUC is extremely variable, as shown by the high coefficient of variation (82%). The Cmax is also highly variable with this method of drug administration, demonstrating a coefficient of variation of 72%. The Therapeutic Time Ratio for instilled liquid sufentanil sublingually was calculated as 0.06, very similar to the IV sufentanil arm for this study which demonstrated a Ratio of 0.03. Therefore, this instilled sublingual liquid profile does not provide the advantageous therapeutic plateau observed with the sublingual NanoTabs®. These findings support that the high sublingual bioavailability observed from the bioadhesive formulations claimed in this application (NanoTabs®) is not intrinsic to the molecule but rather it is a direct result of the unique design of the dosage form and its formulation. The NanoTabs®'s strong adherence in the sublingual cavity minimizes the variability in the surface area available for absorption, as is the case of a liquid solution, thus improving delivery of the molecule to the systemic circulation. In addition, owing to its unique design and small dimensions, the NanoTab® does not elicit significant saliva production, thus reducing the potential for ingestion of the released drug. Both factors contribute to the higher and more uniform drug absorption from the sublingual cavity.
[0145] An additional part of this study in Example 4 was the determination of the bioavailablity of swallowed sufentanil NanoTabs®. Since there is little to no data on sufentanil GI bioavailability in the literature, it was important to further evaluate the low bioavailability of this route of administration to further support the observation that drug from the sublingual use of NanoTabs® could not be swallowed and maintain a high bioavailability. As indicated by the PK analysis data in Table 7, oral bioavailability of sufentanil from the swallowed NanoTabs® is very low, approximately 12%. In addition, as predicted from the known erratic GI uptake of fentanyl congeners, the swallowed NanoTabs® demonstrated extremely high variability both in the amount of drug absorbed (AUC) and the pharmacokinetics of absorption (Cmax, Tmax) as shown in Table 7. These data support the conclusion that the bioadhesive sublingual NanoTabs® of the invention strongly adhere in the sublingual cavity in such a manner that they don't dislodge, thus avoiding oral ingestion and avoiding the high variability of plasma levels which is typical when drug is absorbed via the GI route.
[0146] Additional studies evaluating other drugs, such as fentanyl and alfentanil, formulated into NanoTabs® were also performed in Beagle dogs and are more fully described in Examples 5 and 6 below. These studies support the claim that the NanoTab® can effectively deliver a variety of drugs sublingually with high bioavailability. Fentanyl NanoTabs® were created in both a medium and a slow disintegrating NanoTab® formulations (see Tables 8 and 9). Both formulations resulted in high bioavailability (95% and 90%, respectively), much higher than with any other fentanyl oral transmucosal formulation patented to date. The coefficient of variation of the AUCs was extremely low (10.5% and 4.5%, respectively). These data support the attributes of the NanoTab® and demonstrate that these attributes are not limited to a specific drug. The slower disintegrating fentanyl NanoTab® displayed a slower Tmax (50 minutes vs. 22 minutes) and a longer half-life (154 minutes vs. 121 minutes) compared to the medium disintegrating version. These data further demonstrate the ability of the NanoTab® to modulate PK based on excipient selection.
[0147] Alfentanil NanoTabs® resulted in a bioavailability of 94% compared to IV alfentanil and a coefficient of variation of 5% for the AUC5 7% for Cmax and 28% for Tmax. The Therapeutic Time Ratio was calculated as 0.33, compared to 0.04 for the IV alfentanil arm of this study (calculated using a published IV elimination half-life of 104 min for alfentanil in dogs). Therefore, the alfentanil NanoTab® formulation (as described in Example 6) produces an 8-fold improved Therapeutic Time Ratio over the IV alfentanil arm. The high bioavailability of this formulation again supports the claim that minimal swallowing of drug occurs with use of the NanoTab®.
In Vitro NanoTab® Tests.
Bioadhesion.
[0148] The mucoadhesive strength is determined by attaching the tablets to the bottom of a hanging platform and determining the force required to detach the formulations from a porcine buccal mucosa substrate. The mucoadhesive testing system consisting of a precision load cell (GS-500 Tranducer techniques, Temecula, CA) and a hook attachment. The load cell generates analogue signals, which are converted into digital signals through a data acquisition system equipped with an A/D converter (Model 500 A, Keithley Metrabyte, Taunton, MA) and an IBM computer. Data were analyzed using EasyLx software (Keithley Metrabyte). A hanging platform comprised of a glass slide attached with plastic plunger (8 cm) on the top and a circular-steel projection (0.5cm) with flat surface on the bottom is attached to the load cell. A flat-surfaced tablet die serves as a lower static-platform. The mucosa is mounted onto the lower platform using a screw-clamp. To determine the force of adhesion, the optimum level of that variable is kept constant in the subsequent evaluations. Between each measurement, the mucosal surface is rinsed with 4 mL of purified water. The excess water is wiped with a soft tissue paper and the mucosa is wetted with a known volume of phosphate buffer of pH 6.8. The hanging platform with the film is brought down and placed over the surface of mucosa with a known applied force for a required time. The detachment force is measured and converted to N/cm2. Studies are performed in triplicate at room temperature (23-25 0C). Adhesion and peak detachment force can be used to evaluate the bioadhesive strength of dosage forms comprising various formulations of the invention.
Drug Dissolution Kinetics.
[0149] Drug dissolution kinetics is determined by a standard USP dissolution apparatus, such as Type I, II and/or Type IV, suitably modified for a given dosage form such as a dosage form containing a very small amount of active drug. Drug release from the dosage form can be monitored using one of the standard analytical methods, such as UV spectrophotometry, HPLC or LC/MS. The dissolution medium is defined as a physiological buffer such as phosphate, Tris or other at a pH range between 6.5-7.8. A dosage form of the invention may be manufactured to have a dissolution time from 30 seconds up to 1 minute, 2 minutes, 3 minutes, 4 minutes, 5 minutes, 10 minutes, 15 minutes, 30 minutes, 1 hour, 2 hours, 4 hours, 8 hours or longer.
Dosage Form Erosion Kinetics.
[0150] Dosage form erosion can be monitored by observing the disappearance over time of the sublingual NanoTab® by visual examination. Complete dosage form erosion may be evident by visual examination in about 30 seconds up to 1 minute, 2 minutes, 3 minutes, 4 minutes, 5 minutes, 10 minutes, 15 minutes, 30 minutes, 1 hour, 2 hours, 4 hours or as long as 8 hours or longer, dependent upon the patient and circumstances of drug administration as well as the intrinsic tablet excipients. It will be understood that the composition of the oral transmucosal formulations of the present invention may be adjusted to provide for both a range of doses and a range of erosion times to fit particular clinical situations.
Pharmaceutically Active Ingredient(s)
[0151] The invention provides small volume dosage forms or NanoTabs® for oral transmucosal delivery of a formulation comprising any drug that can be delivered by the oral transmucosal route and in an amount that is appropriate to the small size of the NanoTab®. One example of use of the NanoTabs® of the invention is with application to pain-relief. When the NanoTabs® of the invention are used for treatment of pain, they will comprise a drug such as an opioid or opioid agonist, for the treatment of acute or break-through pain. Opioids are powerful analgesics and are utilized to treat both acute and chronic pain of moderate to severe intensity throughout the world. However, they can also have severe respiratory depressive effects if not used appropriately and they also suffer from a high abuse potential. In 1998, a total of 36,848 opiate exposures (pure and mixed preparations) were reported to U.S. poison control centers, of which 1227 (3.3%) resulted in major toxicity and 161 (0.4%) resulted in death. The predominant cause of morbidity and mortality from pure opioid overdoses is via respiratory complications.
[0152] Opioids are still widely used for the treatment of pain, and are generally delivered intravenously, orally, epidurally, transdermally, rectally and intramuscularly. Morphine and its analogues are commonly delivered intravenously and are effective against severe, chronic and acute pain.
[0153] Opioids exert their actions via the mu opioid receptor, which is located on peripheral nerve terminals, both pre- and post-synaptically in the spinal cord, brainstem, mid-brain and cortical regions associated with sensory and pain processing.
[0154] The active agent in such formulations may include sufentanil, or a sufentanil congener such as alfentanil, fentanyl, lofentanil, carfentanil, remifentanil, trefentanil, or mirfentanil. One preferred embodiment utilizes sufentanil as the active agent. Another preferred embodiment utilizes a sufentanil congener as the active agent. Yet another preferred embodiment utilizes a combination of sufentanil and at least one additional agent for treatment of analgesia as the active agent. The active agent may also include any opioid or opioid agonist such as morphine or a derivative thereof.
[0155] A dosage form of the invention may comprise at least 0.001% percent by weight of the pharmaceutically active ingredient. The pharmaceutically active drug is typically present in a therapeutically effective amount from about 0.25μg to 99.9mg, from about lμg to 50mg or from about lμg to lOmg.
[0156] Preferably, the dosage form comprises from about at least 0.005% to as much as 99.9% by weight, e.g., from about 0.25μg to 99.9mg, from about 1 μg to 50mg or from about 1 μg to 1 Omg of sufentanil; a sufentanil congener such as alfentanil, fentanyl, lofentanil, carfentanil, remifentanil, trefentanil, or mirfentanil.
[0157] In alternative embodiments, a formulation of the invention includes a combination of two or more opioid analogues, such as sufentanil plus an opioid such as sufentanil, alfentanil, fentanyl, lofentanil, carfentanil, remifentanil, trefentanil or mirfentanil. Various opioid drugs have different pharmacokinetic profiles and different interactions with mu opioid receptor splice variants and, therefore, may be used in combination to enhance the therapeutic effect.
[0158] In alternative embodiments, the drug dosage form of the invention may include at least one opioid drug and one or more other drugs wherein the other drug may be an opioid or non- opioid drug. The non-opioid drug may be added to increase analgesic efficacy or to help deter abuse or to avoid opioid-induced side effects.
[0159] In some embodiments, the oral dosage formulations of the invention include an opioid antagonist, such as naloxone. In such embodiments, naloxone is provided in an appropriate concentration to inhibit activity of the opioid component of the formulation were it to be injected.
[0160] The invention finds utility in the treatment of both opioid naive patients and opioid tolerant patients.
[0161] The term "opioid naive patient" is used herein with reference to a patient who has not received repeated administration of an opioid substance over a period of weeks to months.
[0162] The term "opioid tolerant patient" as used herein means a physiological state characterized by a decrease in the effects of an opioid substance (e.g., analgesia, nausea or sedation) with chronic administration. An opioid substance is a drug, hormone, or other chemical substance that has analgesic, sedative and/or narcotic effects similar to those containing opium or its derivatives. If analgesic tolerance develops, the dose of opioid substance is increased to result in the same level of analgesia. This tolerance may not extend to side effects and side effects may not be well tolerated as the dose is increased. [0163] In certain embodiments, the dosage form of the invention may comprise at least 0.001% percent by weight of the active ingredient, e.g., sufentanil, alfentanil, fentanyl, lofentanil, carfentanil, remifentanil, trefentanil, mirfentanil. Preferably, the dosage form comprises from about at least 0.005% to as much as 99.9% by weight of sufentanil, alfentanil, fentanyl, lofentanil, carfentanil, remifentanil, trefentanil or mirfentanil. The percentage of active ingredient(s) will vary dependent upon the size of the dosage form and nature of the active ingredient(s), optimized to obtain maximal delivery via the oral mucosal route. In some aspects of the invention more than one active ingredient may be included in a single dosage form.
[0164] In various embodiments, the formulation of the present invention generally provides appropriate pain relief in all types of patients including children, adults of all ages who are opioid tolerant or naive and non-human mammals. The invention finds utility in both the inpatient and out-patient setting.
[0165] The use of sufentanil clinically has predominantly been limited to IV administration in operating rooms or intensive care units. There have been a few studies on the use of liquid sufentanil preparations for low-dose intranasal administration (Helmers et al., 1989; Jackson K, et al., J Pain Symptom Management 2002: 23(6): 450-452) and case reports of sublingual delivery of a liquid sufentanil preparation (Gardner-Nix J., J Pain Symptom Management. 2001 Aug; 22(2):627-30; Kunz KM, Theisen JA, Schroeder ME, Journal of Pain and Symptom Management, 8:189-190, 1993). In most of these studies, the smallest dosing of sufentanil in adults was 5 meg in opioid naive patients. Liquid administered to the oral or nasal mucosa suffers from lower bioavailability and possibly a shorter duration of action as demonstrated by our Animal Studies (sublingual liquid) as well as the literature (nasal liquid drops — Helmers et al., 1989). Gardner-Nix describes only analgesic data (not pharmacokinetic data) produced by liquid sublingual sufentanil and describes the analgesic onset of liquid sublingual sufentanil occurring within 6 minutes but the duration of pain relief lasted only approximately 30 minutes. Prior to this patent application, no pharmacokinetic data has been published on the use of sublingual sufentanil in any dosage form.
[0166] Opioids are known to produce physical dependence, possible addictive behaviors and tolerance with long-term use. Cells exposed to opioids can demonstrate mu opioid receptor internalization (rapid endocytosis). The in vitro mu-opioid receptor endocytosis of a series of clinically used opioids was evaluated alone and in combination with morphine in human embryonic kidney (HEK) 293 cells (Koch et al., MoI Pharmacol. 67(l):12-4, 2005). The results indicated that the endocytotic potency of opioid drugs is negatively correlated with their ability to cause receptor desensitization and opioid tolerance in HEK 293 cells and that opioids with high endocytotic efficacies might cause reduced opioid tolerance. The results shown in Koch et al., 2005 indicate that sufentanil is an opioid with high endocytotic efficacy and is therefore less likely to cause opioid tolerance than related opioid analogues tested.
[0167] Sufentanil (N- [(4-(Methoxy methyl- 1 ~(2-(2-thienyl)ethyl)-4-piperidinyl)]-N- phenylpropanamide), is used as a primary anesthetic, to produce balanced general anesthesia in cardiac surgery, for epidural administration during labor and delivery and has been administered experimentally in both intranasal and liquid oral formulations. A commercial form of sufentanil used for IV delivery is the SUFENTA FORTE® formulation. This liquid formulation contains 0.075 mg/ml sufentanil citrate (equivalent to 0.05 mg of sufentanil base) and 9.0 mg/ml sodium chloride in water. It has a plasma elimination half-life of 148 minutes, and 80% of the administered dose is excreted in 24 hours.
[0168] Fentanyl (N-(I -phenethyl-4-piperidyl)-N-phenyl-propanamide) was first synthesized in Belgium in the late 1950s, and has an analgesic potency of about 80 times that of morphine. Fentanyl and its congeners are mu opiate agonists that were originally developed as anesthesia agents, and are often administered intravenously due to rapid onset of analgesia. Following intravenous administration, the analgesic action of fentanyl is more prompt and less prolonged than that of morphine and meperidine. Following transbuccal administration by a lozenge (e.g., Actiq®), consumption of the lozenge is usually complete within 30 minutes, the bioavailability is 50%, although the Tmax of the 200 meg Actiq dosage ranges from 20 — 120 minutes displaying the erratic GI uptake due to swallowing of 75% of the drug (Actiq® package insert). More recent publications on the Tmax of Actiq indicate that these original times were skewed towards more rapid onset (Fentora package insert indicates a range of Tmax for Actiq extending to 240 minutes). Fentora has a slightly improved PK profile, with a 65% bioavailability, due to swallowing of 50% of the drug. Therefore, one major disadvantage of this treatment is that substantial amounts of lozenge-administered fentanyl are swallowed by the patient. Fentanyl and other opiate agonists, have the potential for deleterious side effects including respiratory depression, nausea, vomiting and constipation. Since fentanyl has a 30% bioavailability from the GI route, this swallowed drug can contribute to the Cmax plasma levels to a significant degree and results in the erratic Cmax and Tmax observed with these products.
[0169] Although sufentanil and fentanyl have many similarities as potent mu-opioid receptor agonists, they have been shown to differ in many key ways. Multiple studies have demonstrated sufentanil to be in the range of 7 — 24 times more potent than fentanyl (SUFENTA® package insert; Paix A, et al. Pain, 63:263-69, 1995; Reynolds L, et al., Pain, 110:182-188, 2004). Therefore, sufentanil may be administered using a smaller dosage form, avoiding the increased saliva response of a larger dosage form and thereby minimizing swallowing of the drug and the minimal and variable GI uptake, which is associated with a larger dosage form.
[0170] In addition, the lipid solubility (octanol-water partition coefficient) of sufentanil (1778:1) is greater than fentanyl (816:1). Sufentanil also displays increased protein binding (91 - 93%) compared with fentanyl (80 - 85%) (SUFENTA® and Actiq® package inserts, respectively). Sufentanil has a pKa of 8.01, whereas the pKa of fentanyl is 8.43 (Paradis et al., Therapeutic Drug Monitoring, 24:768-74, 2002). These differences can affect various pharmacokinetic parameters, for example, sufentanil has been shown to have a faster onset of action and faster recovery times than fentanyl (Sanford et al., Anesthesia and Analgesia, 65:259- 66, 1986). This is advantageous for the treatment of acute pain when repeated dosing is available, such as in the present invention. Use of sufentanil can result in more rapid pain relief with the ability to titrate the effect and avoid overdosing.
[0171] Importantly, sufentanil has been shown to produce endocytosis of the mu-opioid receptor 80,000 times more potently than fentanyl (Koch et al., Molecular Pharmacology, 67:280-87, 2005). The result of this receptor internalization is that neurons continue to respond to sufentanil more robustly over time than with fentanyl, suggesting that clinically less tolerance would develop to sufentanil compared to fentanyl with repeated dosing.
[0172] Sufentanil has been used experimentally in adults in the form of an oral liquid (Gardner-Nix J., 2001; Kunz et al., 1993), and as nasal drops (Helmers et al., 1989), and nasal spray (Jackson et al., 2002), as described above. No pharmacokinetic data has been published on sublingual sufentanil in any dosage form.
10173] Congeners of sufentanil and fentanyl find use in the compositions and methods of the invention, examples of which include remϊfentanil and alfentanil.
[0174] Remifentanil is a potent fentanyl congener that is metabolized much more rapidly than fentanyl or sufentanil, but may be suitable for treatment of acute pain when delivered via a sustained-release formulation. A NanoTab® of the invention typically comprises from about 0.25 meg to 99.9 mg of remifentanil. The dose ranges for the remifentanil formulation may include 0.1 mcg/kg — 50 mcg/kg over a time period of 20 minutes, for example, for both adult and pediatric patients. These dosages may be repeated at appropriate time intervals, which may be shorter than the time intervals for fentanyl or sufentanil.
[0175] Alfentanil is also a potent fentanyl congener that is rapidly metabolized but may be suitable for use in a sustained-release formulation. A NanoTab® of the invention typically comprises from about 10 meg to about 10 mg of alfentanil. Appropriate dosing of alfentanil may be in the range of 1 mcg/kg — 2000 mcg/kg over 20 minutes, for example, for both adult and pediatric patients. These dosages may be repeated at appropriate time intervals, which may be shorter than the time intervals for fentanyl or sufentanil.
[0176] Patients suffering from chronic painful conditions can also have intermittent exacerbations of their pain, requiring acute use of fast-acting breakthrough opioids in addition to their use of slow-onset time-release opioids for their baseline chronic pain.
[0177] Breakthrough pain or procedural pain can be intense for short periods of time, as short as 1 or 2 minutes or as long as 30 minutes or more, therefore there would be a significant advantage in providing an opioid formulation that produced more rapid clinically effective plasma levels with a more consistent and predictable period of effect, but also had a limited half- life to avoid excessive opioid dosing for short duration pain events.
[0178] Opioids remain the most powerful from of analgesics, however, improved forms are needed that have minimal side effects, and can be provided in a manner in which patient use can be easily tracked by the physician. [0179] Using current treatment methods, pain control is attempted using a number of interventions, which generally include: patient-controlled analgesia (PCA), continuous epidural infusion (CEI), other types of acute pain control, palliative care pain control, and home health patient pain control. These methods meet with varying degrees of success with respect to duration of control, ease of treatment and safety versus side effects.
[0180] The need for rapid treatment of acute pain occurs in many different clinical situations, including post-operative recuperation, rheumatoid arthritis, failed back, end-stage cancer, etc. Post-operatively, for example, patients suffer from severe pain for the first few days followed by days of mild to moderate levels of pain.
[0181] The most common analgesic used to treat moderate to severe post-operative pain is IV morphine. This is either delivered on an "as needed" basis by a nurse to the patient by an IV injection or commonly a morphine syringe is placed in a PCA pump and the patient self- administers the opioid by pressing a button which has a lock-out feature. Other opioids, such as hydromorphone and fentanyl may also be used in this manner.
[0182] Treatment of acute pain is also necessary for patients in an outpatient setting. For example, many patients suffer from chronic pain and require the use of opioids on a weekly or daily basis to treat their pain. While they may have a long-acting oral or transdermal opioid preparations to treat their chronic underlying pain levels, they often need short-acting potent opioids to treat their severe breakthrough pain levels.
[0183] Treatment of acute pain is also necessary "in the field" under highly sub-optimal conditions. Paramedics or military medics often are required to treat severe acute pain in un- sterile situations, where needles used for IV or IM administration can result in unintended needle sticks, risk of infection, etc. Oral opioid tablets often take 60 minutes to provide relief which is too long for someone in severe pain.
[0184] In a number of clinical settings, there is clearly a need for a formulation that produces effective pain relief in a manner that is titratable, may be used safely and conveniently, and provides pain relief for severe breakthrough or intermittent pain over an appropriate period of time. [0185] The drug delivery dosage forms or formulations of the invention contain from about 0.25 to about 200mcg of sufentanil per dosage form for oral transmucosal delivery. In one exemplary embodiment of the invention, each dosage form contains from about 0.25 to about 200mcg of sufentanil, alone or combination with one or more other therapeutic agents or drugs.
[0186] As will be understood by those of skill in the art, the dose will be on the low end of the range for children and the high end of the range for adults dependent upon body mass, in particular when administered long term to opioid-tolerant adults. Small-volume oral transmucosal drug delivery dosage forms of sufentanil have not been described.
[0187] Exemplary formulations of the invention for administration to children (pediatric patients) contain from about 0.25 to about 120mcg of sufentanil per dosage form. For example, a formulation of the invention for administration to children may contain about 0.25, 0.5, 1, 2.5, 4, 5, 6, 8, 10, 15, 20, 40, 60 or 120mcg of sufentanil for oral transmucosal delivery. It follows that for pediatric patients, an exemplary dose range is from at least about 0.02 mcg/kg to about 0.5 mcg/kg with a preferable range of from about 0.05 to about 0.3 mcg/kg.
[0188] Exemplary formulations of the invention for administration to adults contain from about 2.5 to about 200mcg of sufentanil per dosage form. For example, a formulation of the invention for administration to adults may contain about 2.5, 3, 5, 7.5, 10, 15, 20, 40, 60, 80, 100, 120, 140, 180 or 200mcg or more of sufentanil for oral transmucosal delivery.
[0189] In yet another example of the invention, each dosage form contains from about 2 to about 1500mcg of fentanyl, alone or combination with one or more other therapeutic agents or drugs. As will be understood by those of skill in the art, the dose will be on the low end of the range for children and the high end of the range for adults dependent upon body mass, in particular when administered long term to opioid-tolerant adults.
[0190] Exemplary dosage forms of the invention for administration to children (pediatric patients) contain from about 2 to about 900mcg of fentanyl per dosage form. For example, a dosage form of the invention for administration to children may contain about 2, 3.75, 7.5, 18.75, 30, 37.5, 45, 60, 75, 112.5, 150, 300, 450 or 900mcg of fentanyl for oral transmucosal delivery. [0191] Exemplary dosage forms of the invention for administration to adults contain from about 18.75 to about 1500mcg of fentanyl per dosage form. For example, a dosage form of the invention for administration to adults may contain about 18.75, 22.5, 37.5, 56, 75, 112.5, 150, 300, 450, 600, 750, 900, 1050, 1350 or 1500mcg or more of fentanyl for oral transmucosal delivery.
[0192] In one exemplary embodiment, a dosage form for use in the treatment of pain may comprise from about 0.25 to about 200mcg of sufentanil, from about 0. 5 to about 120mcg of sufentanil, from about 2.5 to about 40 meg of sufentanil, from about 2.5 to about 15.0 meg of sufentanil, from about 2.0 to about 1500 meg of fentanyl, from about 20 to about 1200 meg of fentanyl, or from about 100 to about 900 meg of fentanyl.
[0193] The dosage forms of the invention contain from about 10 to about 10000 meg of alfentanil per dosage form for oral transmucosal delivery. As will be understood by those of skill in the art, the dose will be on the low end of the range for children and the high end of the range for adults dependent upon body mass, in particular when administered long term to opioid- tolerant adults.
[0194] Exemplary dosage forms of the invention for administration to children (pediatric patients) contain from about 10 to about 6300 meg of alfentanil per dosage form. For example, a dosage form of the invention for administration to children may contain about 10, 25, 50, 130, 210, 280, 310, 420, 600, 780, 1050, 2100, 3000 or 6300 meg of alfentanil for oral transmucosal delivery.
[0195] Exemplary dosage forms of the invention for administration to adults contain from about 70 to about 10000 meg of alfentanil per dosage form. For example, a dosage form of the invention for administration to adults may contain about 70, 140, 160, 210, 280, 310, 420, 600, 780, 1050, 2100, 3000, 6300 or 10000 meg or more of alfentanil for oral transmucosal delivery.
[0196] In a different exemplary embodiment, a dosage form for use in the treatment of pain may comprise from about 0.25 to about 200 meg of sufentanil in combination with from about 2 to about 1500 meg of fentanyl or from about 0.25 to about 200 meg of sufentanil or from about 2 to about 1500 meg of fentanyl in combination with one or more additional drugs. [0197] Following delivery of a single dose of a sufentanil-, alfentanil-, or fentanyl-containing dosage form of the invention to a human subject, the plasma level of sufentanil, alfentanil or fentanyl may reach a maximum level between 0 and 60 minutes, between 5 and 50 minutes or between 10 and 40 minutes after administration.
Methods for delivery of Oral Transmucosal Dosage Forms
[0198] A device for NanoTab® delivery can use a variety of mechanical or electromechanical methods to expel the NanoTab® into the oral or sublingual space. For example the NanoTab can be forcibly expelled by means of a spring, compressed air, or other mechanism once activated.
Methods of Making Oral Transmucosal Dosage Forms
[0199] Methods of making a drug-containing dosage forms for oral transmucosal delivery, such as a NanoTab® is also provided by the invention. By way of example, the method includes the steps of weighing the drug and one or more of bioadhesins, binders, hydrogel forming excipients, bulking agents, lubricants or glidants and factors that affect dissolution time, possibly powder grinding, dry powder mixing and tableting via direct compression.
[0200] Alternatively, a wet granulation process may be used. Such a method (such as high shear granulation process) involves mixing the active ingredient and possibly some excipients in a mixer. The binder may be one of the excipients added in the dry mix state or dissolved in the fluid used for granulating. The granulating solution or suspension is added to the dry powders in the mixer and mixed until the desired characteristics are achieved. This usually produces a granule that will be of suitable characteristics for producing dosage forms with adequate hardness, dissolution, content uniformity, and other physical characteristics. After the wet granulation step, the product is most often dried and/or then milled after drying to get a major percentage of the product within a desired size range. Sometimes, the product is dried after being wet sized using a device such as an oscillating granulator, or a mill. The dry granulation may then processed to get an acceptable size range by first screening with a sieving device, and then milling the oversized particles. In some instances, an appropriate glidant is added to improve the flow properties of the granules; suitable glidants include silicas (such as SILOID and SILOX silicas — trademarks of Grace Davison Products, Aerosil - trademark of Degussa Pharma).
[0201] Additionally, the formulation may be manufactured by alternative granulation processes, all known to those skilled in the art, such as spray fluid bed granulation, extrusion and spheronization or fluid bed rotor granulation.
[0202] It will be understood that the formulation will be converted into a dosage form for delivery to a subject using procedures routinely employed by those of skill in the art. The process for preparation of the dosage form is optimized in order to achieve high dose content uniformity, which is particularly important for the potent compounds, which are generally present in mass ratios of 0.01-10% w/w.
[0203] Many methods of making dosage forms for use in the invention are known in the art and may be employed in practicing the present invention, such as direct compression, wet granulation, etc.
[0204] A NanoTab® dosage form of the invention may or may not have a coating on the external surface of the dosage form.
Utility Of The Small- Volume Oral Transmucosal Dosage Forms Of The Invention.
[0205] The dosage forms of the invention find utility in delivery of any drug that can be administered by the oral transmucosal route. The small volume of an oral transmucosal dosage form or NanoTab® of the invention is that it provides for high bioavailability, low variability in Tmax, low variability in Cmax and low variability in AUC. The NanoTabs® of the invention also provide for controlled dissolution, solubility and stability, resulting in controlled release of the drug over time resulting in prolonged plasma levels within the therapeutic window.
[0206] In one exemplary embodiment described in detail herein, the dosage forms of the invention find utility in treating a subject suffering from pain that may be associated with any of a variety of identifiable or unidentifiable etiologies. In this embodiment, the dosage forms of the invention find utility in suppression or mitigation of pain. The term "treatment" or "management" of pain is used here to generally describe regression, suppression, or mitigation of pain so as to make the subject more comfortable, as determined for example by pain score.
[0207] The term "acute pain" is used herein with reference to pain that is typically present for less than one month, however, in some cases pain that is present for as long as three months may also be considered to be "acute".
[0208] The term "chronic pain" is used herein with reference to pain that is typically present for longer than one month.
[0209] The dosage forms of the invention find particular utility in the treatment of acute pain or other conditions "in the field", i.e., under highly sub-optimal conditions. Paramedics or military medics often are required to treat severe acute pain or other injuries or conditions in non-sterile situations, where needles used for IV or IM administration can result in unintended needle sticks, risk of infection, etc. Oral opioid tablets often take 60 minutes to provide relief which is too long for someone in severe pain. The dosage forms of the invention find utility in addressing this need.
[0210] The dosage forms of the invention find further utility in pediatric applications, since the comfortable and secure nature of the dosage form will allow small children to readily accept this mode of therapy and will reliably deliver drug transmucosally. Specific examples include, but are not limited to, treatment of pediatric acute pain when IV access is not available or inconvenient, treatment of pediatric asthma when the child is not able to use an inhaled route of administration effectively, treatment of nausea when a child can not or will not swallow a pill, pre-procedural sedation when a child is NPO (no oral intake allowed) or a more rapid onset is required.
[0211] The dosage forms of the invention find further utility in veterinary applications. Specific examples include, but are not limited to, any treatment of an acute condition for which IV administration is not readily available or inconvenient, such as pain relief, anxiety/stress relief, pre-procedural sedation, etc.
[0212] Oral transmucosal drug delivery is simple, non-invasive, and can be administered by the caregiver or the patient with minimal discomfort. Generally, oral transmucosal delivery of pharmaceuticals is achieved using solid dosage forms such as lozenges or tablets, however, liquids, sprays, gels, gums, powders, and films and the like may also be used.
[0213] For certain drugs, such as those with poor bioavailability via the GI tract, such as many lipophilic opioids, oral transmucosal delivery may provide a better delivery route than GI delivery. For drugs such as lipophilic opioids, oral transmucosal delivery has shorter onset time (i.e., the time from administration to therapeutic effect) than does oral GI delivery and provides significantly improved bioavailability.
10214] The following examples are provided to illustrate the invention and are not intended to limit any aspect of the invention as set forth above or in the claims below.
EXAMPLES
In Vivo Pharmacokinetics.
[0215] The dosage forms for the NanoTabs® described above can be tested for in vivo drug pharmacokinetics in both humans and a suitable animal model following sublingual administration. The following examples demonstrate the ability of the NanoTab® dosage forms to allow a consistent absorption profile of sufentanil citrate following sublingual administration in human volunteers and an awake, alert Beagle dog model.
Example 1. Sublingual Sufentanil NanoTabs® Administered Sublingually in Adult Human Volunteers.
Table 1. Sufentanil NanoTab® Formulations Used in the Human Clinical Study
#46 #47 n
%, - M. _ass
Figure imgf000051_0001
Figure imgf000051_0002
Calculated Strength (Sufentanil base) 0.002506159 0.005012
[0216] A human clinical study was performed using healthy volunteers. The study was performed with 12 subjects (6 men and 6 women) using Sufentanil NanoTabs® (formulations #46 - #48 shown in Table 1) manufactured to have a volume of 5 μL, a mass of approximately 5.5 mg, and determined to have a uniform size for all dosage strengths with dimensions of approximately 3 mm in diameter and 0.8 mm in thickness. Sufentanil NanoTabs® contained either 2.5 μg, 5 μg or 10 μg of sufentanil base corresponding to 3.7 μg, 7.5μg or 15 μg of sufentanil citrate, respectively. All excipients were inactive and have GRAS ("generally recognized as safe") status. The sufentanil NanoTabs® were tested for sublingual use. Study staff administered individual NanoTabs® to a subject by placing them directly at the base of the frenulum using blunt-tipped forceps.
NanoTab® Attributes
Bioadhesion
[02171 The bioadhesion was measured as described earlier on the sufentanil clinical trial formulation (#46 - #48) without the sufentanil component. The bioadhesion force required for displacement of the NanoTab® was measured as 0.046 + 0.01 N/cm2.
In Vitro Evaluation Of Dissolution
[0218] Sufentanil citrate dissolution from NanoTab® formulations #46, #47 and #48 was evaluated in a Type II in vitro dissolution system, as described earlier, and is show in Figure 1 below.
[0219] For bioavailability calculations, intravenous sufentanil, 5 μg was diluted in 0.9% saline to a total volume of 20 mL, and was administered through an IV catheter as a continuous infusion over 10 minutes. Plasma samples were drawn from a different IV catheter at a remote location. This human trial was a cross-over design with wash-out periods between transitions from higher to lower doses. Subjects were blocked with the opioid antagonist naltrexone daily to avoid opioid-induced side-effects.
• Day 0: IV sufentanil Infusion: o Seventeen samples were collected:
-5.0 (before the start of infusion), 2.5, 5, 7.5, 10, 12.5, 15, 20, 30, 45, 60, 90, 120, 160, 320, 480 and 640 minutes
• Day 2: sublingual 2.5 μg sufentanil NanoTabs®; o Seventeen samples:
-5.0 (before NanoTab® administration), 2.5, 5, 7.5, 10, 12.5, 15, 20, 30, 45, 60, 90, 120, 160, 320, 480 and 640 minutes
• Day 3: sublingual 5.0 μg sufentanil NanoTabs®; o Seventeen samples:
-5.0 (before NanoTab® administration), 2.5, 5, 7.5, 10, 12.5, 15, 20, 30, 45, 60, 90, 120, 160, 320, 480 and 640 minutes
• Day 4: sublingual 10.0 μg sufentanil NanoTabs®; o Seventeen samples:
-5.0 (before NanoTab® administration), 2.5, 5, 7.5, 10, 12.5, 15, 20, 30, 45, 60, 90, 120, 160, 320, 480 and 640 minutes
• Day 7: sublingual 5.0 μg sufentanil NanoTabs® repeated 4 times at 10 minute intervals; o Twenty three samples:
-5.0 (before the first NanoTab® administration), 5, 7.5 minutes
10 (immediately prior to the second NanoTab® administration), 15, 17.5 minutes
20 (immediately prior to the third NanoTab® administration), 25, 27.5 minutes
30 (immediately prior to the fourth NanoTab® administration), 35, 40, 45, 50, 55, 60, 90, 120, 150, 190, 350, 510 and 670 minutes
[0220] The total volume of blood required for pharmacokinetic sampling was approximately 455 mL.
[0221] Sufentanil concentrations in plasma samples were determined using a validated LC- MS/MS sufentanil human plasma assay. The assay demonstrated good inter-day precision and accuracy at the high, medium and low quality control sample concentrations. Erosion Time
[0222] The NanoTabs® for this study eroded over a period of 10-30 minutes in all subjects. After placement of each sufentanil sublingual NanoTabs® in the sublingual cavity of the 12 healthy volunteers, a remarkably consistent pharmacokinetic profile was obtained for the three dosages (Figure 2).
Table 2. PK Analyses of the IV (5 meg) and Sublingual Sufentanil NanoTab® Dosing Arms in the Human Clinical Study using Three Dosage Strengths (2.5 meg = #46, 5 meg = #47, 10 meg #48)
Figure imgf000054_0001
calculated by the formula: TTR= (Time spent above 50% of Cmax) /(IV Terminal elimination half-life). The denominator is obtained from literature and is 148 min in humans for sufentanil.
Example 2. In vivo Evaluation of Sublingual Sufentanil NanoTabs® in a Dog Model. [0223] The following Examples 2-5 are using the Beagle dog model and the formulations for the NanoTabs® all are using a NanoTab® with a total mass of 5.5 mg. The in vivo pharmacokinetics (PK) of sufentanil following sublingual administration of the 5 meg NanoTabs® (formulation #44 for dogs, which is the same as the human formulation #47) described above were evaluated in a healthy Beagle dog model. Briefly, single 5mcg NanoTabs ,® described above were administered sublingually in fully awake healthy dogs by direct placement in the sublingual cavity. A total of three dogs were evaluated. Following administration, the position of the NanoTab® in the sublingual cavity was observed visually at 5 - 15 minute intervals following administration. The sublingual sufentanil PK was compared with that of IV administered sufentanil at the same dose level.
[0224] All dogs were catheterized via the cephalic vein for blood collections up to 2 hours post-dosing. Through the 2-hour post-dose blood collection, all dogs were fitted with an Elizabethan collar to prevent removal of the catheter. The catheter was removed following the 2- hour blood collection. The 4-, 8-, and 24-hour post-dose blood collection were collected from the cephalic or other suitable vein. Approximately 2 ml of blood were collected into pre-chilled tubes containing potassium EDTA at the following timepoints: prior to dosing and approximately 1, 3, 5, 10. 15, 30 min, 1, 2, 4, 8 and 24 hours post-dose. The samples were analyzed with the appropriately validated LC/MS/MS method for the determination of sufentanil citrate in dog plasma. The sufentanil plasma concentrations and the pharmacokinetic results are shown in Figure 3 and Table 3.
Table 3. PK Analysis of Sufentanil Sublingual NanoTabs® Compared to Intravenous Sufentanil in Beagle Does.
Figure imgf000055_0001
1 Represents the relative time that the drug achieves therapeutic levels (above 50% of Cmnx) and it is calculated by the formula: TTR= (Time spent above 50% OfC11111x) / (IV Terminal elimination half-life). The denominator is obtained from literature and is 139 miπ in beagle dogs for sufentanil.
Example 3: Exemplary Sufentanil Dosage Forms to Control Drug Release and In Vivo Pharmacokinetics.
[02251 F°r purposes of illustration, a longer duration NanoTab® dosage form (formulation #58) was prepared with sufentanil citrate in order to evaluate a slower rate of drug release and in vivo pharmacokinetics of a longer-acting dosage form. This slower disintegrating sufentanil NanoTab®, as described in Table 4 was prepared by direct compression and tested as described above. The range of erosion times in dogs was 35 — 120 minutes and the bioadhesion of the placebo formulation was measured as described above and determined to be 0.18 + 0.08 N/cm2.
[0226] Sample analysis was performed using a validated LC/MS/MS method for analysis of sufentanil in dog plasma. Pharmacokinetic analysis was performed using a non-compartmental model of absorption. Sufentanil plasma concentrations are shown graphed in Figure 4. The results of a limited PK analysis are shown in Table 5.
Table 4. Slow Disintegrating Sufentanil NanoTab® Dosage Formulation.
Figure imgf000056_0001
07 000529
Table 5. PK Analyses for the Slow-Disintegrating Sublingual Sufentanil NanoTab in Beagle Dogs.
Figure imgf000057_0001
Represents the relative time that the drug achieves therapeutic levels (above 50% of Cmικ) and it is calculated by the formula: TTR= (Time spent above 50% of Cmax) / (IV Terminal elimination half-life). The denominator is obtained from the literature and is 139 min in beagle dogs for sufentanil.
Example 4. In Vivo Study of Sublingual Sufentanil Solution and Swallowing of Sufentanil NanoTabs® in a Dog Model.
A. Evaluation of Bioavailability of Sufentanil Following Sublingual Administration of a Solution Dosage Form
[0227] The bioavailability of sufentanil following sublingual administration from a solution as compared to that intravenously was evaluated in a healthy, conscious Beagle dog animal model, as indicated in Table 6. In both arms of the study the commercially available formulation of sufentanil citrate (Sufenta® 50 μg/mL) was used and was dosed at the same total dose of 5 μg of sufentanil base. Intravenous administrations (Group 1) were performed by single administration (n=3) of Sufenta® 50 μg/mL by bolus injection to the cephalic vein via a sterile needle and syringe of appropriate size. For the sublingual administrations (Group 2) the test article was prepared by appropriately diluting Sufenta® 50 μg/mL with 0.9% w/w to the same final dose of 5 μg of sufentanil base and was administered twice sublingually (n=6 total), with each dose separated by a minimum of a 2-day washout. Doses were slowly applied under the tongue, adjacent to the frenulum via a sterile syringe. Blood samples were collected from a jugular or other suitable vein prior to dosing and approximately 1, 3, 5, 10, 15, 30 min, 1, 2, 4, 8 and 24 hours post-dose. Approximately 2 mL of blood were collected per time-point into pre- chilled tubes containing K2 EDTA. The samples were centrifuged at 3,000 x g for approximately 10 minutes in a refrigerated centrifuge. Plasma was collected and frozen within 20 minutes of centrifugation at approximately -700C and was maintained at the same temperature until analysis. Sample analysis was performed using a validated LC/MS/MS method for analysis of sufentanil in dog plasma.
[0228] Pharmacokinetic analysis was performed using a non-compartmental model of absorption. The sufentanil plasma concentrations are graphed in Figure 5. The results of the PK analysis are shown in Table 7.
B. Evaluation of Bioavailability of Sufentanil Following Oral Ingestion of a NanoTab
[0229] The bioavailability of sufentanil following ingestion of a 5 meg sufentanil NanoTab (formulation #44, which is the same formulation as #47 used in the human study above) as compared to intravenous sufentanil administration was evaluated in a healthy, conscious Beagle dog animal model, as described in the previous example. A single 5 meg NanoTab® was administered twice orally, with each dose separated by a minimum of a 2-day washout for a total of n=6 (Table 6). The NanoTabs® were placed manually as far back as possible in the throat and flushed with water to promote the swallow response in the animal. Pharmacokinetic analysis was performed using a non-compartmental model of absorption. The sufentanil plasma concentrations are shown graphed in Figure 5. The results of the PK analysis are shown in Table 7.
Table 6. Organization of Test Groups
Figure imgf000058_0001
a = Expressed as a free base. b = Same animals will be used for Groups 1 through 3 with a minimum 2-day washout period between dosing. c = Group 2 & 3 animals were dosed twice with a minimum 2-day washout period for a total of n=6 d = "Normal (0.9% w/w) saline was used to dilute the test article (Sufenta® 50 μg/mL) to the desired concentration.
Table 7. PK Analyses of Intravenously Administered Sufentanil Compared to a Sublingually Instilled Sufentanil Solution and an Ingested Sufentanil NanoTab® in Beagle Dogs.
Figure imgf000059_0001
Represents the relative time that the drug achieves therapeutic levels (above 50% of Cmax) and it is calculated by the formula: TTR= (Time spent above 50% of Cmαx) / (IV Terminal elimination half-life). The denominator is obtained from the literature and is 139 min. in beagle dogs for sufentanil.
Example 5. In vivo Evaluation of Sublingual Fentanyl NanoTabs® in a Dog Model.
[0230] For purposes of demonstrating the superiority of the NanoTab® and its attributes over other commercial fentanyl oral transmucosal preparations, fentanyl NanoTab® dosage forms were prepared with fentanyl citrate in order to evaluate the rate of drug release and in vivo pharmacokinetics of various dosage forms. Both medium (formulation #60) and slow (formulation #62) disintegrating fentanyl NanoTabs®, as described in Table 8, were evaluated with both dosage forms prepared by direct compression. The erosion time in dogs of formulation #60 ranged from 5 -20 minutes and the bioadhesion was measured at 0.056 ± 0.01 N/cm2for the placebo formulation. The erosion time in dogs for formulation #62 ranged from 35 — 65 minutes and the bioadhesion for the placebo formulation was measured at 0.18 + 0.08 N/cm2. [0231] The commercially available formulation of fentanyl citrate (Sublimaze 50 μg/mL) was used and was dosed IV at 70 μg of fentanyl base. Intravenous administrations were performed by single administration (n=3) of Sublimaze® 50 μg/mL by bolus injection to the cephalic vein via a sterile needle and syringe of appropriate size. For the sublingual administrations the NanoTabs® were administered sublingually (n = 3 in each group) by placement under the tongue, adjacent to the frenulum via forceps. These parameters are shown in Table 9. The fentanyl plasma concentrations are graphed in Figure 6. PK analysis was performed using a non-compartmental absorption model. The results of the PK analysis are shown in Table 10. Blood sampling and storage mirrored the conditions described earlier; sample analysis was performed using a validated LC/MS/MS method for analysis of fentanyl in dog plasma.
Table 8. Exemplary Fentanyl NanoTab Dosage Forms
Figure imgf000061_0001
Table 9. Dosing Parameters for Fentanyl NanoTabs in Beagle Dogs
Figure imgf000061_0002
Table 10. PK Analyses of Medium-Disintegrating (formulation #60) and Slow-Disintegrating (formulation #62) Fentanyl NanoTabs® Compared to Intravenous Fentanyl Administration.
Figure imgf000062_0001
calculated by the formula: TTR= (Time spent above 50% of Cmax) / (IV Terminal elimination half-life). The denominator is obtained from the literature and is 244 min. in beagle dogs for fentanyl.
Example 6: In vivo Evaluation of Sublingual Alfentanil HCl NanoTabs® in a Dog Model.
[0232] For purposes of illustration of another drug use for the NanoTab®, an additional NanoTab® dosage form was prepared with alfentanil HCl in order to demonstrate the ability of the dosage forms described in this application to effectively improve the PK of alfentanil compared to that of the IV route of administration. The formulation composition, a medium disintegrating NanoTab®, is described in Table 11. The erosion time in dogs of formulation #63 was 20 minutes and the bioadhesion was measured at 0.056 + 0.01 N/cm2 for the placebo formulation.
[0233] The dosing parameters for this study are shown in Table 12. The alfentanil plasma concentrations are graphed in Figure 7. PK analysis was performed using a non-compartmental absorption model. The results of the PK analysis are shown in Table 13. Blood sampling and storage mirrored the conditions described earlier; sample analysis was performed using a validated LC/MS/MS method for analysis of alfentanil in dog plasma. Table 11. Exemplary Alfentanil NanoTab Dosage Form
Figure imgf000063_0001
Table 12. Dosing Parameters for Administration of Sublingual Alfentanil NanoTabs and an Intravenous Alfentanil Solution in Beagle Dogs.
Figure imgf000063_0002
a = Expressed as a free base. b = Same animals were used for Groups 1 and 2 with a minimum 2-day washout period between dosing.
Table 13. PK Analyses of Alfentanil Sublingual NanoTabs® compared to Intravenous Alfentanil in Beagle Dogs.
Figure imgf000063_0003
Represents the relative time that the drug achieves therapeutic levels (above 50% of Cmax) and it is calculated by the formula: TTR= (Time spent above 50% of Craax) / (IV Terminal elimination half-life). The denominator is obtained from literature and is 104 min. in beagle dogs.

Claims

WHAT IS CLAIMED IS:
1. A dissolvable small volume dosage form for oral transrnucosal administration of a drug comprising, a predetermined unit dosage of a pharmaceutically active amount of a drug, wherein said dosage form is a NanoTab®.
2. The NanoTab® according to Claim 1, wherein said dosage form has bioadhesive characteristics.
3. The NanoTab® according to Claim 1, wherein said dosage form adheres to the oral mucosa.
4. The NanoTab® according to Claim 3, wherein said oral mucosal membrane is a sublingual membrane.
5. The NanoTab® according to Claim 3, wherein said oral mucosal membrane is a buccal membrane.
6. The NanoTab® according to Claim 1, wherein said dosage form has a mass of less than lOOmg.
7. The NanoTab according to Claim 1, wherein said dosage form has a volume of less than lOOμl.
8. The NanoTab® according to Claim 4, wherein said dosage form has a mass of less than lOOmg.
9. The NanoTab® according to Claim 4, wherein said dosage form has a volume of less than lOOμl.
10. The NanoTab® according to Claim 1, wherein said dosage form has a mass selected from the group consisting of less than lOOmg, less than 90mg, less than 80mg, less than 70mg, less than 60mg, less than 5OnIg7 less than 40mg, less than 30mg, less than 20mg and less than 10mg.
11. The NanoTab® according to Claim 1, wherein said dosage form has a volume selected from the group consisting of less than lOOμl, less than 90μl, less than 80μl, less than 70μl, less than 60 μl, less than 50μl, less than 40μl, less than 30μl, less than 20μl and less than lOμl.
12. The NanoTab® according to Claim 4, wherein said dosage form has a mass selected from the group consisting of less than lOOmg, less than 90mg, less than 80ing, less than 70mg, less than 60mg, less than 50mg, less than 40mg, less than 30mg, less than 20mg and less than 10mg.
13. The NanoTab® according to Claim 4, wherein said dosage form has a volume selected from the group consisting of less than lOOμl, less than 90μl, less than 80μl, less than 70μl, less than 60 μl, less than 50μl, less than 40μl, less than 30μl, less than 20μl and less than lOμl.
14. The NanoTab® according to Claim 11, wherein said dosage form has a volume of less than 20μl.
15. The NanoTab® according to Claim 13, wherein said dosage form has a volume of less than 20μl.
16. The NanoTab according to Claim 10, wherein said dosage form has a mass of less than 20mg.
17. The NanoTab according to Claim 12, wherein said dosage form has a mass of less than 20mg.
18. The NanoTab® according to Claim 10, wherein said dosage form is a dissolvable drug-containing dosage form of the hydrogel-forming type.
19. The NanoTab® according to Claim 10, wherein said dosage form is a dissolvable drug-containing dosage form of the eroding type.
20. The NanoTab® according to Claim 12, wherein said dosage form is a dissolvable drug-containing dosage form of the hydrogel-forming type.
21. The NanoTab® according to Claim 12, wherein said dosage form is a dissolvable drug-containing dosage form of the eroding type.
22. The NanoTab® according to Claim 11, wherein said dosage form is a dissolvable drug-containing dosage form of the hydrogel-forming type.
23. The NanoTab® according to Claim 11 , wherein said dosage form is a dissolvable drug-containing dosage form of the eroding type.
24. The NanoTab according to Claim 13, wherein said dosage form is a dissolvable drug-containing dosage form of the hydrogel-forming type.
25. The NanoTab® according to Claim 13, wherein said dosage form is a dissolvable drug-containing dosage form of the eroding type.
26. The NanoTab® according to Claim 1, wherein said dosage form has a thickness of from about 0.5 to about 3.0 mm.
27. The NanoTab® according to Claim 1, wherein said dosage form has a diameter of from about 1.0 to about 30.0 mm.
28. The NanoTab® according to Claim 1, wherein said pharmaceutically active drug is present in a therapeutically effective amount from about 0.25μg to 99.9mg.
29. The NanoTab® according to Claim 10, wherein said pharmaceutically active drug is present in a therapeutically effective amount from about 0.25μg to 99.9mg.
30. The NanoTab® according to Claim 11, wherein said pharmaceutically active drug is present in a therapeutically effective amount from about 0.25μg to 99.9mg.
31. The NanoTab® according to Claim 1, wherein said pharmaceutically active drug is present in a therapeutically effective amount from about 1 μg to 50mg.
32. The NanoTab® according to Claim 10, wherein said pharmaceutically active drug is present in a therapeutically effective amount from about lμg to 50mg.
33. The NanoTab® according to Claim 11, wherein said pharmaceutically active drug is present in a therapeutically effective amount from about lμg to 50μg.
34. The NanoTab® according to Claim 1, wherein said pharmaceutically active drug is present in a therapeutically effective amount from about lμg to 10mg.
35. The NanoTab® according to Claim 10, wherein said pharmaceutically active drug is present in a therapeutically effective amount from about lμg to lOmg.
36. The NanoTab® according to Claim 11, wherein said pharmaceutically active drug is present in a therapeutically effective amount from about lμg to 10mg.
37. The NanoTab® according to Claim 1, wherein said pharmaceutically active drug is an opioid selected from the group consisting of sufentanil, alfentanil, fentanyl, lofentanil, carfentanil, remifentanil, trefentanil, and mirfentanil.
38. The NanoTab® according to Claim 10, wherein said pharmaceutically active drug is an opioid selected from the group consisting of sufentanil, alfentanil, fentanyl, lofentanil, carfentanil, remifentanil, trefentanil, and mirfentanil.
39. The NanoTab® according to Claim 11, wherein said pharmaceutically active drug is an opioid selected from the group consisting of sufentanil, alfentanil, fentanyl, lofentanil, carfentanil, remifentanil, trefentanil, and mirfentanil.
40. The NanoTab® according to Claim 37, wherein said NanoTab® comprises from about 0.25 meg to 200 micrograms (meg) of sufentanil.
41. The NanoTab® according to Claim 38, wherein said NanoTab® comprises from about 0.25 meg to 200 micrograms (meg) of sufentanil.
42. The NanoTab® according to Claim 39, wherein said NanoTab® comprises from about 0.25 meg to 200 micrograms (meg) of sufentanil.
43. The NanoTab® according to Claim 37, wherein said NanoTab® comprises from about 2.5 meg to 100 meg of sufentanil.
44. The NanoTab® according to Claim 38, wherein said NanoTab® comprises from about 2.5 meg to 100 meg of sufentanil.
45. The NanoTab® according to Claim 39, wherein said NanoTab® comprises from about 2.5 meg to 100 meg of sufentanil.
46. The NanoTab® according to Claim 37, wherein said NanoTab® comprises a dose of from about 0.02 meg to 5 micrograms per kilogram (mcg/kg) of sufentanil.
47. The NanoTab® according to Claim 38, wherein said NanoTab® comprises a dose of from about 0.02 meg to 5 micrograms per kilogram (mcg/kg) of sufentanil.
48. The NanoTab® according to Claim 39, wherein said NanoTab® comprises a dose of from about 0.02 meg to 5 micrograms per kilogram (mcg/kg) of sufentanil.
49. The NanoTab® according to Claim 37, wherein said NanoTab® comprises a dose of sufentanil selected from the group consisting of 2.5 meg, 5 meg, 10 meg and 15 meg.
50. The NanoTab® according to Claim 38, wherein said NanoTab® comprises a dose of sufentanil selected from the group consisting of 2.5 meg, 5 meg, 10 meg and 15 meg.
51. The NanoTab® according to Claim 39, wherein said NanoTab® comprises a dose of sufentanil selected from the group consisting of 2.5 meg, 5 meg, 10 meg and 15 meg..
52. The NanoTab® according to Claim 37, wherein said NanoTab® comprises from about 10 meg to 10 mg of alfentanil.
53. The NanoTab® according to Claim 38, wherein said NanoTab® comprises from about 10 meg to 10 mg of alfentanil.
54. The NanoTab® according to Claim 39, wherein said NanoTab® comprises from about 10 meg to 10 mg of alfentanil.
55. The NanoTab® according to Claim 37, wherein said NanoTab® comprises from about 2 meg to 1500 meg of fentanyl.
56. The NanoTab® according to Claim 38, wherein said NanoTab® comprises from about 2 meg to 1500 meg of fentanyl.
57. The NanoTab® according to Claim 39, wherein said NanoTab® comprises from about 2 meg to 1500 meg of fentanyl.
58. The NanoTab® according to Claim 37, wherein said NanoTab® comprises from about 50 meg to 1500 meg of fentanyl.
59. The NanoTab® according to Claim 38, wherein said NanoTab® comprises from about 50 meg to 1500 meg of fentanyl.
60. The NanoTab® according to Claim 39, wherein said NanoTab® comprises from about 50 meg to 1500 meg of fentanyl.
61. The NanoTab® according to Claim 37, wherein said NanoTab® comprises from about 200 meg to 1500 meg of fentanyl.
62. The NanoTab® according to Claim 38, wherein said NanoTab® comprises from about 200 meg to 1500 meg of fentanyl.
63. The NanoTab® according to Claim 39, wherein said NanoTab® comprises from about 200 meg to 1500 meg of fentanyl.
64. The NanoTab® according to Claim 37, wherein said NanoTab® comprises from about 0.25 meg to 99.9 mg of lofentanil.
65. The NanoTab® according to Claim 38, wherein said NanoTab® comprises from about 0.25 meg to 99.9 mg of lofentanil.
66. The NanoTab® according to Claim 39, wherein said NanoTab® comprises from about 0.25 meg to 99.9 mg of lofentanil.
67. The NanoTab® according to Claim 37, wherein said NanoTab® comprises from about 0.25 meg to 99.9 mg of carfentanil.
68. The NanoTab® according to Claim 38, wherein said NanoTab® comprises from about 0.25 meg to 99.9 mg of carfentanil.
69. The NanoTab® according to Claim 39, wherein said NanoTab® comprises from about 0.25 meg to 99.9 mg of carfentanil.
70. The NanoTab according to Claim 37, wherein said NanoTab comprises from about 0.25 meg to 99.9 mg of remifentanil.
71. The NanoTab® according to Claim 38, wherein said NanoTab® comprises from about 0.25 meg to 99.9 mg of remifentanil.
72. The NanoTab® according to Claim 39, wherein said NanoTab® comprises from about 0.25 meg to 99.9 mg of remifentanil.
73. The NanoTab® according to Claim 37, wherein said NanoTab® comprises from about 0.25 meg to 99.9 mg of trefentanil.
74. The NanoTab® according to Claim 38, wherein said NanoTab® comprises from about 0.25 meg to 99.9 mg of trefentanil.
75. The NanoTab® according to Claim 39, wherein said NanoTab® comprises from about 0.25 meg to 99.9 mg of trefentanil.
76. The NanoTab® according to Claim 37, wherein said NanoTab® comprises from about 0.25 meg to 99.9 mg of mirfentanil.
77. The NanoTab® according to Claim 38, wherein said NanoTab® comprises from about 0.25 meg to 99.9 mg of mirfentanil.
78. The NanoTab® according to Claim 39, wherein said NanoTab® comprises from about 0.25 meg to 99.9 mg of mirfentanil.
79. The NanoTab according to Claim 10, wherein said dosage form has a shape selected from the group consisting of a round disc with a flat, concave, or convex face, an ellipsoid shape a spherical shape and a polygon with three or more edges and flat, concave, or convex faces.
80. The NanoTab® according to Claim 11, wherein said dosage form has a shape selected from the group consisting of a round disc with a flat, concave, or convex face, an ellipsoid shape a spherical shape and a polygon with three or more edges and flat, concave, or convex faces.
81. The NanoTab® according to Claim 10, wherein said NanoTab® is designed for self- administration by a subject.
82. The NanoTab® according to Claim 11, wherein said NanoTab® is designed for self- administration by a subject.
83. The NanoTab® according to Claim 81, wherein said self administration is accomplished using a device.
84. The NanoTab® according to Claim 82, wherein said self administration is accomplished using a device.
85. The NanoTab® according to Claim 1, wherein the erosion time of said NanoTab® is from 30 seconds up to a time selected from the group consisting of 1 minute, 2 minutes, 3 minutes, 4 minutes, 5 minutes, 10 minutes, 15 minutes, 30 minutes, 1 hour, 2 hours, 4 hours and 8 hours.
86. The NanoTab® according to Claim 1 , wherein the erosion time of said NanoTab® is from 30 seconds up to a time selected from the group consisting of 1 minute, 2 minutes, 3 minutes, 4 minutes, 5 minutes, 10 minutes, 15 minutes, 30 minutes, 1 hour, 2 hours, 4 hours and 8 hours.
87. The NanoTab® according to Claim 9, wherein the erosion time of said NanoTab® is from 30 seconds up to a time selected from the group consisting of 1 minute, 2 minutes, 3 minutes, 4 minutes, 5 minutes, 10 minutes, 15 minutes, 30 minutes, 1 hour, 2 hours, 4 hours and 8 hours.
88. The NanoTab® according to Claim 37, wherein a single oral transmucosal administration of said NanoTab® to a subject results in a bioavailability of greater than 65%.
89. The NanoTab® according to Claim 38, wherein a single oral transmucosal administration of said NanoTab® to a subject results in a bioavailability of greater than 65%.
90. The NanoTab® according to Claim 39, wherein a single oral transmucosal administration of said NanoTab® to a subject results in a bioavailability of greater than 65%.
91. The NanoTab® according to Claim 37, wherein a single oral transmucosal administration of said NanoTab® to a subject results in a bioavailability of greater than 75%.
92. The NanoTab® according to Claim 38, wherein a single oral transmucosal administration of said NanoTab® to a subject results in a bioavailability of greater than 75%.
93. The NanoTab® according to Claim 39, wherein a single oral transmucosal administration of said NanoTab® to a subject results in a bioavailability of greater than 75%.
94. The NanoTab® according to Claim 37, wherein a single oral transmucosal administration of said NanoTab® to a subject results in a bioavailability of greater than 85%.
95. The NanoTab® according to Claim 38, wherein a single oral transmucosal administration of said NanoTab® to a subject results in a bioavailability of greater than 85%.
96. The NanoTab® according to Claim 39, wherein a single oral transmucosal administration of said NanoTab® to a subject results in a bioavailability of greater than 85%.
97. The NanoTab according to Claim 37, wherein a single oral transmucosal administration of said NanoTab® to a subject results in a bioavailability of greater than 90%.
98. The NanoTab® according to Claim 38, wherein a single oral transmucosal administration of said NanoTab® to a subject results in a bioavailability of greater than 90%.
99. The NanoTab® according to Claim 39, wherein a single oral transmucosal administration of said NanoTab® to a subject results in a bioavailability of greater than 90%.
100. The NanoTab® according to Claim 37, wherein a single oral transmucosal administration of said NanoTab® to a subject results in a bioavailability of greater than 94%.
101. The NanoTab® according to Claim 38, wherein a single oral transmucosal administration of said NanoTab® to a subject results in a bioavailability of greater than 94%.
102. The NanoTab® according to Claim 39, wherein a single oral transmucosal administration of said NanoTab® to a subject results in a bioavailability of greater than 94%.
103. The NanoTab® according to Claim 37, wherein a single oral transmucosal administration of said NanoTab® to a subject results in an AUC with a coefficient of variation of less than 30%.
104. The NanoTab® according to Claim 38, wherein a single oral transmucosal administration of said NanoTab® to a subject results in an AUC with a coefficient of variation of less than 30%.
105. The NanoTab R according to Claim 39, wherein a single oral transmucosal administration of said NanoTab® to a subject results in an AUC with a coefficient of variation of less than 30%.
106. The NanoTab® according to Claim 37, wherein a single oral transmucosal administration of said NanoTab® to a subject results in an AUC with a coefficient of variation of less than 40%.
107. The NanoTab® according to Claim 38, wherein a single oral transmucosal administration of said NanoTab® to a subject results in an AUC with a coefficient of variation of less than 40%.
108. The NanoTab® according to Claim 39, wherein a single oral transmucosal administration of said NanoTab® to a subject results in an AUC with a coefficient of variation of less than 40%.
109. The NanoTab® according to Claim 37, wherein repeated oral transmucosal administration of said NanoTab® to a subject results in a bioavailability of greater than 65%. '
110. The NanoTab® according to Claim 38, wherein repeated oral transmucosal administration of said NanoTab® to a subject results in a bioavailability of greater than 65%.
1 1 1. The NanoTab® according to Claim 39, wherein repeated oral transmucosal administration of said NanoTab® to a subject results in a bioavailability of greater than 65%.
112. The NanoTab® according to Claim 37, wherein repeated oral transmucosal admini strati on of said NanoTab® to a subject results in a bioavailability of greater than 75%.
113. The NanoTab® according to Claim 38, wherein repeated oral transmucosal administration of said NanoTab® to a subject results in a bioavailability of greater than 75%.
114. The NanoTab® according to Claim 39, wherein repeated oral transmucosal administration of said NanoTab® to a subject results in a bioavailability of greater than 75%.
115. The NanoTab® according to Claim 37, wherein repeated oral transmucosal administration of said NanoTab® to a subject results in a bioavailability of greater than 85%.
116. The NanoTab® according to Claim 38, wherein repeated oral transmucosal administration of said NanoTab® to a subject results in a bioavailability of greater than 85%.
117. The NanoTab® according to Claim 39, wherein repeated oral transmucosal administration of said NanoTab to a subject results in a bioavailability of greater than 85%.
1 18. The NanoTab® according to Claim 37, wherein repeated oral transmucosal administration of said NanoTab R to a subject results in a bioavailability of greater than 90%.
119. The NanoTab® according to Claim 38, wherein repeated oral transmucosal administration of said NanoTab® to a subject results in a bioavailability of greater than 90%.
120. The NanoTab® according to Claim 39, wherein repeated oral transmucosal administration of said NanoTab® to a subject results in a bioavailability of greater than 90%.
121. The NanoTab® according to Claim 37, wherein repeated oral transmucosal administration of said NanoTab® to a subject results in a bioavailability of greater than 95%.
122. The NanoTab® according to Claim 38, wherein repeated oral transmucosal administration of said NanoTab® to a subject results in a bioavailability of greater than 95%.
123. The NanoTab® according to Claim 39, wherein repeated oral transmucosal administration of said NanoTab® to a subject results in a bioavailability of greater than 95%.
124. The NanoTab® according to Claim 37, wherein a single oral transmucosal administration of said drug dosage form to a subject results in a Cm0x with a coefficient of variation of less than 30%.
125. The NanoTab® according to Claim 38, wherein a single oral transmucosal administration of said drug dosage form to a subject results in a Cmax with a coefficient of variation of less than 30%.
126. The NanoTab® according to Claim 39, wherein a single oral transmucosal administration of said drug dosage form to a subject results in a Cmax with a coefficient of variation of less than 30%.
127. The NanoTab according to Claim 37, wherein a single oral transmucosal administration of said drug dosage form to a subject results in a Cmax with a coefficient of variation of less than 40%.
128. The NanoTab according to Claim 38, wherein a single oral transmucosal administration of said drug dosage form to a subject results in a Cmax with a coefficient of variation of less than 40%.
129. The NanoTab® according to Claim 39, wherein a single oral transmucosal administration of said drug dosage form to a subject results in a Cmax with a coefficient of variation of less than 40%.
130. The NanoTab® according to Claim 40, wherein a single oral transmucosal administration of said drug dosage form to a subject results in a Tmax with a coefficient of variation of less than 40%.
131. The NanoTab® according to Claim 41, wherein a single oral transmucosal administration of said drug dosage form to a subject results in a Tmax with a coefficient of variation of less than 40%.
132. The NanoTab® according to Claim 42, wherein a single oral transmucosal administration of said drug dosage form to a subject results in a Tmax with a coefficient of variation of less than 40%.
133. The NanoTab® according to Claim 37, wherein a single oral transmucosal administration of said drug dosage form results in a plasma half-life of from about 30 minutes to about 4 hours.
134. The NanoTab® according to Claim 38, wherein a single oral transmucosal administration of said drug dosage form results in a plasma half-life of from about 30 minutes to about 4 hours.
135. The NanoTab® according to Claim 39, wherein a single oral transmucosal administration of said drug dosage form results in a plasma half-life of from about 30 minutes to about 4 hours.
136. The NanoTab® according to Claim 37, wherein a single oral transmucosal administration of said drug dosage form results in a therapeutic time ratio of greater than 0.07.
137. The NanoTab according to Claim 38, wherein a single oral transmucosal administration of said drug dosage form results in a therapeutic time ratio of greater than 0.07.
138. The NanoTab® according to Claim 39, wherein a single oral transmucosal administration of said drug dosage form results in a therapeutic time ratio of greater than 0.07.
139. The NanoTab® according to Claim 37, wherein a single oral transmucosal administration of said drug dosage form results in a therapeutic time ratio of from about 0.5 to about 2.0.
140. The NanoTab® according to Claim 38, wherein a single oral transmucosal administration of said drug dosage form results in a therapeutic time ratio of from about 0.5 to about 2.0.
141. The NanoTab® according to Claim 39, wherein a single oral transmucosal administration of said drug dosage form results in a therapeutic time ratio of from about 0.5 to about 2.0.
142. The NanoTab® according to Claim 3, wherein the amount of drug in said NanoTab® that is absorbed via the oral transmucosal route is selected from the group consisting of at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98% and at least 99% of the total amount of drug in said dosage form.
143. The NanoTab according to Claim 7, wherein the amount of drug in said NanoTab® that is absorbed via the oral transmucosal route is selected from the group consisting of at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98% and at least 99% of the total amount of drug in said dosage form.
144. The NanoTab® according to Claim 9, wherein the amount of drug in said NanoTab® that is absorbed via the oral transmucosal route is selected from the group consisting of at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98% and at least 99% of the total amount of drug in said dosage form.
145. The NanoTab® according to Claim 142, wherein the amount of drug in said NanoTab® that is absorbed via the oral transmucosal route is at least 75% of the total amount of drug in said dosage form.
146. The NanoTab® according to Claim 143, wherein the amount of drug in said NanoTab® that is absorbed via the oral transmucosal route is at least 75% of the total amount of drug in said dosage form.
147. The NanoTab® according to Claim 144, wherein the amount of drug in said NanoTab® that is absorbed via the oral transmucosal route is at least 75% of the total amount of drug in said dosage form.
148. A method of treating a subject exhibiting a symptomatic medical condition comprising, administering a NanoTab® according to Claim 1, wherein said NanoTab® comprises a pharmaceutically active amount of a drug effective to reduce or eliminate said symptoms in the subject.
149. A method of treating a subject exhibiting a symptomatic medical condition comprising, administering a NanoTab® according to Claim 4, wherein said NanoTab® comprises a pharmaceutically active amount of a drug effective to reduce or eliminate said symptoms in the subject.
150. A method of treating a subject exhibiting a symptomatic medical condition comprising, administering a NanoTab® according to Claim 10, wherein said NanoTab® comprises a pharmaceutically active amount of a drug effective to reduce or eliminate said symptoms in the subject.
151. The method of treating a subject exhibiting a symptomatic medical condition, comprising, administering a NanoTab® according to Claim 11, wherein said NanoTab® comprises a pharmaceutically active amount of a drug effective to reduce or eliminate said symptoms in the subject.
152. The method according to Claim 148, wherein said symptomatic medical condition is pain.
153. The method according to Claim 149, wherein said symptomatic medical condition is pain.
154. The method according to Claim 150, wherein said symptomatic medical condition is pain.
155. The method according to Claim 151, wherein said symptomatic medical condition is pain.
156. A method of a treating pain in a subject comprising, administering a NanoTab® according to Claim 37, wherein said NanoTab® comprises a pharmaceutically active amount of a drug effective to reduce or eliminate symptoms of pain, wherein following administration of said NanoTab® symptoms of pain are reduced or eliminated in said subject.
157. A method of a treating pain in a subject comprising, administering a NanoTab® according to Claim 38, wherein said NanoTab® comprises a pharmaceutically active amount of a drug effective to reduce or eliminate symptoms of pain, wherein following administration of said NanoTab symptoms of pain are reduced or eliminated in said subject.
15 S . A method of a treating pain in a subj ect comprising, administering a NanoTab® according to Claim 39, wherein said NanoTab® comprises a pharmaceutically active amount of a drug effective to reduce or eliminate symptoms of pain, wherein following administration of said NanoTab® symptoms of pain are reduced or eliminated in said subject.
159. The method according to Claim 156, wherein said symptomatic medical condition is acute pain.
160. The method according to Claim 156, wherein said symptomatic medical condition is breakthrough pain.
161. The method according to Claim 156, wherein said symptomatic medical condition is post-operative pain.
162. The method according to Claim 157, wherein said symptomatic medical condition is acute pain.
163. The method according to Claim 157, wherein said symptomatic medical condition is breakthrough pain.
164. The method according to Claim 157, wherein said symptomatic medical condition is post-operative pain.
165. The method according to Claim 158, wherein said symptomatic medical condition is acute pain.
166. The method according to Claim 158, wherein said symptomatic medical condition is breakthrough pain.
167. The method according to Claim 158, wherein said symptomatic medical condition is post-operative pain.
PCT/US2007/000529 2006-01-06 2007-01-08 Small-volume oral transmucosal dosage forms WO2007081949A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
JP2008549612A JP5183490B2 (en) 2006-01-06 2007-01-08 Small volume oral transmucosal dosage form
EP20070716451 EP1978996A4 (en) 2006-01-06 2007-01-08 Small-volume oral transmucosal dosage forms
CN200780007142.9A CN101394863B (en) 2006-01-06 2007-01-08 Small-volume oral transmucosal dosage forms
CA2636088A CA2636088C (en) 2006-01-06 2007-01-08 Small-volume oral transmucosal dosage forms
EP16163199.9A EP3072504B1 (en) 2006-01-06 2007-01-08 Small-volume oral transmucosal dosage forms
EP20161845.1A EP3685829A1 (en) 2006-01-06 2007-01-08 Small-volume oral transmucosal dosage forms
KR1020087019313A KR101503074B1 (en) 2006-01-06 2007-01-08 Small-volume oral transmucosal dosage forms

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US75693706P 2006-01-06 2006-01-06
US60/756,937 2006-01-06
US11/650,174 US8202535B2 (en) 2006-01-06 2007-01-05 Small-volume oral transmucosal dosage forms
US11/650,174 2007-01-05

Publications (2)

Publication Number Publication Date
WO2007081949A2 true WO2007081949A2 (en) 2007-07-19
WO2007081949A3 WO2007081949A3 (en) 2007-11-01

Family

ID=38256991

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/000529 WO2007081949A2 (en) 2006-01-06 2007-01-08 Small-volume oral transmucosal dosage forms

Country Status (9)

Country Link
US (8) US8202535B2 (en)
EP (3) EP1978996A4 (en)
JP (2) JP5183490B2 (en)
KR (1) KR101503074B1 (en)
CA (1) CA2636088C (en)
DK (1) DK3072504T3 (en)
ES (1) ES2788507T3 (en)
PT (1) PT3072504T (en)
WO (1) WO2007081949A2 (en)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009021106A1 (en) * 2007-08-07 2009-02-12 Acelrx Pharmaceuticals, Inc. Compositions and methods for procedural sedation and analgesia using oral transmucosal dosage forms
WO2010059504A1 (en) * 2008-11-21 2010-05-27 Acelrx Pharmaceuticals, Inc. Sufentanil solid dosage forms comprising oxygen scavengers and methods of using the same
US20110091544A1 (en) * 2009-10-16 2011-04-21 Acelrx Pharmaceuticals, Inc. Compositions and Methods for Mild Sedation, Anxiolysis and Analgesia in the Procedural Setting
US8535714B2 (en) 2006-01-06 2013-09-17 Acelrx Pharmaceuticals, Inc. Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
US8778393B2 (en) 2006-01-06 2014-07-15 Acelrx Pharmaceuticals, Inc. Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
US8815911B2 (en) 2012-05-02 2014-08-26 Orexo Ab Alfentanil composition for the treatment of acute pain
US8865743B2 (en) 2006-01-06 2014-10-21 Acelrx Pharmaceuticals, Inc. Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
US8865211B2 (en) 2006-01-06 2014-10-21 Acelrx Pharmaceuticals, Inc. Bioadhesive drug formulations for oral transmucosal delivery

Families Citing this family (319)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9060770B2 (en) 2003-05-20 2015-06-23 Ethicon Endo-Surgery, Inc. Robotically-driven surgical instrument with E-beam driver
US20070084897A1 (en) 2003-05-20 2007-04-19 Shelton Frederick E Iv Articulating surgical stapling instrument incorporating a two-piece e-beam firing mechanism
US8215531B2 (en) 2004-07-28 2012-07-10 Ethicon Endo-Surgery, Inc. Surgical stapling instrument having a medical substance dispenser
US11890012B2 (en) 2004-07-28 2024-02-06 Cilag Gmbh International Staple cartridge comprising cartridge body and attached support
US9237891B2 (en) 2005-08-31 2016-01-19 Ethicon Endo-Surgery, Inc. Robotically-controlled surgical stapling devices that produce formed staples having different lengths
US7934630B2 (en) 2005-08-31 2011-05-03 Ethicon Endo-Surgery, Inc. Staple cartridges for forming staples having differing formed staple heights
US7669746B2 (en) 2005-08-31 2010-03-02 Ethicon Endo-Surgery, Inc. Staple cartridges for forming staples having differing formed staple heights
US11246590B2 (en) 2005-08-31 2022-02-15 Cilag Gmbh International Staple cartridge including staple drivers having different unfired heights
US10159482B2 (en) 2005-08-31 2018-12-25 Ethicon Llc Fastener cartridge assembly comprising a fixed anvil and different staple heights
US11484312B2 (en) 2005-08-31 2022-11-01 Cilag Gmbh International Staple cartridge comprising a staple driver arrangement
US20070106317A1 (en) 2005-11-09 2007-05-10 Shelton Frederick E Iv Hydraulically and electrically actuated articulation joints for surgical instruments
US9289583B2 (en) 2006-01-06 2016-03-22 Acelrx Pharmaceuticals, Inc. Methods for administering small volume oral transmucosal dosage forms using a dispensing device
US9066847B2 (en) 2007-01-05 2015-06-30 Aceirx Pharmaceuticals, Inc. Storage and dispensing devices for administration of oral transmucosal dosage forms
US8252328B2 (en) * 2006-01-06 2012-08-28 Acelrx Pharmaceuticals, Inc. Bioadhesive drug formulations for oral transmucosal delivery
US8357114B2 (en) 2006-01-06 2013-01-22 Acelrx Pharmaceuticals, Inc. Drug dispensing device with flexible push rod
US8753308B2 (en) 2006-01-06 2014-06-17 Acelrx Pharmaceuticals, Inc. Methods for administering small volume oral transmucosal dosage forms using a dispensing device
US11278279B2 (en) 2006-01-31 2022-03-22 Cilag Gmbh International Surgical instrument assembly
US7845537B2 (en) 2006-01-31 2010-12-07 Ethicon Endo-Surgery, Inc. Surgical instrument having recording capabilities
US11793518B2 (en) 2006-01-31 2023-10-24 Cilag Gmbh International Powered surgical instruments with firing system lockout arrangements
US11224427B2 (en) 2006-01-31 2022-01-18 Cilag Gmbh International Surgical stapling system including a console and retraction assembly
US8708213B2 (en) 2006-01-31 2014-04-29 Ethicon Endo-Surgery, Inc. Surgical instrument having a feedback system
US8186555B2 (en) 2006-01-31 2012-05-29 Ethicon Endo-Surgery, Inc. Motor-driven surgical cutting and fastening instrument with mechanical closure system
US20120292367A1 (en) 2006-01-31 2012-11-22 Ethicon Endo-Surgery, Inc. Robotically-controlled end effector
US20110290856A1 (en) 2006-01-31 2011-12-01 Ethicon Endo-Surgery, Inc. Robotically-controlled surgical instrument with force-feedback capabilities
US8820603B2 (en) 2006-01-31 2014-09-02 Ethicon Endo-Surgery, Inc. Accessing data stored in a memory of a surgical instrument
US7753904B2 (en) 2006-01-31 2010-07-13 Ethicon Endo-Surgery, Inc. Endoscopic surgical instrument with a handle that can articulate with respect to the shaft
US8992422B2 (en) 2006-03-23 2015-03-31 Ethicon Endo-Surgery, Inc. Robotically-controlled endoscopic accessory channel
US8322455B2 (en) 2006-06-27 2012-12-04 Ethicon Endo-Surgery, Inc. Manually driven surgical cutting and fastening instrument
US10568652B2 (en) 2006-09-29 2020-02-25 Ethicon Llc Surgical staples having attached drivers of different heights and stapling instruments for deploying the same
US11291441B2 (en) 2007-01-10 2022-04-05 Cilag Gmbh International Surgical instrument with wireless communication between control unit and remote sensor
US8684253B2 (en) 2007-01-10 2014-04-01 Ethicon Endo-Surgery, Inc. Surgical instrument with wireless communication between a control unit of a robotic system and remote sensor
US8652120B2 (en) 2007-01-10 2014-02-18 Ethicon Endo-Surgery, Inc. Surgical instrument with wireless communication between control unit and sensor transponders
US20080169332A1 (en) 2007-01-11 2008-07-17 Shelton Frederick E Surgical stapling device with a curved cutting member
US11039836B2 (en) 2007-01-11 2021-06-22 Cilag Gmbh International Staple cartridge for use with a surgical stapling instrument
US20090001130A1 (en) 2007-03-15 2009-01-01 Hess Christopher J Surgical procedure using a cutting and stapling instrument having releasable staple-forming pockets
US11857181B2 (en) 2007-06-04 2024-01-02 Cilag Gmbh International Robotically-controlled shaft based rotary drive systems for surgical instruments
US8931682B2 (en) 2007-06-04 2015-01-13 Ethicon Endo-Surgery, Inc. Robotically-controlled shaft based rotary drive systems for surgical instruments
US7753245B2 (en) 2007-06-22 2010-07-13 Ethicon Endo-Surgery, Inc. Surgical stapling instruments
US11849941B2 (en) 2007-06-29 2023-12-26 Cilag Gmbh International Staple cartridge having staple cavities extending at a transverse angle relative to a longitudinal cartridge axis
JP5410110B2 (en) 2008-02-14 2014-02-05 エシコン・エンド−サージェリィ・インコーポレイテッド Surgical cutting / fixing instrument with RF electrode
US9179912B2 (en) 2008-02-14 2015-11-10 Ethicon Endo-Surgery, Inc. Robotically-controlled motorized surgical cutting and fastening instrument
US7819298B2 (en) 2008-02-14 2010-10-26 Ethicon Endo-Surgery, Inc. Surgical stapling apparatus with control features operable with one hand
US8636736B2 (en) 2008-02-14 2014-01-28 Ethicon Endo-Surgery, Inc. Motorized surgical cutting and fastening instrument
US7866527B2 (en) 2008-02-14 2011-01-11 Ethicon Endo-Surgery, Inc. Surgical stapling apparatus with interlockable firing system
US9770245B2 (en) 2008-02-15 2017-09-26 Ethicon Llc Layer arrangements for surgical staple cartridges
DK2303359T3 (en) * 2008-05-29 2020-04-27 Hoffmann La Roche Modular medical infusion device with means of identification / approval between its components
US11648005B2 (en) 2008-09-23 2023-05-16 Cilag Gmbh International Robotically-controlled motorized surgical instrument with an end effector
US9005230B2 (en) 2008-09-23 2015-04-14 Ethicon Endo-Surgery, Inc. Motorized surgical instrument
US9386983B2 (en) 2008-09-23 2016-07-12 Ethicon Endo-Surgery, Llc Robotically-controlled motorized surgical instrument
US8210411B2 (en) 2008-09-23 2012-07-03 Ethicon Endo-Surgery, Inc. Motor-driven surgical cutting instrument
US8608045B2 (en) 2008-10-10 2013-12-17 Ethicon Endo-Sugery, Inc. Powered surgical cutting and stapling apparatus with manually retractable firing system
US8517239B2 (en) 2009-02-05 2013-08-27 Ethicon Endo-Surgery, Inc. Surgical stapling instrument comprising a magnetic element driver
CN102341048A (en) 2009-02-06 2012-02-01 伊西康内外科公司 Driven surgical stapler improvements
WO2010107761A1 (en) 2009-03-18 2010-09-23 Acelrx Pharmaceuticals, Inc. Improved storage and dispensing devices for administration of oral transmucosal dosage forms
US20110050412A1 (en) * 2009-08-18 2011-03-03 Cynthia Wittman Voice activated finding device
US8851354B2 (en) 2009-12-24 2014-10-07 Ethicon Endo-Surgery, Inc. Surgical cutting instrument that analyzes tissue thickness
US20110288128A1 (en) 2010-05-21 2011-11-24 Acelrx Pharmaceuticals, Inc. Oral Transmucosal Administration of Sufentanil
US8783543B2 (en) 2010-07-30 2014-07-22 Ethicon Endo-Surgery, Inc. Tissue acquisition arrangements and methods for surgical stapling devices
US8777004B2 (en) 2010-09-30 2014-07-15 Ethicon Endo-Surgery, Inc. Compressible staple cartridge comprising alignment members
US10945731B2 (en) 2010-09-30 2021-03-16 Ethicon Llc Tissue thickness compensator comprising controlled release and expansion
US11812965B2 (en) 2010-09-30 2023-11-14 Cilag Gmbh International Layer of material for a surgical end effector
US9241714B2 (en) 2011-04-29 2016-01-26 Ethicon Endo-Surgery, Inc. Tissue thickness compensator and method for making the same
US9788834B2 (en) 2010-09-30 2017-10-17 Ethicon Llc Layer comprising deployable attachment members
US11298125B2 (en) 2010-09-30 2022-04-12 Cilag Gmbh International Tissue stapler having a thickness compensator
US9320523B2 (en) 2012-03-28 2016-04-26 Ethicon Endo-Surgery, Llc Tissue thickness compensator comprising tissue ingrowth features
US9629814B2 (en) 2010-09-30 2017-04-25 Ethicon Endo-Surgery, Llc Tissue thickness compensator configured to redistribute compressive forces
US11925354B2 (en) 2010-09-30 2024-03-12 Cilag Gmbh International Staple cartridge comprising staples positioned within a compressible portion thereof
US8695866B2 (en) 2010-10-01 2014-04-15 Ethicon Endo-Surgery, Inc. Surgical instrument having a power control circuit
WO2012120506A2 (en) 2011-03-09 2012-09-13 Pixcell Medical Technologies Ltd. Disposable cartridge for preparing a sample fluid containing cells for analysis
BR112013027794B1 (en) 2011-04-29 2020-12-15 Ethicon Endo-Surgery, Inc CLAMP CARTRIDGE SET
US9072535B2 (en) 2011-05-27 2015-07-07 Ethicon Endo-Surgery, Inc. Surgical stapling instruments with rotatable staple deployment arrangements
US11207064B2 (en) 2011-05-27 2021-12-28 Cilag Gmbh International Automated end effector component reloading system for use with a robotic system
AU2012279438A1 (en) * 2011-07-01 2014-01-23 Baxter Corporation Englewood Systems and methods for intelligent patient interface device
US9772270B2 (en) 2011-08-16 2017-09-26 Elwha Llc Devices and methods for recording information on a subject's body
US9443061B2 (en) 2011-08-16 2016-09-13 Elwha Llc Devices and methods for recording information on a subject's body
US9286615B2 (en) * 2011-08-16 2016-03-15 Elwha Llc Devices and methods for recording information on a subject's body
US20130053719A1 (en) * 2011-08-22 2013-02-28 William Oren Wekell Asthma monitoring device
RU2014143258A (en) 2012-03-28 2016-05-20 Этикон Эндо-Серджери, Инк. FABRIC THICKNESS COMPENSATOR CONTAINING MANY LAYERS
CN104334098B (en) 2012-03-28 2017-03-22 伊西康内外科公司 Tissue thickness compensator comprising capsules defining a low pressure environment
MX353040B (en) 2012-03-28 2017-12-18 Ethicon Endo Surgery Inc Retainer assembly including a tissue thickness compensator.
US9101358B2 (en) 2012-06-15 2015-08-11 Ethicon Endo-Surgery, Inc. Articulatable surgical instrument comprising a firing drive
US9408606B2 (en) 2012-06-28 2016-08-09 Ethicon Endo-Surgery, Llc Robotically powered surgical device with manually-actuatable reversing system
BR112014032776B1 (en) 2012-06-28 2021-09-08 Ethicon Endo-Surgery, Inc SURGICAL INSTRUMENT SYSTEM AND SURGICAL KIT FOR USE WITH A SURGICAL INSTRUMENT SYSTEM
US9289256B2 (en) 2012-06-28 2016-03-22 Ethicon Endo-Surgery, Llc Surgical end effectors having angled tissue-contacting surfaces
US9282974B2 (en) 2012-06-28 2016-03-15 Ethicon Endo-Surgery, Llc Empty clip cartridge lockout
JP6290201B2 (en) 2012-06-28 2018-03-07 エシコン・エンド−サージェリィ・インコーポレイテッドEthicon Endo−Surgery,Inc. Lockout for empty clip cartridge
US20140001231A1 (en) 2012-06-28 2014-01-02 Ethicon Endo-Surgery, Inc. Firing system lockout arrangements for surgical instruments
US11202631B2 (en) 2012-06-28 2021-12-21 Cilag Gmbh International Stapling assembly comprising a firing lockout
US9700310B2 (en) 2013-08-23 2017-07-11 Ethicon Llc Firing member retraction devices for powered surgical instruments
WO2014134046A1 (en) * 2013-02-27 2014-09-04 Welch Allyn, Inc. Anti-loss for medical devices
JP6382235B2 (en) 2013-03-01 2018-08-29 エシコン・エンド−サージェリィ・インコーポレイテッドEthicon Endo−Surgery,Inc. Articulatable surgical instrument with a conductive path for signal communication
JP6345707B2 (en) 2013-03-01 2018-06-20 エシコン・エンド−サージェリィ・インコーポレイテッドEthicon Endo−Surgery,Inc. Surgical instrument with soft stop
US9629629B2 (en) 2013-03-14 2017-04-25 Ethicon Endo-Surgey, LLC Control systems for surgical instruments
US9649110B2 (en) 2013-04-16 2017-05-16 Ethicon Llc Surgical instrument comprising a closing drive and a firing drive operated from the same rotatable output
BR112015026109B1 (en) 2013-04-16 2022-02-22 Ethicon Endo-Surgery, Inc surgical instrument
MX369362B (en) 2013-08-23 2019-11-06 Ethicon Endo Surgery Llc Firing member retraction devices for powered surgical instruments.
BR112016021943B1 (en) 2014-03-26 2022-06-14 Ethicon Endo-Surgery, Llc SURGICAL INSTRUMENT FOR USE BY AN OPERATOR IN A SURGICAL PROCEDURE
US10013049B2 (en) 2014-03-26 2018-07-03 Ethicon Llc Power management through sleep options of segmented circuit and wake up control
CN106456158B (en) 2014-04-16 2019-02-05 伊西康内外科有限责任公司 Fastener cartridge including non-uniform fastener
US20150297223A1 (en) 2014-04-16 2015-10-22 Ethicon Endo-Surgery, Inc. Fastener cartridges including extensions having different configurations
BR112016023807B1 (en) 2014-04-16 2022-07-12 Ethicon Endo-Surgery, Llc CARTRIDGE SET OF FASTENERS FOR USE WITH A SURGICAL INSTRUMENT
JP6636452B2 (en) 2014-04-16 2020-01-29 エシコン エルエルシーEthicon LLC Fastener cartridge including extension having different configurations
US10111679B2 (en) 2014-09-05 2018-10-30 Ethicon Llc Circuitry and sensors for powered medical device
BR112017004361B1 (en) 2014-09-05 2023-04-11 Ethicon Llc ELECTRONIC SYSTEM FOR A SURGICAL INSTRUMENT
US11311294B2 (en) 2014-09-05 2022-04-26 Cilag Gmbh International Powered medical device including measurement of closure state of jaws
US10105142B2 (en) 2014-09-18 2018-10-23 Ethicon Llc Surgical stapler with plurality of cutting elements
US11523821B2 (en) 2014-09-26 2022-12-13 Cilag Gmbh International Method for creating a flexible staple line
MX2017003960A (en) 2014-09-26 2017-12-04 Ethicon Llc Surgical stapling buttresses and adjunct materials.
US9924944B2 (en) 2014-10-16 2018-03-27 Ethicon Llc Staple cartridge comprising an adjunct material
US10517594B2 (en) 2014-10-29 2019-12-31 Ethicon Llc Cartridge assemblies for surgical staplers
US11141153B2 (en) 2014-10-29 2021-10-12 Cilag Gmbh International Staple cartridges comprising driver arrangements
US9844376B2 (en) 2014-11-06 2017-12-19 Ethicon Llc Staple cartridge comprising a releasable adjunct material
US10736636B2 (en) 2014-12-10 2020-08-11 Ethicon Llc Articulatable surgical instrument system
BR112017012996B1 (en) 2014-12-18 2022-11-08 Ethicon Llc SURGICAL INSTRUMENT WITH AN ANvil WHICH IS SELECTIVELY MOVABLE ABOUT AN IMMOVABLE GEOMETRIC AXIS DIFFERENT FROM A STAPLE CARTRIDGE
US9943309B2 (en) 2014-12-18 2018-04-17 Ethicon Llc Surgical instruments with articulatable end effectors and movable firing beam support arrangements
US9844374B2 (en) 2014-12-18 2017-12-19 Ethicon Llc Surgical instrument systems comprising an articulatable end effector and means for adjusting the firing stroke of a firing member
US9844375B2 (en) 2014-12-18 2017-12-19 Ethicon Llc Drive arrangements for articulatable surgical instruments
US9987000B2 (en) 2014-12-18 2018-06-05 Ethicon Llc Surgical instrument assembly comprising a flexible articulation system
US10085748B2 (en) 2014-12-18 2018-10-02 Ethicon Llc Locking arrangements for detachable shaft assemblies with articulatable surgical end effectors
NZ732808A (en) 2014-12-23 2021-12-24 Acelrx Pharmaceuticals Inc Systems, devices and methods for dispensing oral transmucosal dosage forms
US11154301B2 (en) 2015-02-27 2021-10-26 Cilag Gmbh International Modular stapling assembly
US10245033B2 (en) 2015-03-06 2019-04-02 Ethicon Llc Surgical instrument comprising a lockable battery housing
JP2020121162A (en) 2015-03-06 2020-08-13 エシコン エルエルシーEthicon LLC Time dependent evaluation of sensor data to determine stability element, creep element and viscoelastic element of measurement
US10548504B2 (en) 2015-03-06 2020-02-04 Ethicon Llc Overlaid multi sensor radio frequency (RF) electrode system to measure tissue compression
US9993248B2 (en) 2015-03-06 2018-06-12 Ethicon Endo-Surgery, Llc Smart sensors with local signal processing
US10213201B2 (en) 2015-03-31 2019-02-26 Ethicon Llc Stapling end effector configured to compensate for an uneven gap between a first jaw and a second jaw
US10603429B2 (en) 2015-04-27 2020-03-31 Capsule Technologies, Inc. Subcutaneous injection system with adhesive injection site indicator
US10105139B2 (en) 2015-09-23 2018-10-23 Ethicon Llc Surgical stapler having downstream current-based motor control
US10238386B2 (en) 2015-09-23 2019-03-26 Ethicon Llc Surgical stapler having motor control based on an electrical parameter related to a motor current
US10299878B2 (en) 2015-09-25 2019-05-28 Ethicon Llc Implantable adjunct systems for determining adjunct skew
US10478188B2 (en) 2015-09-30 2019-11-19 Ethicon Llc Implantable layer comprising a constricted configuration
US10736633B2 (en) 2015-09-30 2020-08-11 Ethicon Llc Compressible adjunct with looping members
US11890015B2 (en) 2015-09-30 2024-02-06 Cilag Gmbh International Compressible adjunct with crossing spacer fibers
ES2947769T3 (en) 2015-10-30 2023-08-18 Vertical Pharmaceuticals Llc Apparatus and methods for dispensing oral transmucosal dosage forms
US10265068B2 (en) 2015-12-30 2019-04-23 Ethicon Llc Surgical instruments with separable motors and motor control circuits
US10292704B2 (en) 2015-12-30 2019-05-21 Ethicon Llc Mechanisms for compensating for battery pack failure in powered surgical instruments
US10368865B2 (en) 2015-12-30 2019-08-06 Ethicon Llc Mechanisms for compensating for drivetrain failure in powered surgical instruments
JP6911054B2 (en) 2016-02-09 2021-07-28 エシコン エルエルシーEthicon LLC Surgical instruments with asymmetric joint composition
US11213293B2 (en) 2016-02-09 2022-01-04 Cilag Gmbh International Articulatable surgical instruments with single articulation link arrangements
US11224426B2 (en) 2016-02-12 2022-01-18 Cilag Gmbh International Mechanisms for compensating for drivetrain failure in powered surgical instruments
US10448948B2 (en) 2016-02-12 2019-10-22 Ethicon Llc Mechanisms for compensating for drivetrain failure in powered surgical instruments
US11083837B2 (en) 2016-03-22 2021-08-10 International Business Machines Corporation Secure medication delivery
US20170274145A1 (en) * 2016-03-22 2017-09-28 International Business Machines Corporation Secure medication delivery
US10376444B2 (en) 2016-03-22 2019-08-13 International Business Machines Corporation Secure medication delivery
US10828028B2 (en) 2016-04-15 2020-11-10 Ethicon Llc Surgical instrument with multiple program responses during a firing motion
US10492783B2 (en) 2016-04-15 2019-12-03 Ethicon, Llc Surgical instrument with improved stop/start control during a firing motion
US11607239B2 (en) 2016-04-15 2023-03-21 Cilag Gmbh International Systems and methods for controlling a surgical stapling and cutting instrument
US10426467B2 (en) 2016-04-15 2019-10-01 Ethicon Llc Surgical instrument with detection sensors
US10357247B2 (en) 2016-04-15 2019-07-23 Ethicon Llc Surgical instrument with multiple program responses during a firing motion
US10456137B2 (en) 2016-04-15 2019-10-29 Ethicon Llc Staple formation detection mechanisms
US11179150B2 (en) 2016-04-15 2021-11-23 Cilag Gmbh International Systems and methods for controlling a surgical stapling and cutting instrument
US10335145B2 (en) 2016-04-15 2019-07-02 Ethicon Llc Modular surgical instrument with configurable operating mode
US11317917B2 (en) 2016-04-18 2022-05-03 Cilag Gmbh International Surgical stapling system comprising a lockable firing assembly
US20170296173A1 (en) 2016-04-18 2017-10-19 Ethicon Endo-Surgery, Llc Method for operating a surgical instrument
US10433840B2 (en) 2016-04-18 2019-10-08 Ethicon Llc Surgical instrument comprising a replaceable cartridge jaw
US10588631B2 (en) 2016-12-21 2020-03-17 Ethicon Llc Surgical instruments with positive jaw opening features
US10524789B2 (en) 2016-12-21 2020-01-07 Ethicon Llc Laterally actuatable articulation lock arrangements for locking an end effector of a surgical instrument in an articulated configuration
JP6983893B2 (en) 2016-12-21 2021-12-17 エシコン エルエルシーEthicon LLC Lockout configuration for surgical end effectors and replaceable tool assemblies
US10675026B2 (en) 2016-12-21 2020-06-09 Ethicon Llc Methods of stapling tissue
US11134942B2 (en) 2016-12-21 2021-10-05 Cilag Gmbh International Surgical stapling instruments and staple-forming anvils
JP2020501779A (en) 2016-12-21 2020-01-23 エシコン エルエルシーEthicon LLC Surgical stapling system
JP7010956B2 (en) 2016-12-21 2022-01-26 エシコン エルエルシー How to staple tissue
US10675025B2 (en) 2016-12-21 2020-06-09 Ethicon Llc Shaft assembly comprising separately actuatable and retractable systems
US11419606B2 (en) 2016-12-21 2022-08-23 Cilag Gmbh International Shaft assembly comprising a clutch configured to adapt the output of a rotary firing member to two different systems
US10588632B2 (en) 2016-12-21 2020-03-17 Ethicon Llc Surgical end effectors and firing members thereof
US10980536B2 (en) 2016-12-21 2021-04-20 Ethicon Llc No-cartridge and spent cartridge lockout arrangements for surgical staplers
US20180168615A1 (en) 2016-12-21 2018-06-21 Ethicon Endo-Surgery, Llc Method of deforming staples from two different types of staple cartridges with the same surgical stapling instrument
US9731103B1 (en) 2017-01-13 2017-08-15 Berkshire Biomedical, LLC Computerized oral prescription administration devices and associated systems and methods
US10792226B2 (en) 2017-06-07 2020-10-06 Berkshire Biomedical, LLC Refill and dosage management devices and associated systems and methods for use with computerized oral prescription administration devices
JOP20190030A1 (en) * 2017-06-14 2019-02-26 Grow Solutions Tech Llc Precision seeder heads and seeder components that include precision seeder heads
US10881399B2 (en) 2017-06-20 2021-01-05 Ethicon Llc Techniques for adaptive control of motor velocity of a surgical stapling and cutting instrument
US10307170B2 (en) 2017-06-20 2019-06-04 Ethicon Llc Method for closed loop control of motor velocity of a surgical stapling and cutting instrument
US11382638B2 (en) 2017-06-20 2022-07-12 Cilag Gmbh International Closed loop feedback control of motor velocity of a surgical stapling and cutting instrument based on measured time over a specified displacement distance
US11071554B2 (en) 2017-06-20 2021-07-27 Cilag Gmbh International Closed loop feedback control of motor velocity of a surgical stapling and cutting instrument based on magnitude of velocity error measurements
US10779820B2 (en) 2017-06-20 2020-09-22 Ethicon Llc Systems and methods for controlling motor speed according to user input for a surgical instrument
US11517325B2 (en) 2017-06-20 2022-12-06 Cilag Gmbh International Closed loop feedback control of motor velocity of a surgical stapling and cutting instrument based on measured displacement distance traveled over a specified time interval
US11090046B2 (en) 2017-06-20 2021-08-17 Cilag Gmbh International Systems and methods for controlling displacement member motion of a surgical stapling and cutting instrument
US11653914B2 (en) 2017-06-20 2023-05-23 Cilag Gmbh International Systems and methods for controlling motor velocity of a surgical stapling and cutting instrument according to articulation angle of end effector
US10993716B2 (en) 2017-06-27 2021-05-04 Ethicon Llc Surgical anvil arrangements
US11324503B2 (en) 2017-06-27 2022-05-10 Cilag Gmbh International Surgical firing member arrangements
US11141154B2 (en) 2017-06-27 2021-10-12 Cilag Gmbh International Surgical end effectors and anvils
US11266405B2 (en) 2017-06-27 2022-03-08 Cilag Gmbh International Surgical anvil manufacturing methods
US11259805B2 (en) 2017-06-28 2022-03-01 Cilag Gmbh International Surgical instrument comprising firing member supports
US11058424B2 (en) 2017-06-28 2021-07-13 Cilag Gmbh International Surgical instrument comprising an offset articulation joint
US11246592B2 (en) 2017-06-28 2022-02-15 Cilag Gmbh International Surgical instrument comprising an articulation system lockable to a frame
EP4070740A1 (en) 2017-06-28 2022-10-12 Cilag GmbH International Surgical instrument comprising selectively actuatable rotatable couplers
US11564686B2 (en) 2017-06-28 2023-01-31 Cilag Gmbh International Surgical shaft assemblies with flexible interfaces
US20190000461A1 (en) 2017-06-28 2019-01-03 Ethicon Llc Surgical cutting and fastening devices with pivotable anvil with a tissue locating arrangement in close proximity to an anvil pivot axis
US10765427B2 (en) 2017-06-28 2020-09-08 Ethicon Llc Method for articulating a surgical instrument
US10932772B2 (en) 2017-06-29 2021-03-02 Ethicon Llc Methods for closed loop velocity control for robotic surgical instrument
US11471155B2 (en) 2017-08-03 2022-10-18 Cilag Gmbh International Surgical system bailout
US11304695B2 (en) 2017-08-03 2022-04-19 Cilag Gmbh International Surgical system shaft interconnection
US11399829B2 (en) 2017-09-29 2022-08-02 Cilag Gmbh International Systems and methods of initiating a power shutdown mode for a surgical instrument
US11134944B2 (en) 2017-10-30 2021-10-05 Cilag Gmbh International Surgical stapler knife motion controls
US11090075B2 (en) 2017-10-30 2021-08-17 Cilag Gmbh International Articulation features for surgical end effector
US10842490B2 (en) 2017-10-31 2020-11-24 Ethicon Llc Cartridge body design with force reduction based on firing completion
US11197670B2 (en) 2017-12-15 2021-12-14 Cilag Gmbh International Surgical end effectors with pivotal jaws configured to touch at their respective distal ends when fully closed
US10779826B2 (en) 2017-12-15 2020-09-22 Ethicon Llc Methods of operating surgical end effectors
US11071543B2 (en) 2017-12-15 2021-07-27 Cilag Gmbh International Surgical end effectors with clamping assemblies configured to increase jaw aperture ranges
US10835330B2 (en) 2017-12-19 2020-11-17 Ethicon Llc Method for determining the position of a rotatable jaw of a surgical instrument attachment assembly
US11076853B2 (en) 2017-12-21 2021-08-03 Cilag Gmbh International Systems and methods of displaying a knife position during transection for a surgical instrument
US11311290B2 (en) 2017-12-21 2022-04-26 Cilag Gmbh International Surgical instrument comprising an end effector dampener
US10682134B2 (en) 2017-12-21 2020-06-16 Ethicon Llc Continuous use self-propelled stapling instrument
US10441509B2 (en) 2018-03-16 2019-10-15 Berkshire Biomedical, LLC Computerized oral prescription administration with refillable medication dispensing devices and associated systems and methods
US11207065B2 (en) 2018-08-20 2021-12-28 Cilag Gmbh International Method for fabricating surgical stapler anvils
US11324501B2 (en) 2018-08-20 2022-05-10 Cilag Gmbh International Surgical stapling devices with improved closure members
US11045192B2 (en) 2018-08-20 2021-06-29 Cilag Gmbh International Fabricating techniques for surgical stapler anvils
US11039834B2 (en) 2018-08-20 2021-06-22 Cilag Gmbh International Surgical stapler anvils with staple directing protrusions and tissue stability features
US11253256B2 (en) 2018-08-20 2022-02-22 Cilag Gmbh International Articulatable motor powered surgical instruments with dedicated articulation motor arrangements
US11291440B2 (en) 2018-08-20 2022-04-05 Cilag Gmbh International Method for operating a powered articulatable surgical instrument
US11450420B2 (en) * 2018-08-21 2022-09-20 Vivera Pharmaceuticals Inc. Secure smart dosing system with automated delivery, measurement, and management for pills
US11090449B2 (en) * 2018-08-21 2021-08-17 Vivera Pharmaceuticals Inc. Smart inhaler device with automated dose delivery, measurement, and management
US11083850B2 (en) * 2018-08-21 2021-08-10 Vivera Pharmaceuticals Inc. Secure smart dosing system with automated delivery, measurement, and management
US11172929B2 (en) 2019-03-25 2021-11-16 Cilag Gmbh International Articulation drive arrangements for surgical systems
US11147551B2 (en) 2019-03-25 2021-10-19 Cilag Gmbh International Firing drive arrangements for surgical systems
US11147553B2 (en) 2019-03-25 2021-10-19 Cilag Gmbh International Firing drive arrangements for surgical systems
US11696761B2 (en) 2019-03-25 2023-07-11 Cilag Gmbh International Firing drive arrangements for surgical systems
US11253254B2 (en) 2019-04-30 2022-02-22 Cilag Gmbh International Shaft rotation actuator on a surgical instrument
US11452528B2 (en) 2019-04-30 2022-09-27 Cilag Gmbh International Articulation actuators for a surgical instrument
US11471157B2 (en) 2019-04-30 2022-10-18 Cilag Gmbh International Articulation control mapping for a surgical instrument
US11426251B2 (en) 2019-04-30 2022-08-30 Cilag Gmbh International Articulation directional lights on a surgical instrument
US11432816B2 (en) 2019-04-30 2022-09-06 Cilag Gmbh International Articulation pin for a surgical instrument
US11903581B2 (en) 2019-04-30 2024-02-20 Cilag Gmbh International Methods for stapling tissue using a surgical instrument
US11648009B2 (en) 2019-04-30 2023-05-16 Cilag Gmbh International Rotatable jaw tip for a surgical instrument
US10729860B1 (en) 2019-05-22 2020-08-04 Berkshire Biomedical, LLC Computerized oral prescription administration for securely dispensing a medication and associated systems and methods
US11298132B2 (en) 2019-06-28 2022-04-12 Cilag GmbH Inlernational Staple cartridge including a honeycomb extension
US11298127B2 (en) 2019-06-28 2022-04-12 Cilag GmbH Interational Surgical stapling system having a lockout mechanism for an incompatible cartridge
US11241235B2 (en) 2019-06-28 2022-02-08 Cilag Gmbh International Method of using multiple RFID chips with a surgical assembly
US11291451B2 (en) 2019-06-28 2022-04-05 Cilag Gmbh International Surgical instrument with battery compatibility verification functionality
US11224497B2 (en) 2019-06-28 2022-01-18 Cilag Gmbh International Surgical systems with multiple RFID tags
US11553971B2 (en) 2019-06-28 2023-01-17 Cilag Gmbh International Surgical RFID assemblies for display and communication
US11771419B2 (en) 2019-06-28 2023-10-03 Cilag Gmbh International Packaging for a replaceable component of a surgical stapling system
US11399837B2 (en) 2019-06-28 2022-08-02 Cilag Gmbh International Mechanisms for motor control adjustments of a motorized surgical instrument
US11376098B2 (en) 2019-06-28 2022-07-05 Cilag Gmbh International Surgical instrument system comprising an RFID system
US11684434B2 (en) 2019-06-28 2023-06-27 Cilag Gmbh International Surgical RFID assemblies for instrument operational setting control
US11638587B2 (en) 2019-06-28 2023-05-02 Cilag Gmbh International RFID identification systems for surgical instruments
US11246678B2 (en) 2019-06-28 2022-02-15 Cilag Gmbh International Surgical stapling system having a frangible RFID tag
US11051807B2 (en) 2019-06-28 2021-07-06 Cilag Gmbh International Packaging assembly including a particulate trap
US11464601B2 (en) 2019-06-28 2022-10-11 Cilag Gmbh International Surgical instrument comprising an RFID system for tracking a movable component
US11853835B2 (en) * 2019-06-28 2023-12-26 Cilag Gmbh International RFID identification systems for surgical instruments
US11478241B2 (en) 2019-06-28 2022-10-25 Cilag Gmbh International Staple cartridge including projections
US11627959B2 (en) 2019-06-28 2023-04-18 Cilag Gmbh International Surgical instruments including manual and powered system lockouts
US11497492B2 (en) 2019-06-28 2022-11-15 Cilag Gmbh International Surgical instrument including an articulation lock
US11523822B2 (en) 2019-06-28 2022-12-13 Cilag Gmbh International Battery pack including a circuit interrupter
US11219455B2 (en) 2019-06-28 2022-01-11 Cilag Gmbh International Surgical instrument including a lockout key
US11259803B2 (en) 2019-06-28 2022-03-01 Cilag Gmbh International Surgical stapling system having an information encryption protocol
US11426167B2 (en) 2019-06-28 2022-08-30 Cilag Gmbh International Mechanisms for proper anvil attachment surgical stapling head assembly
US11660163B2 (en) 2019-06-28 2023-05-30 Cilag Gmbh International Surgical system with RFID tags for updating motor assembly parameters
CN110236941B (en) * 2019-07-25 2021-11-23 深圳市金灿华实业有限公司 Timing and quantitative medicine taking plastic medicine bottle
US11304696B2 (en) 2019-12-19 2022-04-19 Cilag Gmbh International Surgical instrument comprising a powered articulation system
US11291447B2 (en) 2019-12-19 2022-04-05 Cilag Gmbh International Stapling instrument comprising independent jaw closing and staple firing systems
US11844520B2 (en) 2019-12-19 2023-12-19 Cilag Gmbh International Staple cartridge comprising driver retention members
US11529137B2 (en) 2019-12-19 2022-12-20 Cilag Gmbh International Staple cartridge comprising driver retention members
US11446029B2 (en) 2019-12-19 2022-09-20 Cilag Gmbh International Staple cartridge comprising projections extending from a curved deck surface
US11529139B2 (en) 2019-12-19 2022-12-20 Cilag Gmbh International Motor driven surgical instrument
US11607219B2 (en) 2019-12-19 2023-03-21 Cilag Gmbh International Staple cartridge comprising a detachable tissue cutting knife
US11911032B2 (en) 2019-12-19 2024-02-27 Cilag Gmbh International Staple cartridge comprising a seating cam
US11701111B2 (en) 2019-12-19 2023-07-18 Cilag Gmbh International Method for operating a surgical stapling instrument
US11576672B2 (en) 2019-12-19 2023-02-14 Cilag Gmbh International Surgical instrument comprising a closure system including a closure member and an opening member driven by a drive screw
US11504122B2 (en) 2019-12-19 2022-11-22 Cilag Gmbh International Surgical instrument comprising a nested firing member
US11234698B2 (en) 2019-12-19 2022-02-01 Cilag Gmbh International Stapling system comprising a clamp lockout and a firing lockout
US11464512B2 (en) 2019-12-19 2022-10-11 Cilag Gmbh International Staple cartridge comprising a curved deck surface
US11559304B2 (en) 2019-12-19 2023-01-24 Cilag Gmbh International Surgical instrument comprising a rapid closure mechanism
USD975850S1 (en) 2020-06-02 2023-01-17 Cilag Gmbh International Staple cartridge
USD967421S1 (en) 2020-06-02 2022-10-18 Cilag Gmbh International Staple cartridge
USD975278S1 (en) 2020-06-02 2023-01-10 Cilag Gmbh International Staple cartridge
USD966512S1 (en) 2020-06-02 2022-10-11 Cilag Gmbh International Staple cartridge
USD976401S1 (en) 2020-06-02 2023-01-24 Cilag Gmbh International Staple cartridge
USD974560S1 (en) 2020-06-02 2023-01-03 Cilag Gmbh International Staple cartridge
USD975851S1 (en) 2020-06-02 2023-01-17 Cilag Gmbh International Staple cartridge
US20220031351A1 (en) 2020-07-28 2022-02-03 Cilag Gmbh International Surgical instruments with differential articulation joint arrangements for accommodating flexible actuators
USD980425S1 (en) 2020-10-29 2023-03-07 Cilag Gmbh International Surgical instrument assembly
US11452526B2 (en) 2020-10-29 2022-09-27 Cilag Gmbh International Surgical instrument comprising a staged voltage regulation start-up system
US11617577B2 (en) 2020-10-29 2023-04-04 Cilag Gmbh International Surgical instrument comprising a sensor configured to sense whether an articulation drive of the surgical instrument is actuatable
US11779330B2 (en) 2020-10-29 2023-10-10 Cilag Gmbh International Surgical instrument comprising a jaw alignment system
USD1013170S1 (en) 2020-10-29 2024-01-30 Cilag Gmbh International Surgical instrument assembly
US11896217B2 (en) 2020-10-29 2024-02-13 Cilag Gmbh International Surgical instrument comprising an articulation lock
US11844518B2 (en) 2020-10-29 2023-12-19 Cilag Gmbh International Method for operating a surgical instrument
US11717289B2 (en) 2020-10-29 2023-08-08 Cilag Gmbh International Surgical instrument comprising an indicator which indicates that an articulation drive is actuatable
US11517390B2 (en) 2020-10-29 2022-12-06 Cilag Gmbh International Surgical instrument comprising a limited travel switch
US11534259B2 (en) 2020-10-29 2022-12-27 Cilag Gmbh International Surgical instrument comprising an articulation indicator
US11849943B2 (en) 2020-12-02 2023-12-26 Cilag Gmbh International Surgical instrument with cartridge release mechanisms
US11627960B2 (en) 2020-12-02 2023-04-18 Cilag Gmbh International Powered surgical instruments with smart reload with separately attachable exteriorly mounted wiring connections
US11890010B2 (en) 2020-12-02 2024-02-06 Cllag GmbH International Dual-sided reinforced reload for surgical instruments
US11737751B2 (en) 2020-12-02 2023-08-29 Cilag Gmbh International Devices and methods of managing energy dissipated within sterile barriers of surgical instrument housings
US11744581B2 (en) 2020-12-02 2023-09-05 Cilag Gmbh International Powered surgical instruments with multi-phase tissue treatment
US11653920B2 (en) 2020-12-02 2023-05-23 Cilag Gmbh International Powered surgical instruments with communication interfaces through sterile barrier
US11653915B2 (en) 2020-12-02 2023-05-23 Cilag Gmbh International Surgical instruments with sled location detection and adjustment features
US11678882B2 (en) 2020-12-02 2023-06-20 Cilag Gmbh International Surgical instruments with interactive features to remedy incidental sled movements
US11793514B2 (en) 2021-02-26 2023-10-24 Cilag Gmbh International Staple cartridge comprising sensor array which may be embedded in cartridge body
US11696757B2 (en) 2021-02-26 2023-07-11 Cilag Gmbh International Monitoring of internal systems to detect and track cartridge motion status
US11730473B2 (en) 2021-02-26 2023-08-22 Cilag Gmbh International Monitoring of manufacturing life-cycle
US11744583B2 (en) 2021-02-26 2023-09-05 Cilag Gmbh International Distal communication array to tune frequency of RF systems
US11812964B2 (en) 2021-02-26 2023-11-14 Cilag Gmbh International Staple cartridge comprising a power management circuit
US11749877B2 (en) 2021-02-26 2023-09-05 Cilag Gmbh International Stapling instrument comprising a signal antenna
US11701113B2 (en) 2021-02-26 2023-07-18 Cilag Gmbh International Stapling instrument comprising a separate power antenna and a data transfer antenna
US11925349B2 (en) 2021-02-26 2024-03-12 Cilag Gmbh International Adjustment to transfer parameters to improve available power
US11723657B2 (en) 2021-02-26 2023-08-15 Cilag Gmbh International Adjustable communication based on available bandwidth and power capacity
US11751869B2 (en) 2021-02-26 2023-09-12 Cilag Gmbh International Monitoring of multiple sensors over time to detect moving characteristics of tissue
US11737749B2 (en) 2021-03-22 2023-08-29 Cilag Gmbh International Surgical stapling instrument comprising a retraction system
US11717291B2 (en) 2021-03-22 2023-08-08 Cilag Gmbh International Staple cartridge comprising staples configured to apply different tissue compression
US11759202B2 (en) 2021-03-22 2023-09-19 Cilag Gmbh International Staple cartridge comprising an implantable layer
US11826042B2 (en) 2021-03-22 2023-11-28 Cilag Gmbh International Surgical instrument comprising a firing drive including a selectable leverage mechanism
US11826012B2 (en) 2021-03-22 2023-11-28 Cilag Gmbh International Stapling instrument comprising a pulsed motor-driven firing rack
US11723658B2 (en) 2021-03-22 2023-08-15 Cilag Gmbh International Staple cartridge comprising a firing lockout
US11806011B2 (en) 2021-03-22 2023-11-07 Cilag Gmbh International Stapling instrument comprising tissue compression systems
US11903582B2 (en) 2021-03-24 2024-02-20 Cilag Gmbh International Leveraging surfaces for cartridge installation
US11849945B2 (en) 2021-03-24 2023-12-26 Cilag Gmbh International Rotary-driven surgical stapling assembly comprising eccentrically driven firing member
US11896218B2 (en) 2021-03-24 2024-02-13 Cilag Gmbh International Method of using a powered stapling device
US11786239B2 (en) 2021-03-24 2023-10-17 Cilag Gmbh International Surgical instrument articulation joint arrangements comprising multiple moving linkage features
US11849944B2 (en) 2021-03-24 2023-12-26 Cilag Gmbh International Drivers for fastener cartridge assemblies having rotary drive screws
US11857183B2 (en) 2021-03-24 2024-01-02 Cilag Gmbh International Stapling assembly components having metal substrates and plastic bodies
US11744603B2 (en) 2021-03-24 2023-09-05 Cilag Gmbh International Multi-axis pivot joints for surgical instruments and methods for manufacturing same
US11793516B2 (en) 2021-03-24 2023-10-24 Cilag Gmbh International Surgical staple cartridge comprising longitudinal support beam
US11896219B2 (en) 2021-03-24 2024-02-13 Cilag Gmbh International Mating features between drivers and underside of a cartridge deck
US11832816B2 (en) 2021-03-24 2023-12-05 Cilag Gmbh International Surgical stapling assembly comprising nonplanar staples and planar staples
US11786243B2 (en) 2021-03-24 2023-10-17 Cilag Gmbh International Firing members having flexible portions for adapting to a load during a surgical firing stroke
US20220378424A1 (en) 2021-05-28 2022-12-01 Cilag Gmbh International Stapling instrument comprising a firing lockout
US11877745B2 (en) 2021-10-18 2024-01-23 Cilag Gmbh International Surgical stapling assembly having longitudinally-repeating staple leg clusters

Family Cites Families (271)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2621655A (en) * 1951-10-11 1952-12-16 Kenneth L Gothard Tablet dispensing gun
US3162322A (en) 1962-03-29 1964-12-22 John E Gilbertson Sanitary dispenser for cartridges holding fluid medicants
US3238941A (en) 1963-06-19 1966-03-08 Frost Eng Dev Balling gun
GB1142325A (en) * 1965-05-14 1969-02-05 Higham Stanley Russell Means for administering drugs
US3757781A (en) 1971-09-17 1973-09-11 R Smart Tool for administering pills to animals
US3780735A (en) 1972-02-03 1973-12-25 J Crouter Dose syringe
US3789845A (en) * 1973-01-29 1974-02-05 J Long Capsule and tablet administration for animals
FR2278317A1 (en) * 1974-07-19 1976-02-13 Commissariat Energie Atomique ORAL IMPLANT FOR ADMINISTERING SOLUBILIZABLE PRODUCTS
US4060083A (en) 1976-04-01 1977-11-29 Hanson Raymond L Pill gun
US4237884A (en) 1978-03-17 1980-12-09 Victor Erickson Medication dispenser
GB2042888B (en) 1979-03-05 1983-09-28 Teijin Ltd Preparation for administration to the mucosa of the oral or nasal cavity
US4229447A (en) 1979-06-04 1980-10-21 American Home Products Corporation Intraoral methods of using benzodiazepines
US4465191A (en) * 1982-06-14 1984-08-14 Darbo Rolf E Personal tablet dispenser
US4474308A (en) 1982-09-30 1984-10-02 Michel Bergeron Tablet ejector
US4489853A (en) 1982-12-15 1984-12-25 Korte Jay S Pill dispensing device
GB8332556D0 (en) 1983-12-06 1984-01-11 Reckitt & Colmann Prod Ltd Analgesic compositions
US5288498A (en) 1985-05-01 1994-02-22 University Of Utah Research Foundation Compositions of oral nondissolvable matrixes for transmucosal administration of medicaments
US4863737A (en) 1985-05-01 1989-09-05 University Of Utah Compositions and methods of manufacture of compressed powder medicaments
US5855908A (en) 1984-05-01 1999-01-05 University Of Utah Research Foundation Non-dissolvable drug-containing dosage-forms for use in the transmucosal delivery of a drug to a patient
DE3421468A1 (en) 1984-06-08 1985-12-19 Dr. Rentschler Arzneimittel Gmbh & Co, 7958 Laupheim LIPID NANOPELLETS AS A CARRIER SYSTEM FOR MEDICINAL PRODUCTS FOR PERORAL USE
DE3572440D1 (en) * 1984-06-19 1989-09-28 Basf Ag Gastro-resistant cylindrical pancreatine-microtablets
US5132114A (en) 1985-05-01 1992-07-21 University Of Utah Research Foundation Compositions and methods of manufacture of compressed powder medicaments
US5785989A (en) 1985-05-01 1998-07-28 University Utah Research Foundation Compositions and methods of manufacturing of oral dissolvable medicaments
US5288497A (en) 1985-05-01 1994-02-22 The University Of Utah Compositions of oral dissolvable medicaments
US4671953A (en) 1985-05-01 1987-06-09 University Of Utah Research Foundation Methods and compositions for noninvasive administration of sedatives, analgesics, and anesthetics
US5122127A (en) 1985-05-01 1992-06-16 University Of Utah Apparatus and methods for use in administering medicaments by direct medicament contact to mucosal tissues
US4764378A (en) * 1986-02-10 1988-08-16 Zetachron, Inc. Buccal drug dosage form
US4733797A (en) 1986-09-22 1988-03-29 Haber Terry M Dosage sealing, monitoring and dispensing assembly
DE3632546A1 (en) * 1986-09-25 1988-03-31 Knoll Ag DOSAGE DISPENSER
US4785969A (en) 1986-11-10 1988-11-22 Pyxis Corporation Medication dispensing system
US4950234A (en) 1987-05-26 1990-08-21 Sumitomo Pharmaceuticals Company, Limited Device for administering solid preparations
US4915948A (en) 1987-08-31 1990-04-10 Warner-Lambert Company Tablets having improved bioadhesion to mucous membranes
FR2619718B1 (en) 1987-09-02 1991-07-12 Medibrevex NOVEL GALENIC FORMS OF BETA-2-MIMETICS FOR PER- AND SUBLINGUAL ADMINISTRATION
US4873076A (en) 1988-04-29 1989-10-10 Baker Cummins Pharmaceuticals, Inc. Method of safely providing anesthesia or conscious sedation
JP2620642B2 (en) 1988-04-29 1997-06-18 ベーカー ノートン ファーマシューティカルズ インコーポレイテッド Drugs to antagonize the decrease in mean blood pressure observed after parenteral administration of a combination of a narcotic analgesic and a benzodiazepine
JPH02121039A (en) 1988-10-31 1990-05-08 Toshiba Corp Load prediction simulation system for computer system
US5236714A (en) 1988-11-01 1993-08-17 Alza Corporation Abusable substance dosage form having reduced abuse potential
US5112616A (en) 1988-11-30 1992-05-12 Schering Corporation Fast dissolving buccal tablet
AT391300B (en) 1989-04-12 1990-09-10 Hinterreiter Ignaz TABLET DISPENSER
US5110008A (en) 1989-09-29 1992-05-05 Moulding Jr Thomas S Dispenser adapted to isolate the dispensed objects by compression between two moveable structures
US5223264A (en) 1989-10-02 1993-06-29 Cima Labs, Inc. Pediatric effervescent dosage form
US5178878A (en) 1989-10-02 1993-01-12 Cima Labs, Inc. Effervescent dosage form with microparticles
US5190185A (en) 1990-05-18 1993-03-02 Baxter International Inc. Medication transport and dispensing magazine
GB9015522D0 (en) * 1990-07-13 1990-08-29 Braithwaite Philip W Inhaler
JPH06509559A (en) 1991-03-19 1994-10-27 セラピューティック パッチ リサーチ エヌ.ブイ. Amino alcohol derivative compositions and methods as membrane permeation enhancers
US5296234A (en) 1991-10-11 1994-03-22 Abbott Laboratories Holder and packaging for a hardened medicated matrix
US5263596A (en) 1991-12-02 1993-11-23 Williams David R Medication dispenser station sub-assembly
US5348158A (en) 1991-12-19 1994-09-20 G. D. Searle & Co. Dispenser pack for the successive dispensing of a drug
NL9200844A (en) 1992-05-13 1993-12-01 De Wijdeven Gijsbertus G P Van DEVICE AND METHOD FOR INJECTING WITH A SOLID SUBSTANCE.
US5352680A (en) 1992-07-15 1994-10-04 Regents Of The University Of Minnesota Delta opioid receptor antagonists to block opioid agonist tolerance and dependence
US5292307A (en) * 1992-09-16 1994-03-08 Dolzine Theodore W Dispensing package for unit dosage
US5694919A (en) 1993-01-29 1997-12-09 Aradigm Corporation Lockout device for controlled release of drug from patient-activated dispenser
US5507277A (en) 1993-01-29 1996-04-16 Aradigm Corporation Lockout device for controlled release of drug from patient-activateddispenser
US5724957A (en) 1993-01-29 1998-03-10 Aradigm Corporation Intrapulmonary delivery of narcotics
US5489689A (en) * 1993-09-30 1996-02-06 Mallinckrodt Chemical, Inc. Preparation of piperidine derivatives
US5366113A (en) 1993-12-13 1994-11-22 Kim David S Pill dispenser
US5540665A (en) 1994-01-31 1996-07-30 Alza Corporation Gas driven dispensing device and gas generating engine therefor
US5507807A (en) * 1994-03-01 1996-04-16 Shippert; Ronald D. Apparatus for the release of a substance within a patient
US5489025A (en) * 1994-03-01 1996-02-06 Romick; Jerome M. Unit-dose medication dispenser and multiple-dispenser frame therefor
US6685013B2 (en) 1994-07-13 2004-02-03 Centrix, Inc. Single patient dose medicament dispenser with applicator
US6328159B1 (en) 1994-07-13 2001-12-11 Centrix, Inc Single patient dose medicament dispenser with applicator
US5660273A (en) 1994-07-13 1997-08-26 Centrix, Inc. Single patient dose medicament dispenser with applicator
MX9701957A (en) 1994-09-16 1998-02-28 Glaxo Wellcome Lab Sa Inhalation device.
US5584805A (en) 1995-03-17 1996-12-17 Sutton; Matthew R. Animal pill-dispenser gun
US6881208B1 (en) 1995-06-05 2005-04-19 Joseph B. Phipps Method and device for transdermal electrotransport delivery of fentanyl and sufentanil
EP0836511B1 (en) 1995-06-05 2004-04-07 Alza Corporation Device for transdermal electrotransport delivery of fentanyl and sufentanil
US6425892B2 (en) 1995-06-05 2002-07-30 Alza Corporation Device for transdermal electrotransport delivery of fentanyl and sufentanil
US6216033B1 (en) 1996-05-22 2001-04-10 Alza Corporation Device for transdermal electrotransport delivery of fentanyl and sufentanil
US5984888A (en) 1995-06-07 1999-11-16 Kimberly-Clark Worldwide, Inc. Applicator and coating
CA2224244C (en) 1995-06-07 2007-03-20 O'neil, Christine Patient controlled drug delivery device
US5710551A (en) 1995-07-26 1998-01-20 Ridgeway; Donald G. Self-medication monitoring system
CA2184316A1 (en) 1995-09-12 1997-03-13 Wei-Chi Liao Buccal delivery system for therapeutic agents
AUPN603895A0 (en) 1995-10-19 1995-11-09 University Of Queensland, The Production of analgesic synergy by co-administration of sub-analgesic doses of two strong opioids
GB2309966A (en) 1996-02-07 1997-08-13 Harwill Ind Pty Ltd Teat device for administering medicaments
US5995938A (en) 1996-02-27 1999-11-30 Whaley; Susan S. Medication compliance system
WO1998001180A1 (en) * 1996-07-05 1998-01-15 Novo Nordisk A/S Instrument for inserting a suppository
NL1003596C2 (en) 1996-07-15 1997-05-27 Cons Health Entrepreneurs Bv Vending machine dispenser.
US6248789B1 (en) 1996-08-29 2001-06-19 Stuart L. Weg Administration of ketamine to manage pain and to reduce drug dependency
US5800832A (en) 1996-10-18 1998-09-01 Virotex Corporation Bioerodable film for delivery of pharmaceutical compounds to mucosal surfaces
US5954641A (en) 1997-09-08 1999-09-21 Informedix, Inc. Method, apparatus and operating system for managing the administration of medication and medical treatment regimens
US5752620A (en) 1996-11-13 1998-05-19 Pearson Ventures, L.L.C. Medication dispenser
US6529446B1 (en) 1996-12-20 2003-03-04 Telaric L.L.C. Interactive medication container
US5968547A (en) * 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
US5950632A (en) 1997-03-03 1999-09-14 Motorola, Inc. Medical communication apparatus, system, and method
US6024981A (en) 1997-04-16 2000-02-15 Cima Labs Inc. Rapidly dissolving robust dosage form
US5945651A (en) 1997-07-17 1999-08-31 Chorosinski; Leonard Remotely programmable medication dispensing system
JPH1147233A (en) 1997-07-30 1999-02-23 Teikoku Seiyaku Co Ltd Plaster agent and preservation method thereof
US5850937A (en) 1997-08-14 1998-12-22 Rauche; Stephen J. Dispenser with means for alerting a user
AU9062998A (en) 1997-09-11 1999-03-29 Nycomed Danmark A/S Modified release multiple-units compositions of non-steroid anti-inflammatory drug substances (nsaids)
US6660295B2 (en) 1997-09-30 2003-12-09 Alza Corporation Transdermal drug delivery device package with improved drug stability
US20030185761A1 (en) 1997-10-01 2003-10-02 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating pain
KR100569763B1 (en) 1997-10-03 2006-04-11 워너-램버트 캄파니 엘엘씨 Compressed Nitroglycerin Tablet and Its Method of Manufacture
WO2000066458A1 (en) 1997-10-30 2000-11-09 HALLIN, Cristian under the firm of TELUM PRODUCTI N A tablet dispenser
US5997518A (en) * 1998-01-14 1999-12-07 Laibovitz; Robert A. Apparatus and method for delivery of small volumes of liquid
KR20010040398A (en) 1998-01-23 2001-05-15 마가렛 에이.혼 Chemically modified mutant enzymes and methods for producing them and screening them
US5981552A (en) 1998-10-23 1999-11-09 Taylor Pharmaceuticals Sublingual and buccal compositions of droperidol and method for treating migraine
US6350470B1 (en) 1998-04-29 2002-02-26 Cima Labs Inc. Effervescent drug delivery system for oral administration
US6200604B1 (en) 1998-03-27 2001-03-13 Cima Labs Inc. Sublingual buccal effervescent
US20030091629A1 (en) 1998-03-27 2003-05-15 Cima Labs Inc. Sublingual buccal effervescent
US6974590B2 (en) 1998-03-27 2005-12-13 Cima Labs Inc. Sublingual buccal effervescent
US6576250B1 (en) 1998-03-27 2003-06-10 Cima Labs Inc. Pharmaceutical compositions for rectal and vaginal administration
US6039251A (en) 1998-04-16 2000-03-21 Holowko; Paul L. Method and system for secure control of a medical device
EP1107810B1 (en) 1998-08-28 2005-11-09 Glaxo Group Limited Dispenser
SE9803239D0 (en) 1998-09-24 1998-09-24 Diabact Ab Composition for the treatment of acute pain
SE9803240D0 (en) 1998-09-24 1998-09-24 Diabact Ab A pharmaceutical composition having a rapid action
JP2000142841A (en) 1998-11-17 2000-05-23 Lion Corp Container for small-sized article
JP3459882B2 (en) 1998-11-30 2003-10-27 株式会社バンダイ Article removal device
GB9826192D0 (en) 1998-12-01 1999-01-20 Controlled Theraputics Scotlan Oral transmucosal delivery
US6131765A (en) 1999-01-08 2000-10-17 Barry; William Dean Device for storing and dispensing solid-form medication
WO2000047203A1 (en) 1999-02-12 2000-08-17 Mqs, Inc. Formulation and system for intra-oral delivery of pharmaceutical agents
US6680071B1 (en) 1999-03-03 2004-01-20 R. P. Scherer Technologies, Inc. Opioid agonist in a fast dispersing dosage form
US6252981B1 (en) 1999-03-17 2001-06-26 Semiconductor Technologies & Instruments, Inc. System and method for selection of a reference die
US6835194B2 (en) 1999-03-18 2004-12-28 Durect Corporation Implantable devices and methods for treatment of pain by delivery of fentanyl and fentanyl congeners
US6541021B1 (en) 1999-03-18 2003-04-01 Durect Corporation Devices and methods for pain management
US6234343B1 (en) 1999-03-26 2001-05-22 Papp Enterprises, Llc Automated portable medication radial dispensing apparatus and method
US6601729B1 (en) 1999-03-26 2003-08-05 Papp Enterprises, Llc Automated portable medication radial dispensing apparatus and method using a carrier tape
US6210699B1 (en) 1999-04-01 2001-04-03 Watson Pharmaceuticals, Inc. Oral transmucosal delivery of drugs or any other ingredients via the inner buccal cavity
US6762684B1 (en) 1999-04-19 2004-07-13 Accutrak Systems, Inc. Monitoring system
US6319510B1 (en) 1999-04-20 2001-11-20 Alayne Yates Gum pad for delivery of medication to mucosal tissues
US6190326B1 (en) * 1999-04-23 2001-02-20 Medtrac Technologies, Inc. Method and apparatus for obtaining patient respiratory data
DE60044196D1 (en) * 1999-04-29 2010-05-27 Peter James Brian Lamb APPARATUS FOR TRANSFERRING A NON-FLOWING AGENT IN A VAGINA
GB9911388D0 (en) 1999-05-18 1999-07-14 Glaxo Group Ltd Dispenser
US7919119B2 (en) 1999-05-27 2011-04-05 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
US6395300B1 (en) 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
WO2001012174A1 (en) 1999-08-13 2001-02-22 Vela Pharmaceuticals Inc. Cyclobenzaprine for treating generalized anxiety disorder and compositions thereof
US6264983B1 (en) 1999-09-16 2001-07-24 Rhodia, Inc. Directly compressible, ultra fine acetaminophen compositions and process for producing same
FR2799124B1 (en) 1999-10-01 2004-08-13 Sanofi Synthelabo USE OF ANTAGONISTS OF CENTRAL CANNABINOID RECEPTORS FOR THE PREPARATION OF DRUGS
US6382204B1 (en) 1999-10-14 2002-05-07 Becton Dickinson And Company Drug delivery system including holder and drug container
US6572891B1 (en) * 1999-10-23 2003-06-03 Alkaloid Ad Sublingual oral dosage form
US6264981B1 (en) * 1999-10-27 2001-07-24 Anesta Corporation Oral transmucosal drug dosage using solid solution
ES2272354T3 (en) 1999-12-06 2007-05-01 Mallinckrodt Inc. METHODS FOR THE SYNTHESIS OF ALFENTANILO, SUFFENTANIL REMIFENTANILO.
AR026914A1 (en) * 1999-12-11 2003-03-05 Glaxo Group Ltd MEDICINAL DISTRIBUTOR
AT408488B (en) 1999-12-22 2001-12-27 Scan Messtechnik Gmbh MINIATURIZED SPECTROMETER
US6294999B1 (en) 1999-12-29 2001-09-25 Becton, Dickinson And Company Systems and methods for monitoring patient compliance with medication regimens
US6471645B1 (en) 1999-12-30 2002-10-29 Medtronic, Inc. Communications system for an implantable device and a drug dispenser
NZ521034A (en) 2000-02-28 2004-08-27 Vectura Ltd Improvements in or relating to the delivery of oral drugs
US6364158B1 (en) 2000-03-24 2002-04-02 John Dimoulis Anesthetic dispensing station and method of using same
AU2001262992A1 (en) 2000-05-10 2002-02-18 University Of Kentucky Research Foundation System and method for intranasal administration of opioids
DE10025946A1 (en) * 2000-05-26 2001-11-29 Gruenenthal Gmbh drug combination
AT409366B (en) * 2000-06-20 2002-07-25 Haas Beteiligungsgesellschaft Magazine for accommodating tablets and dispensing them individually
AU2001274307A1 (en) * 2000-06-22 2002-01-02 Pharmasol Ltd Pharmaceutical compositions
PL207845B1 (en) * 2000-07-31 2011-02-28 Nycomed Danmark As Fentanyl composition for nasal administration
MXPA03001407A (en) * 2000-08-18 2003-06-06 Pharmacia Corp Rapidly disintegrating oral formulation of a cyclooxygenase-2 inhibitor.
US20020026330A1 (en) 2000-08-23 2002-02-28 Klein Edward E. System and method for patient medication management and compliance using a portable computing device
US6417184B1 (en) 2000-09-19 2002-07-09 David M. Ockert Triple drug therapy for the treatment and prevention of acute or chronic pain
GB2368061B (en) 2000-10-20 2005-05-11 Gw Pharmaceuticals Ltd Dose dispensing apparatus
US20050054942A1 (en) 2002-01-22 2005-03-10 Melker Richard J. System and method for therapeutic drug monitoring
US20020160043A1 (en) 2001-02-27 2002-10-31 Dennis Coleman Compositions and method of manufacture for oral dissolvable dosage forms
US20050176790A1 (en) * 2001-02-28 2005-08-11 Johannes Bartholomaus Pharmaceutical salts
DE10109763A1 (en) 2001-02-28 2002-09-05 Gruenenthal Gmbh Pharmaceutical salts
JP4850346B2 (en) * 2001-03-15 2012-01-11 救急薬品工業株式会社 Mucosal patch
EP1370318B1 (en) 2001-03-15 2005-07-20 The Government of the United States of America, as represented by the Secretary, Department of Health & Human Services Systems and methods for aerosol delivery of agents
EP1243524A3 (en) 2001-03-16 2004-04-07 Pfizer Products Inc. Pharmaceutical kit for oxygen-sensitive drugs
GB0108228D0 (en) 2001-04-02 2001-05-23 Glaxo Group Ltd Medicament dispenser
GB0108215D0 (en) 2001-04-02 2001-05-23 Glaxo Group Ltd Medicament dispenser
US7125561B2 (en) 2001-05-22 2006-10-24 Euro-Celtique S.A. Compartmentalized dosage form
JP4357842B2 (en) 2001-05-24 2009-11-04 アレックザ ファーマシューティカルズ, インコーポレイテッド Delivery of alprazolam, estazolam, midazolam or triazolam by a prescribed inhalation route
US7458374B2 (en) 2002-05-13 2008-12-02 Alexza Pharmaceuticals, Inc. Method and apparatus for vaporizing a compound
US6805853B2 (en) 2001-11-09 2004-10-19 Alexza Molecular Delivery Corporation Delivery of diazepam through an inhalation route
US7766013B2 (en) 2001-06-05 2010-08-03 Alexza Pharmaceuticals, Inc. Aerosol generating method and device
CA2446904A1 (en) 2001-05-24 2003-04-03 Alexza Molecular Delivery Corporation Delivery of drug esters through an inhalation route
US7090830B2 (en) 2001-05-24 2006-08-15 Alexza Pharmaceuticals, Inc. Drug condensation aerosols and kits
US6564967B1 (en) * 2001-06-29 2003-05-20 Brown & Williamson Tobacco Corporation Child resistant tablet dispenser
US20030008005A1 (en) * 2001-07-05 2003-01-09 R.T. Alamo Ventures, Inc. Sublingual administration of dihydroergotamine for the treatment of migraine
US6685951B2 (en) * 2001-07-05 2004-02-03 R. T. Alamo Ventures I, Inc. Administration of dihydroergotamine as a sublingual spray or aerosol for the treatment of migraine
US20030017175A1 (en) * 2001-07-05 2003-01-23 R.T. Alamo Ventures I, Inc. Sublingual administration of dihydroergotamine for the treatment of migraine
US20030022910A1 (en) * 2001-07-05 2003-01-30 R.T. Alamo Ventures I, Inc. Compositions and methods for sublingual formulations of dihydroergotamine for the treatment of migraine
US20030068356A1 (en) 2001-07-10 2003-04-10 Pather S. Indiran Sequential drug delivery systems
FR2827517B1 (en) 2001-07-23 2003-10-24 Bioalliance Pharma EXTENDED RELEASE BIOADHESIVE THERAPEUTIC SYSTEMS
CA2454243A1 (en) 2001-08-03 2003-02-20 Hill-Rom Services, Inc. Patient point-of-care computer system
US7144587B2 (en) 2001-08-06 2006-12-05 Euro-Celtique S.A. Pharmaceutical formulation containing opioid agonist, opioid antagonist and bittering agent
US6585997B2 (en) 2001-08-16 2003-07-01 Access Pharmaceuticals, Inc. Mucoadhesive erodible drug delivery device for controlled administration of pharmaceuticals and other active compounds
US7896192B2 (en) 2001-09-19 2011-03-01 Avancen MOD Corp. Patient controlled timed medication dispenser
WO2003025864A1 (en) 2001-09-19 2003-03-27 Conley N Sharon Patient controlled timed oral medication dispenser
US7743923B2 (en) 2001-09-19 2010-06-29 Avanced MOD Corporation Patient controlled timed medication dispenser
MXPA04002652A (en) * 2001-09-26 2004-06-07 Pharmacia Corp Organoleptically acceptable intraorally disintegrating compositions.
WO2003035510A1 (en) 2001-10-22 2003-05-01 3M Innovative Properties Company Transdermal/transmucosal patch packaging
US6863901B2 (en) 2001-11-30 2005-03-08 Collegium Pharmaceutical, Inc. Pharmaceutical composition for compressed annular tablet with molded triturate tablet for both intraoral and oral administration
CA2469200A1 (en) 2001-12-17 2003-06-26 Aryx Therapeutics Analgesic delivery systems and methods of use
CA2366887C (en) * 2001-12-31 2011-11-01 Michael Petersen Replicate incorporating an electronic content monitoring system for use in form-fill-seal applications
EP2123318B1 (en) 2002-02-22 2016-01-13 GW Pharma Limited Dose dispensing system and apparatus
US7204425B2 (en) 2002-03-18 2007-04-17 Precision Dynamics Corporation Enhanced identification appliance
US7074426B2 (en) * 2002-03-27 2006-07-11 Frank Kochinke Methods and drug delivery systems for the treatment of orofacial diseases
US20030194420A1 (en) 2002-04-11 2003-10-16 Richard Holl Process for loading a drug delivery device
GB0209783D0 (en) 2002-04-29 2002-06-05 Glaxo Group Ltd Medicament dispenser
US6961541B2 (en) 2002-05-24 2005-11-01 Aeroscout, Inc. Method and apparatus for enhancing security in a wireless network using distance measurement techniques
US6793075B1 (en) 2002-05-30 2004-09-21 Michael Jeter Container for dispensing a liquid and method of using the same
DE10226494A1 (en) * 2002-06-14 2004-01-08 Lts Lohmann Therapie-Systeme Ag Film-shaped mucoadhesive dosage forms for administration of cannabis active ingredients
ES2321601T3 (en) * 2002-06-21 2009-06-09 Glaxo Group Limited DRIVE INDICATOR FOR DISTRIBUTOR DEVICE.
JP2004051502A (en) 2002-07-17 2004-02-19 Jcr Pharmaceuticals Co Ltd Stabilized powder preparation containing growth hormone
WO2004014567A1 (en) * 2002-08-06 2004-02-19 Glaxo Group Limited A dispenser
US9486581B2 (en) 2002-09-11 2016-11-08 Becton, Dickinson And Company Injector device with force lock-out and injection rate limiting mechanisms
US7295890B2 (en) 2002-09-26 2007-11-13 Stratamed Labs, Inc. Prescription drug compliance monitoring system
US6963289B2 (en) 2002-10-18 2005-11-08 Aeroscout, Ltd. Wireless local area network (WLAN) channel radio-frequency identification (RFID) tag system and method therefor
US6999092B2 (en) 2002-10-25 2006-02-14 Fujitsu Limited Image display apparatus in which a specific area display attribute is modifiable
US6726053B1 (en) * 2002-10-29 2004-04-27 John E. Harrold Child resistant multiple dosage blister pack dispenser
GB0226022D0 (en) * 2002-11-07 2002-12-18 Corporate Intellectual Propert Device
US20050013845A1 (en) 2002-11-12 2005-01-20 Warren Stephen L. Adhesive bioerodible ocular drug delivery system
EP1567145B1 (en) 2002-11-18 2009-06-03 Yaupon Therapeutics, Inc. Analgesic uses of (s)-norketamine
BR122019005271B1 (en) * 2002-12-13 2020-10-13 Alphavax, Inc. method for the preparation of alphavirus replicon particles (arps)
US7264139B2 (en) 2003-01-14 2007-09-04 Hypoguard Limited Sensor dispensing device
RU2345791C2 (en) * 2003-01-31 2009-02-10 Орексо Аб Immediate-action pharmaceutical composition
US20040253307A1 (en) * 2003-02-04 2004-12-16 Brian Hague Sugar-free oral transmucosal solid dosage forms and uses thereof
US8992974B2 (en) 2003-02-24 2015-03-31 Pharmaceuticals Productions, Inc. Transmucosal drug delivery system
US20060062812A1 (en) 2003-03-11 2006-03-23 Calvin Ross Novel compositions
GB0305581D0 (en) 2003-03-11 2003-04-16 Dallas Burston Ltd Dispensing devices
CA2522471A1 (en) 2003-04-14 2004-10-28 Pain Therapeutics, Inc. Methods for the treatment of pain comprising opioid antagonists
US7306812B2 (en) 2003-05-09 2007-12-11 Cephalon, Inc. Dissolvable backing layer for use with a transmucosal delivery device
US7276246B2 (en) 2003-05-09 2007-10-02 Cephalon, Inc. Dissolvable backing layer for use with a transmucosal delivery device
US6914668B2 (en) 2003-05-14 2005-07-05 International Technologies (Laser) Ltd. Personal identification verification and controlled substance detection and identification system
JP3967693B2 (en) * 2003-05-23 2007-08-29 株式会社東芝 Semiconductor memory
BR0302017B1 (en) 2003-06-02 2014-10-29 Ems Sigma Pharma Ltda Sublingual pharmaceutical composition based on a benzodiazepine central receptor agonist
US7819847B2 (en) * 2003-06-10 2010-10-26 Hewlett-Packard Development Company, L.P. System and methods for administering bioactive compositions
US7118550B2 (en) 2003-07-10 2006-10-10 B. Braun Medical Side-delivery suppository dispenser
US20050049464A1 (en) 2003-08-29 2005-03-03 Lassers Harold Aaron Remote pharmaceutical administration device
US7248165B2 (en) 2003-09-09 2007-07-24 Motorola, Inc. Method and apparatus for multiple frequency RFID tag architecture
US20050065175A1 (en) 2003-09-24 2005-03-24 Xanodyne Pharmacal, Inc. Oral transmucosal methadone
JP2007507538A (en) 2003-10-02 2007-03-29 エラン ファーマシューティカルズ,インコーポレイテッド Pain relief method
JP2005143211A (en) * 2003-11-06 2005-06-02 Alps Electric Co Ltd Battery charger
US8157788B2 (en) 2003-11-06 2012-04-17 Paolo L. Manfredi Multi-site drug delivery platform
US7540998B2 (en) 2003-11-19 2009-06-02 Biocompatibles Uk Limited Delivery system and prescription method for interstitial radiation therapy using enhanced parametric release sterilization techniques
US7780973B2 (en) * 2003-12-15 2010-08-24 Ethicon Endo-Surgery, Inc. Method and device for minimally invasive implantation of biomaterial
US6999028B2 (en) 2003-12-23 2006-02-14 3M Innovative Properties Company Ultra high frequency radio frequency identification tag
WO2005065317A2 (en) 2003-12-31 2005-07-21 Cima Labs Inc. Effervescent oral fentanyl dosage form
US20070036853A1 (en) 2003-12-31 2007-02-15 Cima Labs Inc. Generally linear effervescent oral fentanyl dosage form and methods of administering
CN102078310B (en) * 2003-12-31 2013-01-23 奇马实验室公司 Generally linear effervescent oral fentanyl dosage form and methods of administering
NZ548215A (en) 2003-12-31 2009-08-28 Cima Labs Inc Effervescent oral opiate dosage form
US20050150489A1 (en) 2004-01-12 2005-07-14 Steve Dunfield Dispensing medicaments based on rates of medicament action
CA2553392A1 (en) 2004-01-16 2005-08-11 Biodel Inc Sublingual drug delivery device
DE602005012244D1 (en) 2004-03-30 2009-02-26 Euro Celtique Sa MANIPULATION SAFE DOSING FORM WITH AN ADSORBEN AND AN ADVERSE MEDIUM
US20050226923A1 (en) * 2004-04-07 2005-10-13 Gassert Chad M Venlafaxine compositions in the form of microtablets
US7004111B2 (en) * 2004-05-26 2006-02-28 Keryl Olson Treat dispenser
US20060026035A1 (en) 2004-07-28 2006-02-02 William Younkes Computer aided interactive medical management information and control system and method
US20060045865A1 (en) * 2004-08-27 2006-03-02 Spherics, Inc. Controlled regional oral delivery
GB0420016D0 (en) 2004-09-09 2004-10-13 Leuven K U Res & Dev Controlled release oral delivery system
US20060067978A1 (en) * 2004-09-29 2006-03-30 Bausch & Lomb Incorporated Process for preparing poly(vinyl alcohol) drug delivery devices
US7119690B2 (en) 2004-10-08 2006-10-10 Proximities, Inc. Identification band using serpentine paths to detect tampering
US7388493B2 (en) 2004-10-08 2008-06-17 Bartronics America, Inc. Method and system for preventing unauthorized removal and use of an RFID apparatus
EP1851539B1 (en) 2004-10-21 2014-04-30 Bayer HealthCare LLC Sensor-dispensing device and method of operating it
CN2776369Y (en) 2004-10-22 2006-05-03 瓦索金爱尔兰有限公司 Distribution system
US20060089858A1 (en) 2004-10-25 2006-04-27 Tun Ling Means and method of applying RFID and PKI technologies for patient safety
FR2883179B1 (en) * 2005-03-18 2009-04-17 Ethypharm Sa COATED TABLET
EP1863456A1 (en) 2005-03-28 2007-12-12 Orexo AB New pharmaceutical compositions useful in the treatment of pain
US20070020186A1 (en) 2005-07-22 2007-01-25 Alpex Pharma S.A. Solid dosage formulations of narcotic drugs having improved buccal adsorption
US20070074722A1 (en) 2005-09-21 2007-04-05 Kurve Technology, Inc. Medicament delivery control, monitoring, and reporting system and method
US20070104763A1 (en) 2005-11-10 2007-05-10 Navinta Llc Composition of fentanyl citrate oral solid transmucosal dosage form, excipient and binding material therefore, and methods of making
WO2007084247A2 (en) 2005-12-28 2007-07-26 Alza Corporation Stable therapeutic formulations
US9289583B2 (en) 2006-01-06 2016-03-22 Acelrx Pharmaceuticals, Inc. Methods for administering small volume oral transmucosal dosage forms using a dispensing device
WO2008085764A1 (en) 2007-01-05 2008-07-17 Acelrx Pharmaceuticals, Inc. Storage and dispensing devices for administration of oral transmucosal dosage forms
US8252328B2 (en) 2006-01-06 2012-08-28 Acelrx Pharmaceuticals, Inc. Bioadhesive drug formulations for oral transmucosal delivery
US8535714B2 (en) * 2006-01-06 2013-09-17 Acelrx Pharmaceuticals, Inc. Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
US8202535B2 (en) 2006-01-06 2012-06-19 Acelrx Pharmaceuticals, Inc. Small-volume oral transmucosal dosage forms
US8753308B2 (en) 2006-01-06 2014-06-17 Acelrx Pharmaceuticals, Inc. Methods for administering small volume oral transmucosal dosage forms using a dispensing device
US8865743B2 (en) 2006-01-06 2014-10-21 Acelrx Pharmaceuticals, Inc. Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
US9066847B2 (en) 2007-01-05 2015-06-30 Aceirx Pharmaceuticals, Inc. Storage and dispensing devices for administration of oral transmucosal dosage forms
US8252329B2 (en) 2007-01-05 2012-08-28 Acelrx Pharmaceuticals, Inc. Bioadhesive drug formulations for oral transmucosal delivery
US8357114B2 (en) 2006-01-06 2013-01-22 Acelrx Pharmaceuticals, Inc. Drug dispensing device with flexible push rod
WO2007084290A2 (en) 2006-01-12 2007-07-26 Orexigen Therapeutics, Inc. Compositions of an anticonvulsant and psychotherapeutic and methods of using the same for reversing weight gain
US20070190130A1 (en) 2006-02-16 2007-08-16 Mark William A Protein hydrolysate excipients
US20070260491A1 (en) 2006-05-08 2007-11-08 Pamela Palmer System for delivery and monitoring of administration of controlled substances
US7581657B2 (en) 2006-05-15 2009-09-01 Dickmann Alexander J Bandage dispenser
US20070286900A1 (en) 2006-06-09 2007-12-13 Catherine Herry Low dose tablets of opioid analgesics and preparation process
US20070299687A1 (en) 2006-06-23 2007-12-27 Pamela Palmer Inpatient system for patient-controlled delivery of oral transmucosal medications dosed as needed
US7744558B2 (en) 2007-06-06 2010-06-29 Maag R John Pill plunger
US20090010992A1 (en) * 2007-07-03 2009-01-08 Aceirx Pharmaceuticals, Inc. Drug formulations for oral transmucosal delivery to pediatric patients
EP3269346A1 (en) 2007-08-07 2018-01-17 Acelrx Pharmaceuticals, Inc. Apparatus for oral drug delivery
US8945592B2 (en) * 2008-11-21 2015-02-03 Acelrx Pharmaceuticals, Inc. Sufentanil solid dosage forms comprising oxygen scavengers and methods of using the same
WO2010107761A1 (en) 2009-03-18 2010-09-23 Acelrx Pharmaceuticals, Inc. Improved storage and dispensing devices for administration of oral transmucosal dosage forms
US8062248B2 (en) 2009-07-14 2011-11-22 Charles Edward Kindel Pill dispenser for pets
US20110091544A1 (en) * 2009-10-16 2011-04-21 Acelrx Pharmaceuticals, Inc. Compositions and Methods for Mild Sedation, Anxiolysis and Analgesia in the Procedural Setting
US20110288128A1 (en) 2010-05-21 2011-11-24 Acelrx Pharmaceuticals, Inc. Oral Transmucosal Administration of Sufentanil

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of EP1978996A4 *

Cited By (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8778393B2 (en) 2006-01-06 2014-07-15 Acelrx Pharmaceuticals, Inc. Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
US10507180B2 (en) 2006-01-06 2019-12-17 Acelrx Pharmaceuticals, Inc. Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
US10342762B2 (en) 2006-01-06 2019-07-09 Acelrx Pharmaceuticals, Inc. Small-volume oral transmucosal dosage forms
US10245228B2 (en) 2006-01-06 2019-04-02 Acelrx Pharmaceuticals, Inc. Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
US9744129B2 (en) 2006-01-06 2017-08-29 Acelrx Pharmaceuticals, Inc. Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
US8865211B2 (en) 2006-01-06 2014-10-21 Acelrx Pharmaceuticals, Inc. Bioadhesive drug formulations for oral transmucosal delivery
US8865743B2 (en) 2006-01-06 2014-10-21 Acelrx Pharmaceuticals, Inc. Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
US8778394B2 (en) 2006-01-06 2014-07-15 Acelrx Pharmaceuticals, Inc. Small-volume oral transmucosal dosage forms
US8535714B2 (en) 2006-01-06 2013-09-17 Acelrx Pharmaceuticals, Inc. Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
CN101820838B (en) * 2007-08-07 2013-06-05 阿塞尔Rx制药有限公司 Compositions and methods for procedural sedation and analgesia using oral transmucosal dosage forms
WO2009021106A1 (en) * 2007-08-07 2009-02-12 Acelrx Pharmaceuticals, Inc. Compositions and methods for procedural sedation and analgesia using oral transmucosal dosage forms
EP2604257A1 (en) 2007-08-07 2013-06-19 Acelrx Pharmaceuticals, Inc. Compositions and methods for procedural sedation and analgesia using oral transmucosal dosage forms
JP2010535805A (en) * 2007-08-07 2010-11-25 エーセルアールエックス ファーマシューティカルズ, インコーポレイテッド Compositions and methods for sedation and analgesia during treatment using oral transmucosal dosage forms
EP3269346A1 (en) 2007-08-07 2018-01-17 Acelrx Pharmaceuticals, Inc. Apparatus for oral drug delivery
CN102231980B (en) * 2008-11-21 2014-07-16 阿塞尔Rx制药有限公司 Sufentanil solid dosage forms comprising oxygen scavengers and methods of using the same
WO2010059504A1 (en) * 2008-11-21 2010-05-27 Acelrx Pharmaceuticals, Inc. Sufentanil solid dosage forms comprising oxygen scavengers and methods of using the same
JP2012509325A (en) * 2008-11-21 2012-04-19 エーセルリクス ファーマシューティカルズ,インク. Sufentanil solid dosage form containing oxygen scavenger and method of use thereof
US8945592B2 (en) * 2008-11-21 2015-02-03 Acelrx Pharmaceuticals, Inc. Sufentanil solid dosage forms comprising oxygen scavengers and methods of using the same
AU2009316874B2 (en) * 2008-11-21 2016-06-16 Vertical Pharmaceuticals, Llc Sufentanil solid dosage forms comprising oxygen scavengers and methods of using the same
US20110091544A1 (en) * 2009-10-16 2011-04-21 Acelrx Pharmaceuticals, Inc. Compositions and Methods for Mild Sedation, Anxiolysis and Analgesia in the Procedural Setting
WO2011047143A1 (en) 2009-10-16 2011-04-21 Acelrx Pharmaceuticals, Inc. Compositions and methods for mild sedation, anxiolysis and analgesia in the procedural setting
US9345698B2 (en) 2012-05-02 2016-05-24 Orexo Ab Alfentanil composition for the treatment of acute pain
US9782396B2 (en) 2012-05-02 2017-10-10 Orexo Ab Alfentanil composition for the treatment of acute pain
US8815911B2 (en) 2012-05-02 2014-08-26 Orexo Ab Alfentanil composition for the treatment of acute pain

Also Published As

Publication number Publication date
US20130165481A1 (en) 2013-06-27
CA2636088C (en) 2017-02-21
US20130158074A1 (en) 2013-06-20
JP2009522370A (en) 2009-06-11
EP3072504B1 (en) 2020-03-18
EP1978996A2 (en) 2008-10-15
EP3685829A1 (en) 2020-07-29
US20100256190A1 (en) 2010-10-07
CA2636088A1 (en) 2007-07-19
KR101503074B1 (en) 2015-03-18
US20200022918A1 (en) 2020-01-23
US20090131479A1 (en) 2009-05-21
WO2007081949A3 (en) 2007-11-01
JP5183490B2 (en) 2013-04-17
US10342762B2 (en) 2019-07-09
DK3072504T3 (en) 2020-05-04
US8226978B2 (en) 2012-07-24
US20100137836A1 (en) 2010-06-03
JP2013049730A (en) 2013-03-14
US8202535B2 (en) 2012-06-19
KR20080084857A (en) 2008-09-19
ES2788507T3 (en) 2020-10-21
US20140350054A1 (en) 2014-11-27
EP3072504A1 (en) 2016-09-28
US8778394B2 (en) 2014-07-15
US8231900B2 (en) 2012-07-31
US8499966B2 (en) 2013-08-06
US8778393B2 (en) 2014-07-15
US20100105735A1 (en) 2010-04-29
PT3072504T (en) 2020-05-06
EP1978996A4 (en) 2013-01-23

Similar Documents

Publication Publication Date Title
US20200022918A1 (en) Small-volume oral transmucosal dosage forms
CN106727271B (en) Small volume oral transmucosal dosage form
US8252328B2 (en) Bioadhesive drug formulations for oral transmucosal delivery
US8865211B2 (en) Bioadhesive drug formulations for oral transmucosal delivery
US8535714B2 (en) Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
US20210000819A1 (en) Abuse resistant transmucosal drug delivery device
ES2439581T3 (en) New non-abuse pharmaceutical composition comprising opioids
US20110288128A1 (en) Oral Transmucosal Administration of Sufentanil
KR20140075682A (en) New abuse-resistant pharmaceutical composition for the treatment of opioid dependence

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2636088

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2008549612

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2874/KOLNP/2008

Country of ref document: IN

REEP Request for entry into the european phase

Ref document number: 2007716451

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2007716451

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 200780007142.9

Country of ref document: CN